



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
16/151,653	01/28/2020	10543206	224990/10-039C3-US/439942	6871

91684 7590 01/08/2020
JONATHAN P. O'BRIEN, PH.D.
HONIGMAN LLP
650 Trade Centre Way
Suite 200
Kalamazoo, MI 49002-0402

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional applicants):

Jo Ann Wilson, San Francisco, CA;
Exelixis, Inc., Alameda, CA
Khalid Shah, South San Francisco, CA;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		16151653
Filing Date		2018-10-04
First Named Inventor	Jo Ann Wilson	
Art Unit	1629	
Examiner Name	To be Determined	
Attorney Docket Number	224990/10-039C3-US/439942	

Change(s) applied to document /K.D.D./ 7/20/2019	47	20050209247		2005-09-22	~~CHIRON CORPORATION~~ Cai, et al.	
	48	20070078159		2007-04-05	MATSUSHIMA, et al.	
	49	20110059081		2011-03-10	~~QUINTILES TRANSNATIONAL CORP.~~ Bacus	
	50	20140256938		2014-09-11	WISON, et al.	
	51	20160220554		2016-08-04	SMITH, et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2009136663	WO		2009-11-12	TAKEDA PHARMACEUTICAL COMPANY LIMITED		☐
	2	2005030140	WO		2005-04-07	EXELIXIS, INC.		☐
	3	2010083414	WO		2010-07-22	EXELIXIS, INC.		☐
	4	2011017639	WO		2011-02-10	EXELIXIS, INC.		☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	16151653
Filing Date	2018-10-04
First Named Inventor	Jo Ann Wilson
Art Unit	1629
Examiner Name	To be Determined
Attorney Docket Number	224990/10-039C3-US/439942

Change(s) applied to document /K.D.D./ 7/20/2019	36	20140200242	~~2014-06-05~~ 7/2014	~~EXELIXIS, INC.~~ Wilson	
	37	20140228401	~~2014-06-26~~ 8/2014	~~EXELIXIS, INC.~~ Aftab et al.	
	38	20140302012	~~2014-07-17~~ 10/2014	~~EXELIXIS, INC.~~ DeCillis et al.	
	39	20140323522	~~2014-08-14~~ 10/2014	~~EXELIXIS, INC.~~ Aftab et al.	
	40	20150057310	~~2014-10-09~~ 2/2015	~~EXELIXIS, INC.~~ Brown et al.	
	41	20150196545	~~2014-10-30~~ 7/2015	~~EXELIXIS, INC.~~ Aftab et al.	
	42	20150202196	~~2015-02-26~~ 7/2015	~~EXELIXIS, INC.~~ Bannen et al.	
	43	20150376133	~~2015-07-16~~ 12/2015	~~EXELIXIS, INC.~~ Bannen et al.	
	44	20160000772	~~2015-07-23~~ 1/2016	~~EXELIXIS, INC.~~ Aftab et al.	
	45	20160051532	~~2015-12-31~~ 2/2016	~~EXELIXIS, INC.~~ Aftab et al.	
	46	20160185725	~~2016-01-07~~ 6/2016	~~EXELIXIS, INC.~~ Bannen; et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16151653
	Filing Date		2018-10-04
	First Named Inventor	Jo Ann Wilson	
	Art Unit	1629	
	Examiner Name	To be Determined	
	Attorney Docket Number	224990/10-039C3-US/439942	

Change(s) applied to document /K.D.D./ 7/20/2019	25	20130197230		8/2013 ~~2013-08-06~~	~~EXELIXIS, INC.~~ Wilson et al.	
	26	20130252940		~~2013-08-13~~ 9/2013	~~EXELIXIS, INC.~~ Bannen et al.	
	27	20130252956		~~2013-08-01~~ 9/2013	~~EXELIXIS, INC.~~ Kallender et al.	
	28	20130330377		~~2013-09-26~~ 12/2013	~~EXELIXIS, INC.~~ Wilson	
	29	20130337015		~~2013-09-20~~ 12/2013	~~EXELIXIS, INC.~~ Wilson	
	30	20140057943		~~2013-12-12~~ 2/2014	~~EXELIXIS, INC.~~ Smith et al.	
	31	20140057908		~~2013-12-19~~ 2/2014	~~EXELIXIS, INC.~~ Smith et al.	
	32	20140066444		~~2014-02-27~~ 3/2014	~~EXELIXIS, INC.~~ Smith et al.	
	33	20140155396		~~2014-02-27~~ 6/2014	~~EXELIXIS, INC.~~ Bannen et al.	
	34	20140179736		~~2014-03-06~~ 6/2014	~~EXELIXIS, INC.~~ Schwab et al.	
	35	20070054928		2007-03-08	BANNEN, et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16151653
	Filing Date		2018-10-04
	First Named Inventor	Jo Ann Wilson	
	Art Unit	1629	
	Examiner Name	To be Determined	
	Attorney Docket Number	224990/10-039C3-US/439942	

	14	20180037552		2018-02-08	BROWN, et al.	
Change(s) applied to document /K.D.D./ 7/20/2019	15	20090274693		2009-11-05	~~EXELIXIS, INC.~~ Gilmer; et al.	
	16	20110077233		2011-03-31	~~EXELIXIS, INC.~~ Bannen et al.	
	17	20120070368		2012-03-22	~~EXELIXIS, INC.~~ Bannen et al.	
	18	20120184523		2012-07-19	~~EXELIXIS, INC.~~ Bannen et al.	
	19	20120252840		2012-10-04	~~EXELIXIS, INC.~~ Aftab et al.	
	20	20120282179		2012-11-08	~~EXELIXIS, INC.~~ Aftab et al.	
	21	20130030172		2013-01-31	~~EXELIXIS, INC.~~ Wilson et al.	
	22	20130142790		~~2013-01-31~~ 6/2013	~~EXELIXIS, INC.~~ Gilmer et al.	
	23	20130143881		~~2013-01-31~~ 6/2013	~~EXELIXIS, INC.~~ Cannon et al.	
	24	20130150363		2013-06-06	~~EXELIXIS, INC.~~ Gilmer et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16151653
	Filing Date		2018-10-04
	First Named Inventor	Jo Ann Wilson	
	Art Unit	1629	
	Examiner Name	To be Determined	
	Attorney Docket Number	224990/10-039C3-US/439942	

Change(s) applied to document /K.D.D./ 7/20/2019	9	8476298		2013-07-02	~~EXELIXIS, INC.~~ Bannen, et al.	
	10	8497284		2013-07-30	~~EXELIXIS, INC.~~ Bannen, et al.	
	11	8673912		2014-03-18	~~EXELIXIS, INC.~~ Cannon, et al.	
	12	8877776		2014-11-04	~~EXELIXIS, INC.~~ Brown, et al.	
	13	9174947		2015-11-03	~~EXELIXIS, INC.~~ Bannen, et al.	
	14	9365516		2016-06-14	~~EXELIXIS, INC.~~ Wilson, et al.	
	15	7166722		2007-01-23	MATSUNAGA, et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20080161305		2008-07-03	FORSYTH, et al.	
	2	20110077233		2011-03-31	BANNEN, et al.	

Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (02-18)

Approved for use through 11/30/2020. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16151653
	Filing Date		2018-10-04
	First Named Inventor	Jo Ann Wilson	
	Art Unit	1629	
	Examiner Name	To be Determined	
	Attorney Docket Number	224990/10-039C3-US/439942	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	9724342		2017-08-08	WILSON, et al.	
	2	9809549		2017-11-07	BROWN, et al.	
Change(s) applied to document, /K.D.D./ 7/20/2019	3	7579473		2009-08-25	~~EXELIXIS, INC.~~ Bannen, et al.	
	4	7977345		2011-07-12	~~EXELIXIS, INC.~~ Bannen, et al.	
	5	7999006		2011-08-16	~~EXELIXIS, INC.~~ Lamb	
	6	8067436		2011-11-29	~~EXELIXIS, INC.~~ Bannen, et al.	
	7	8178532		2012-05-15	~~EXELIXIS, INC.~~ Bannen, et al.	
	8	8314232		2012-11-20	~~EXELIXIS, INC.~~ Deschamps, et al.	

December 6, 2019

Commissioner for Patents
United States Patent and Trademark Office
P. O. Box 1450
Alexandria, VA 22313

Re: US Patent Application No.: 16/151,653
Inventors: Jo Ann Wilson, et al.
Filing Date: October 4, 2018
Title: Processes for Preparing Quinoline Compounds and Pharmaceutical
Compositions Containing Such Compounds
Attorney Docket No.: 224990/10-039C3-US/439942

Dear Sir or Madam:


Enclosed for filing please find the following documents:

1. This Cover Letter to the Commissioner for Patents;
2. Fee Transmittal (PTOL-85 Part B); and
7. Certificate of Transmission under 37 C.F.R. § 1.8(a).

It is believed that due for this submission is the \$1,000.00 Issue Fee set forth in 37 C.F.R. § 1.18(a)(1). Please apply this \$1,000.00 charge to Deposit Account No. 503145, referencing Attorney Docket No. 224990/10-039C3-US/439942. It is believed that no other fees are due at this time. However, if there are any additional charges required, or any credits, please apply them to Deposit Account Number 503145, referencing Attorney Docket Number 224990/10-039C3-US/439942.

Very truly yours,

HONIGMAN LLP



Heidi M. Berven, Ph.D.

HMB/cwg

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

91684 7590 09/06/2019
JONATHAN P. O'BRIEN, PH.D.
HONIGMAN LLP
650 Trade Centre Way
Suite 200
Kalamazoo, MI 49002-0402

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

16/151,653	10/04/2018	Jo Ann Wilson	224990/H-039C3- USA39942	6871
------------	------------	---------------	-----------------------------	------

TITLE OF INVENTION: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

APPLS. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1000	\$0.00	\$0.00	\$1000	12/06/2019

EXAMINER	ART UNIT	CLASS/SUBCLASS
ROZOF, TIMOTHY R.	1625	514-312000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-09 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list

(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,

(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

- Honigman LLP
- Heidi M. Berven, Ph.D.
- Jonathan P. O'Brien, Ph.D.

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Exelixis, Inc.

Alameda, CA

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. Fees submitted: ☒ Issue Fee ☐ Publication Fee (if required) ☐ Advance Order - # of Copies _____

4b. Method of Payment: (Please first reapply any previously paid fee shown above)

☒ Electronic Payment via EFS-Web ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)

☒ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. 503145

5. Change in Entity Status (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

☐ Applicant asserting small entity status. See 37 CFR 1.27

☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____
Typed or printed name Heidi M. Berven, Ph.D.

Date December 6, 2019
Registration No. 48,951

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Jo Ann Wilson, et al.
Application No.: 16/151,653
Filing Date: October 4, 2018
Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1625
Examiner: Timothy R. Rozof
Conf. No.: 6871

Title: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8(a)

The undersigned hereby certifies that the following documents are being submitted in accordance with 37 C.F.R. § 1.6(a)(4) on the 6th day of December, 2019.

1. Cover Letter to the Commissioner for Patents;
2. Fee Transmittal (PTOL-85 Part B); and
3. This Certificate of Transmission under 37 C.F.R. § 1.8(a).

/Debra J. Marquette/

Debra J. Marquette (for Heidi M. Berven, Reg. No. 48,951)

Electronic Patent Application Fee Transmittal

Application Number:	16151653			
Filing Date:	04-Oct-2018			
Title of Invention:	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds			
First Named Inventor/Applicant Name:	Jo Ann Wilson			
Filer:	Heid Marie Berven/Debra Marquette			
Attorney Docket Number:	224990/10-039C3-US/439942			
Filed as Large Entity				
Filing Fees for Utility under 35 USC 111(a)				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
UTILITY APPL ISSUE FEE	1501	1	1000	1000

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Miscellaneous:				
Total in USD (\$)				1000

Electronic Acknowledgement Receipt

EFS ID:	37955895
Application Number:	16151653
International Application Number:	
Confirmation Number:	6871
Title of Invention:	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
First Named Inventor/Applicant Name:	Jo Ann Wilson
Customer Number:	91684
Filer:	Heid Marie Berven/Debra Marquette
Filer Authorized By:	Heid Marie Berven
Attorney Docket Number:	224990/10-039C3-US/439942
Receipt Date:	06-DEC-2019
Filing Date:	04-OCT-2018
Time Stamp:	14:58:52
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	\$ 1000
RAM confirmation Number	E2019B6E59297586
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		16151653.pdf	696159	yes	3
			4f82a4aa6dbdca08972410f947ee16081d3d219b		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Miscellaneous Incoming Letter		1	1	
	Issue Fee Payment (PTO-85B)		2	2	
	Transmittal Letter		3	3	
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	30755	no	2
			923650c668f6b61ef960391d42003ec46d323370		
Warnings:					
Information:					
Total Files Size (in bytes):			726914		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

91684 7590 09/06/2019
JONATHAN P. O'BRIEN, PH.D.
HONIGMAN LLP
650 Trade Centre Way
Suite 200
Kalamazoo, MI 49002-0402

EXAMINER

ROZOF, TIMOTHY R

ART UNIT

PAPER NUMBER

1625

DATE MAILED: 09/06/2019

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
16/151,653	10/04/2018	Jo Ann Wilson	224990/10-039C3- US/439942	6871

TITLE OF INVENTION: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1000	\$0.00	\$0.00	\$1000	12/06/2019

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

91684 7590 09/06/2019
JONATHAN P. O'BRIEN, PH.D.
HONIGMAN LLP
650 Trade Centre Way
Suite 200
Kalamazoo, MI 49002-0402

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
16/151.653	10/04/2018	Jo Ann Wilson	224990/10-039C3- US/439942	6871

TITLE OF INVENTION: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1000	\$0.00	\$0.00	\$1000	12/06/2019

EXAMINER	ART UNIT	CLASS-SUBCLASS
ROZOF, TIMOTHY R	1625	514-312000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-09 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,

(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 _____
2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. Fees submitted: ☐ Issue Fee ☐ Publication Fee (if required) ☐ Advance Order - # of Copies _____

4b. Method of Payment: (Please first reapply any previously paid fee shown above)

☐ Electronic Payment via EFS-Web ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)

☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. _____

5. **Change in Entity Status** (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

☐ Applicant asserting small entity status. See 37 CFR 1.27

☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____

Date _____

Typed or printed name _____

Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
16/151,653	10/04/2018	Jo Ann Wilson	224990/10-039C3- US/439942	6871
91684	7590	09/06/2019	EXAMINER	
JONATHAN P. O'BRIEN, PH.D. HONIGMAN LLP 650 Trade Centre Way Suite 200 Kalamazoo, MI 49002-0402			ROZOF, TIMOTHY R	
			ART UNIT	PAPER NUMBER
			1625	
DATE MAILED: 09/06/2019				

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 16/151,653	Applicant(s) Wilson et al.	
	Examiner TIMOTHY R ROZOF	Art Unit 1625	AIA (FITF) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to August 29, 2019, Amendment & Remarks.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on ____.

2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on ____; the restriction requirement and election have been incorporated into this action.

3. ☒ The allowed claim(s) is/are 35-54. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a) ☐ All b) ☐ Some *c) ☐ None of the:

1. ☐ Certified copies of the priority documents have been received.

2. ☐ Certified copies of the priority documents have been received in Application No. ____.

3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: ____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date ____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)	5. ☐ Examiner's Amendment/Comment
2. ☒ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date ____.	6. ☐ Examiner's Statement of Reasons for Allowance
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material ____.	7. ☐ Other ____.
4. ☐ Interview Summary (PTO-413), Paper No./Mail Date. ____.	

/TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625	
--	--

<i>Search Notes</i> 	Application/Control No. 16/151,653	Applicant(s)/Patent Under Reexamination Wilson et al.
	Examiner TIMOTHY R ROZOF	Art Unit 1625

CPC - Searched*		
Symbol	Date	Examiner
C07D215/233	09/02/2019	TRR
A61K31/47	09/02/2019	TRR

CPC Combination Sets - Searched*		
Symbol	Date	Examiner

US Classification - Searched*			
Class	Subclass	Date	Examiner

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	Date	Examiner
EAST search (please see attached EAST search report)	09/02/2019	TRR

Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner
A61K	31/47	09/02/2019	TRR
C07D	215/233	09/02/2019	TRR

/TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625	
--	--

Issue Classification 	Application/Control No. 16/151,653	Applicant(s)/Patent Under Reexamination Wilson et al.
	Examiner TIMOTHY R ROZOF	Art Unit 1625

CPC						
Symbol					Type	Version
A61K	/	31	/	47	F	2013-01-01
C07D	/	215	/	233	I	2013-01-01

CPC Combination Sets					
Symbol				Type	Version
	/		/		

NONE (Assistant Examiner) _____ (Date) _____		Total Claims Allowed: 20	
/TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625 (Primary Examiner) _____ (Date) 02 September 2019		O.G. Print Claim(s) 1	O.G. Print Figure NONE

Issue Classification 	Application/Control No. 16/151,653	Applicant(s)/Patent Under Reexamination Wilson et al.
	Examiner TIMOTHY R ROZOF	Art Unit 1625

INTERNATIONAL CLASSIFICATION			
CLAIMED			
A61K	/	31	/ 47
C07D	/	215	/ 233

NON-CLAIMED			
/		/	

US ORIGINAL CLASSIFICATION	
CLASS	SUBCLASS

CROSS REFERENCES(S)						
CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)					

NONE		Total Claims Allowed:	
(Assistant Examiner)	(Date)	20	
/TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625 (Primary Examiner)	02 September 2019 (Date)	O.G. Print Claim(s) 1	O.G. Print Figure NONE

Issue Classification 	Application/Control No. 16/151,653	Applicant(s)/Patent Under Reexamination Wilson et al.
	Examiner TIMOTHY R ROZOF	Art Unit 1625

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47
--

CLAIMS															
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
1	35	10	44	19	53										
2	36	11	45	20	54										
3	37	12	46												
4	38	13	47												
5	39	14	48												
6	40	15	49												
7	41	16	50												
8	42	17	51												
9	43	18	52												

NONE (Assistant Examiner) _____ (Date) _____		Total Claims Allowed: 20	
/TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625 (Primary Examiner) _____ (Date) 02 September 2019		O.G. Print Claim(s) 1	O.G. Print Figure NONE

Doc code: IDS

PTO/SB/08a (02-18)

Doc description: Information Disclosure Statement (IDS) Filed

Approved for use through 11/30/2020. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16151653
	Filing Date		2018-10-04
	First Named Inventor	Jo Ann Wilson	
	Art Unit	1625	
	Examiner Name	Timothy R. Rozof	
	Attorney Docket Number	224990/10-039C3-US/439942	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	7169789		2007-01-30	KUBO, et al	
	2	5358941		1994-10-25	BECHARD, et al.	
	3	9717720		2017-08-01	WILSON, et al.	
	4	9969692		2018-05-15	WILSON, et al.	
	5	10034873		2018-07-31	WILSON, et al.	
	6	10039757		2018-09-08	WILSON, et al.	
	7	10166225		2019-01-01	AFTAB, et al.	
If you wish to add additional U.S. Patent citation information please click the Add button.						
U.S.PATENT APPLICATION PUBLICATIONS						

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	16151653
Filing Date	2018-10-04
First Named Inventor	Jo Ann Wilson
Art Unit	1625
Examiner Name	Timothy R. Rozof
Attorney Docket Number	224990/10-039C3-US/439942

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20080004273		2008-01-03	RAEPPEL, et al.	
	2	20140121239		2014-05-01	AFTAB, et al.	
	3	20140221372		2014-08-07	KULKARNI, et al.	
	4	20150133494		2015-05-14	AFTAB, et al.	
	5	20150238477		2015-08-27	AFTAB, Dana T.	
	6	20160031818		2016-02-04	AFTAB, et al.	
	7	20160082019		2016-03-24	SWEENEY, et al.	
	8	20170087143		2017-03-30	AFTAB, et al.	
	9	20090203729		2009-08-13	INOUE, et al.	
	10	20190030021		2019-01-31	WILSON, et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	16151653
Filing Date	2018-10-04
First Named Inventor	Jo Ann Wilson
Art Unit	1625
Examiner Name	Timothy R. Rozof
Attorney Docket Number	224990/10-039C3-US/439942

11	20170057921	2017-03-02	WILSON, et al.
12	20170355678	2017-12-14	BANNEN, et al.
13	20180230100	2018-08-16	WILSON, et al.
14	20180311229	2018-11-01	WILSON, et al.
15	20190151302	2019-05-23	AFTAB, et al.
16	20190091215	2019-03-28	AFTAB, et al.

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2012109510	WO		2012-06-16	WILSON, Jo Ann		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
--------------------	---------	---	----------------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		16151653
Filing Date		2018-10-04
First Named Inventor	Jo Ann Wilson	
Art Unit	1625	
Examiner Name	Timothy R. Rozof	
Attorney Docket Number	224990/10-039C3-US/439942	

1	KIBBE, A.H. Handbook of Pharmaceutical Excipients, 3rd edition: American Pharmactical Association and Pharmaceutical Press, ISBN 0-85369-381-1, 2000 (pages 110,244,305,143,102,501,534,386,160)	☐
---	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/TIMOTHY R ROZOF/	Date Considered	09/02/2019
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	16151653
Filing Date	2018-10-04
First Named Inventor	Jo Ann Wilson
Art Unit	1625
Examiner Name	Timothy R. Rozof
Attorney Docket Number	224990/10-039C3-US/439942

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Meghan M. Klaric/	Date (YYYY-MM-DD)	2019-08-29
Name/Print	Meghan M. Klaric	Registration Number	71,226

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Bibliographic Data

Application No: 16/151,653

Foreign Priority claimed: ☐ Yes ☒ No

35 USC 119 (a-d) conditions met: ☐ Yes ☒ No ☐ Met After Allowance

Verified and Acknowledged: /TIMOTHY R ROZOF/

TRR

Examiner's Signature

Initials

Title: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
10/04/2018	514	1625	224990/10-039C3-US/439942
RULE			

APPLICANTS

Exelixis, Inc., Alameda, CA,

INVENTORS

Jo Ann Wilson San Francisco, CA, UNITED STATES

Khalid Shah South San Francisco, CA, UNITED STATES

CONTINUING DATA

This application is a DIV of 15348716 11/10/2016 PAT 10123999

15348716 is a DIV of 13984559 03/20/2014 PAT 9717720

13984559 is a 371 of PCT/US12/24591 02/10/2012

PCT/US12/24591 has PRO of 61441527 02/10/2011

PCT/US12/24591 has PRO of 61441520 02/10/2011

FOREIGN APPLICATIONS

IF REQUIRED, FOREIGN LICENSE GRANTED**

10/24/2018

STATE OR COUNTRY

UNITED STATES

ADDRESS

JONATHAN P. O'BRIEN, PH.D.

HONIGMAN LLP

650 Trade Centre Way

Suite 200

Kalamazoo, MI 49002-0402

UNITED STATES

FILING FEE RECEIVED

\$1,720

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	8572	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2019/09/02 17:39
L2	6642	L1 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/09/02 17:39
L3	517	L2 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/09/02 17:39
L4	96	L3 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/09/02 17:39
S1	1868	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2014/10/04 13:11
S2	6107	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/10/04 13:12
S3	4920	S2 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2014/10/04 13:12
S4	476	S3 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2014/10/04 13:14
S5	88	S4 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2014/10/04 13:14
S6	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/10/04 13:14
S7	735	S3 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2014/10/04 15:14
S8	11	S5 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2014/10/04 15:15
S10	1907	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2015/06/03 13:56
S11	6748	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2015/06/03 13:56
S12	5294	S11 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2015/06/03 13:56
S13	492	S12 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2015/06/03 13:56

			DERWENT			
S14	96	S13 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2015/06/03 13:56
S15	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2015/06/03 13:56
S16	748	S12 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2015/06/03 13:56
S17	12	S14 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2015/06/03 13:56
S19	1924	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S20	7064	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/01/07 13:23
S21	5473	S20 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S22	494	S21 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S23	96	S22 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S24	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/01/07 13:23
S25	755	S21 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S26	12	S23 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S27	1924	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S28	7064	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/01/07 13:23
S29	5473	S28 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S30	494	S29 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S31	96	S30 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S32	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/01/07 13:23
S33	755	S29 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO;	OR	ON	2016/01/07 13:23

			DERWENT			
S34	12	S31 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S35	0	((A61K31/47.cpc.) or (C07D215/233.cpc.)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/01/07 13:33
S36	5706	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:33
S37	4165	S36 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:33
S38	546	S37 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:34
S39	81	S38 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:34
S42	1925	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S43	7164	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S44	5481	S43 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S45	494	S44 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S46	96	S45 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S47	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S48	756	S44 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S49	12	S46 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S50	1925	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S51	7164	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S52	5481	S51 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S53	494	S52 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S54	96	S53 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO;	OR	ON	2016/04/28 12:34

			DERWENT			
S55	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S56	756	S52 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S57	12	S54 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S58	1925	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S59	7164	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S60	5481	S59 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S61	494	S60 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S62	96	S61 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S63	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S64	756	S60 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S65	12	S62 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S66	1925	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S67	7164	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S68	5481	S67 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S69	494	S68 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S70	96	S69 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S71	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S72	756	S68 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S73	12	S70 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO;	OR	ON	2016/04/28 12:34

			DERWENT			
S74	0	((A61K31/47.cpc.) or (C07D215/233.cpc.)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S75	5906	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S76	4191	S75 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S77	550	S76 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S78	81	S77 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S79	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S80	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S81	5493	S80 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S82	495	S81 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S83	96	S82 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S84	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S85	757	S81 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S86	12	S83 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S87	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S88	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S89	5493	S88 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S90	495	S89 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S91	96	S90 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S92	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO;	OR	OFF	2016/08/05 11:36

			DERWENT			
S93	757	S89 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S94	12	S91 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S95	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S96	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S97	5493	S96 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S98	495	S97 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S99	96	S98 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S100	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S101	757	S97 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S102	12	S99 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S103	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S104	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S105	5493	S104 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S106	495	S105 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S107	96	S106 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S108	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S109	757	S105 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S110	12	S107 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S111	0	((A61K31/47.cpc.) or (C07D215/233.cpc.)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO;	OR	OFF	2016/08/05 11:37

			DERWENT			
S112	6123	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S113	4231	S112 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S114	566	S113 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S115	82	S114 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S116	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S117	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S118	5493	S117 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S119	495	S118 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S120	96	S119 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S121	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S122	757	S118 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S123	12	S120 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S124	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S125	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S126	5493	S125 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S127	495	S126 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S128	96	S127 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S129	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S130	757	S126 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO;	OR	ON	2016/08/05 11:37

			DERWENT			
S131	12	S128 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S132	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S133	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S134	5493	S133 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S135	495	S134 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S136	96	S135 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S137	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S138	757	S134 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S139	12	S136 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S140	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S141	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S142	5493	S141 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S143	495	S142 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S144	96	S143 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S145	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S146	757	S142 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S147	12	S144 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S148	0	((A61K31/47.cpc.) or (C07D215/233.cpc.)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S149	6123	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO;	OR	ON	2016/08/05 11:37

			DERWENT			
S150	4231	S149 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S151	566	S150 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S152	82	S151 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S153	6433	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/01/17 13:35
S154	4302	S153 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/01/17 13:35
S155	573	S154 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/01/17 13:35
S156	83	S155 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/01/17 13:35
S157	7130	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/05/23 14:41
S158	4682	S157 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/05/23 14:41
S159	580	S158 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/05/23 14:41
S160	83	S159 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/05/23 14:41
S161	1	("20120035212").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2017/06/26 14:37
S162	7223	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/06/28 15:15
S163	1	("20120035212").PN.	US-PGPUB; USPAT	OR	OFF	2017/10/12 15:31
S164	1	("20120035212").PN.	US-PGPUB; USPAT	OR	OFF	2017/10/12 17:17
S165	1	("7169789").PN.	USPAT	OR	OFF	2017/10/12 17:35
S166	8124	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2018/06/18 18:05
S167	6268	S166 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2018/06/18 18:05
S168	508	S167 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2018/06/18 18:05
S169	96	S168 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO;	OR	ON	2018/06/18 18:05

			DERWENT			
S170	9188	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/05/28 13:45
S171	5538	S170 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/05/28 13:45
S172	2	((("10123999") or ("9717720")).PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/05/28 13:50
S173	8459	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2019/05/28 13:59
S174	6531	S173 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/05/28 13:59
S175	514	S174 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/05/28 13:59
S176	95	S175 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/05/28 13:59

9/ 2/ 2019 5:40:38 PM
C:\ Users\ trozof\ Documents\ EAST\ Workspaces\ 16151653.wsp

REQUEST FOR CONTINUED EXAMINATION(RCE)TRANSMITTAL (Submitted Only via EFS-Web)

Application Number	16/151,653	Filing Date	2018-10-04	Docket Number (if applicable)	224990/10-039C3-US/439942	Art Unit	1625
First Named Inventor	Jo Ann Wilson			Examiner Name	Timothy R. Rozof		

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. The Instruction Sheet for this form is located at WWW.USPTO.GOV

SUBMISSION REQUIRED UNDER 37 CFR 1.114

Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

☐ Other _____

☒ Enclosed

☐ Amendment/Reply

☒ Information Disclosure Statement (IDS)

☐ Affidavit(s)/ Declaration(s)

☐ Other _____

MISCELLANEOUS

☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months _____
(Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

☐ Other _____

FEES

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

☒ The Director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 503145

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

☒ Patent Practitioner Signature

☐ Applicant Signature

Signature of Registered U.S. Patent Practitioner

Signature	/Meghan M. Klaric/	Date (YYYY-MM-DD)	2019-08-29
Name	Meghan M. Klaric	Registration Number	71226

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16151653
	Filing Date		2018-10-04
	First Named Inventor	Jo Ann Wilson	
	Art Unit	1625	
	Examiner Name	Timothy R. Rozof	
	Attorney Docket Number	224990/10-039C3-US/439942	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	7169789		2007-01-30	KUBO, et al	
	2	5358941		1994-10-25	BECHARD, et al.	
	3	9717720		2017-08-01	WILSON, et al.	
	4	9969692		2018-05-15	WILSON, et al.	
	5	10034873		2018-07-31	WILSON, et al.	
	6	10039757		2018-09-08	WILSON, et al.	
	7	10166225		2019-01-01	AFTAB, et al.	
If you wish to add additional U.S. Patent citation information please click the Add button.						
U.S.PATENT APPLICATION PUBLICATIONS						

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		16151653
Filing Date		2018-10-04
First Named Inventor	Jo Ann Wilson	
Art Unit	1625	
Examiner Name	Timothy R. Rozof	
Attorney Docket Number	224990/10-039C3-US/439942	

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20080004273		2008-01-03	RAEPPEL, et al.	
	2	20140121239		2014-05-01	AFTAB, et al.	
	3	20140221372		2014-08-07	KULKARNI, et al.	
	4	20150133494		2015-05-14	AFTAB, et al.	
	5	20150238477		2015-08-27	AFTAB, Dana T.	
	6	20160031818		2016-02-04	AFTAB, et al.	
	7	20160082019		2016-03-24	SWEENEY, et al.	
	8	20170087143		2017-03-30	AFTAB, et al.	
	9	20090203729		2009-08-13	INOUE, et al.	
	10	20190030021		2019-01-31	WILSON, et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	16151653
Filing Date	2018-10-04
First Named Inventor	Jo Ann Wilson
Art Unit	1625
Examiner Name	Timothy R. Rozof
Attorney Docket Number	224990/10-039C3-US/439942

11	20170057921	2017-03-02	WILSON, et al.
12	20170355678	2017-12-14	BANNEN, et al.
13	20180230100	2018-08-16	WILSON, et al.
14	20180311229	2018-11-01	WILSON, et al.
15	20190151302	2019-05-23	AFTAB, et al.
16	20190091215	2019-03-28	AFTAB, et al.

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2012109510	WO		2012-06-16	WILSON, Jo Ann		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
--------------------	---------	---	----------------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		16151653
Filing Date		2018-10-04
First Named Inventor	Jo Ann Wilson	
Art Unit	1625	
Examiner Name	Timothy R. Rozof	
Attorney Docket Number	224990/10-039C3-US/439942	

1	KIBBE, A.H. Handbook of Pharmaceutical Excipients, 3rd edition: American Pharmactical Association and Pharmaceutical Press, ISBN 0-85369-381-1, 2000 (pages 110,244,305,143,102,501,534,386,160)	☐
---	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	16151653
Filing Date	2018-10-04
First Named Inventor	Jo Ann Wilson
Art Unit	1625
Examiner Name	Timothy R. Rozof
Attorney Docket Number	224990/10-039C3-US/439942

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Meghan M. Klaric/	Date (YYYY-MM-DD)	2019-08-29
Name/Print	Meghan M. Klaric	Registration Number	71,226

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors:	Jo Ann Wilson, et al.	Art Unit:	1625
Application No.:	16/151,653	Examiner:	Timothy R. Rozof
Filing Date:	October 4, 2018	Conf. No.:	6871
Atty. Docket No.:	224990/10-039C3-US/439942		

Title: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8(a)

The undersigned hereby certifies that the following documents are being submitted in accordance with 37 C.F.R. § 1.6(a)(4) on the 29th day of August, 2019.

1. Cover Letter to the Commissioner for Patents;
2. Request for Continued Examination;
3. Request for Continued Examination Transmittal (PTO/SB/30);
4. Information Disclosure Statement (PTO/SB/08a);
5. Foreign Patent Literature (1 document);
6. Non-Patent Literature (1 document); and
7. This Certificate of Transmission under 37 C.F.R. § 1.8(a).

/Amy L. Peters/

Amy L. Peters (for Meghan M. Klaric, Reg. No. 71,226)


(10) International Publication Number
WO 2012/109510 A1(43) International Publication Date
16 August 2012 (16.08.2012)

- (51) **International Patent Classification:**
C07D 215/227 (2006.01) **A61P 35/00** (2006.01)
A61K 31/47 (2006.01)
- (21) **International Application Number:**
PCT/US2012/024591
- (22) **International Filing Date:**
10 February 2012 (10.02.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/441,520 10 February 2011 (10.02.2011) US
61/441,527 10 February 2011 (10.02.2011) US
- (71) **Applicant** (for all designated States except US): **EXELIX-
IS, INC.** [US/US]; 210 East Grand Avenue, South San
Francisco, CA 94080 (US).
- (72) **Inventor; and**
- (75) **Inventor/Applicant** (for US only): **WILSON, Jo Ann**
[US/US]; 74 Seward Street, San Francisco, CA 94114
(US).
- (74) **Agent:** **BERVEN, Heidi, M.**; Honigman, Miller Schwart
And Cohn, LLP, 350 East Michigan Avenue, Suite 300,
Kalamazoo, MI 49007-3800 (US).

- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS(57) **Abstract:** The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, Cl, or X2 is H, Br, Cl, or n1 is 1-2; and n2 is 1-2.

**PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND
PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS**

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to U.S. Provisional Application No. 61/441,520, filed February 10, 2011, and 61/441,527, filed February 10, 2011, which are incorporated herein by reference

FIELD OF THE INVENTION

[0002] This disclosure relates to processes for preparing compounds useful for modulating protein kinase enzymatic activity. More specifically, this disclosure relates to processes for preparing quinolines that are useful for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemo-invasion and to pharmaceutical compositions containing such compounds.

BACKGROUND OF THE INVENTION

[0003] Traditionally, dramatic improvements in the treatment of cancer are associated with identification of therapeutic agents acting through novel mechanisms. One mechanism that can be exploited in cancer treatment is the modulation of protein kinase activity because signal transduction through protein kinase activation is responsible for many of the characteristics of tumor cells. Protein kinase signal transduction is of particular relevance in, for example, renal, gastric, head and neck, lung, breast, prostate, and colorectal cancers; hepatocellular carcinoma; as well as in the growth and proliferation of brain tumor cells.

[0004] Protein kinases can be categorized as receptor type or non-receptor type. Receptor-type tyrosine kinases are comprised of a large number of transmembrane receptors with diverse biological activity. For a detailed discussion of the receptor-type tyrosine kinases, see Plowman et al., DN&P 7(6): 334-339, 1994. Since protein kinases and their ligands play critical roles in various cellular activities, deregulation of protein kinase enzymatic activity can lead to altered cellular properties, such as uncontrolled cell growth associated with cancer. In addition to oncological indications, altered kinase signaling is implicated in numerous other pathological diseases, including, for example, immunological disorders, cardiovascular diseases, inflammatory diseases, and degenerative diseases. Therefore, protein kinases are attractive targets for small molecule drug discovery. Particularly attractive targets for small-molecule modulation with respect to antiangiogenic

and antiproliferative activity include receptor type tyrosine kinases c-Met, KDR, c-Kit, Axl, flt-3, and flt-4.

[0005] The kinase c-Met is the prototypic member of a subfamily of heterodimeric receptor tyrosine kinases (RTKs) which include Met, Ron, and Sea. The endogenous ligand for c-Met is the hepatocyte growth factor (HGF), a potent inducer of angiogenesis. Binding of HGF to c-Met induces activation of the receptor via autophosphorylation, resulting in an increase of receptor dependent signaling, which promotes cell growth and invasion. Anti-HGF antibodies or HGF antagonists have been shown to inhibit tumor metastasis *in vivo* (See: Maulik et al Cytokine & Growth Factor Reviews 2002 13, 41-59). c-Met overexpression has been demonstrated on a wide variety of tumor types including breast, colon, renal, lung, squamous cell myeloid leukemia, hemangiomas, melanomas, astrocytomas, and glioblastomas. Additionally, activating mutations in the kinase domain of c-Met have been identified in hereditary and sporadic renal papilloma and squamous cell carcinoma. (See, e.g., Maulik et al., Cytokine & growth Factor reviews 2002 13, 41-59; Longati et al., Curr Drug Targets 2001, 2, 41-55; Funakoshi et al., Clinica Chimica Acta 2003 1-23).


[0006] Inhibition of epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and ephrin signal transduction will prevent cell proliferation and angiogenesis, two key cellular processes needed for tumor growth and survival (Matter A., Drug Disc. Technol. 2001 6, 1005-1024). Kinase KDR (refers to kinase insert domain receptor tyrosine kinase) and flt-4 (fms-like tyrosine kinase-4) are both VEGF receptors. Inhibition of EGF, VEGF, and ephrin signal transduction will prevent cell proliferation and angiogenesis, two key cellular processes needed for tumor growth and survival (Matter A. Drug Disc. Technol. 2001 6, 1005-1024). EGF and VEGF receptors are desirable targets for small molecule inhibition. All members of the VEGF family stimulate cellular responses by binding to tyrosine kinase receptors (the VEGFRs) on the cell surface, causing them to dimerize and become activated through transphosphorylation. The VEGF receptors have an extracellular portion with immunoglobulin-like domains, a single transmembrane spanning region, and an intracellular portion containing a split tyrosine-kinase domain. VEGF binds to VEGFR-1 and VEGFR-2. VEGFR-2 is known to mediate almost all of the known cellular responses to VEGF.

[0007] Kinase c-Kit (also called stem cell factor receptor or steel factor receptor) is a type 3 receptor tyrosine kinase (RTK) belonging to the platelet-derived growth factor receptor subfamily. Overexpression of c-Kit and c-Kit ligand has been described in variety of human

diseases, including human gastrointestinal stromal tumors, mastocytosis, germ cell tumors, acute myeloid leukemia (AML), NK lymphoma, small-cell lung cancer, neuroblastomas, gynecological tumors, and colon carcinoma. Moreover, elevated expression of c-Kit may also relate to the development of neoplasia associated with neurofibromatosis type 1 (NF-1), mesenchymal tumors GISTs, and mast cell disease, as well as other disorders associated with activated c-Kit.

[0008] Kinase Flt-3 (fms-like tyrosine kinase-3) is constitutively activated via mutation, either in the juxtamembrane region or in the activation loop of the kinase domain, in a large proportion of patients with AML (Reilly, *Leuk. Lymphoma*, 2003, 44: 1-7).

[0009] Small-molecule compounds that specifically inhibit, regulate, and/or modulate the signal transduction of kinases, such as c-Met, VEGFR2, KDR, c-Kit, Axl, flt-3, and flt-4 described above, are particularly desirable as a means to treat or prevent disease states associated with abnormal cell proliferation and angiogenesis. One such small-molecule is compound IA, which has the chemical structure:



IA

WO2005/030140 describes the synthesis of compound IA (Table 2, Compound 12, Example 48) and also discloses the therapeutic activity of this molecule to inhibit, regulate, and/or modulate the signal transduction of kinases (Assays, Table 4, entry 289), the entire contents of which is incorporated herein by reference.


[0010] Although therapeutic efficacy is the primary concern for a therapeutic agent, the pharmaceutical composition can be equally important to its development. Generally, the drug developer endeavors to discover a pharmaceutical composition that possesses desirable properties, such as satisfactory water-solubility (including rate of dissolution), storage stability, hygroscopicity, and reproducibility, all of which can impact the processability, manufacture, and/or bioavailability of the drug.

[0011] Accordingly, there is a need for the discovery of new processes for making quinolines such as compound IA that minimize the formation of undesirable process contaminants or byproducts. There is also a need for new pharmaceutical compositions containing quinolines such as compound IA that are essentially free of process byproducts.

SUMMARY OF THE INVENTION

[0012] These and other needs are met by the present disclosure, which is directed to processes for making and compositions containing quinolines or pharmaceutically acceptable salts thereof.

[0013] In one aspect, the disclosure relates to processes for preparing a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

X^1 is H, Br, Cl, or F;

X^2 is H, Br, Cl, or F;


n_1 is 1-2; and

n_2 is 1-2.


[0014] Intermediates useful in preparing the above compounds are also disclosed.

[0015] The compounds of formula I are useful as protein kinase modulators, and they inhibit various protein kinases including Ret and c-Met.

[0016] In another aspect, the disclosure provides a process for preparing compound IB:



from compound IA:




IA,

comprising:


- (a) heating and agitating a mixture comprising compound IA and L-malic acid, methylethyl ketone, and water;
- (b) cooling the mixture;
- (c) vacuum distilling the mixture successively; and
- (d) isolating the compound of IB by filtration.

[0017] In another aspect, the disclosure provides a process for preparing compound IB:



IB

from compound IA:



IA,


comprising:

- (a) heating and agitating a mixture comprising compound IA and L-malic acid, methylethyl ketone, and water;
- (b) cooling the mixture;
- (c) seeding the mixture with compound IB;
- (d) vacuum distilling the mixture; and

(e) isolating compound IB by filtration.

[0018] In another aspect, the disclosure provides compound I, IA, or IB admixed with

less than 100 ppm 6,7-dimethoxy-quinoline-4-ol, the structure of which is



[0019] In another aspect, the disclosure provides pharmaceutical compositions containing the compound of formula I, compound IA, or compound IB for oral administration.

[0020] In another aspect, the disclosure provides a pharmaceutical tablet composition according to Table 1.

Table 1

Ingredient	% w/w
Compound I	31.68
Microcrystalline Cellulose (MCC) (Avicel PH102)	38.85
Lactose anhydrous 60 M	19.42
Hydroxypropyl Cellulose, EXF	3.00
Croscarmellose Sodium	3.00
Total Intra-granular	95.95
Silicon dioxide, Colloidal PWD	0.30
Croscarmellose Sodium	3.00
Magnesium Stearate	0.75
Total	100.00

[0021] In another aspect, the disclosure provides a pharmaceutical tablet composition according to Table 2.

Table 2

Ingredient	(% w/w)
Compound I	25.0-33.3
Microcrystalline Cellulose, NF	q.s
Hydroxypropyl Cellulose, NF	3
Poloxamer, NF	0-3
Croscarmellose Sodium, NF	6.0
Colloidal Silicon Dioxide, NF	0.5
Magnesium Stearate, NF	0.5-1.0
Total	100

[0022] In another aspect, the disclosure provides a pharmaceutical tablet composition according to Table 2A.

Table 2A

Ingredient	% w/w
Compound IB (10 % drug load as Compound IA)	12.67
MCC	51.52
Lactose	25.76
Hydroxypropyl cellulose	3.0
Croscarmellose Sodium	6.0
Colloidal Silicon Dioxide	0.3
Magnesium Stearate	0.75
Total	100

[0023] In another aspect, the disclosure provides a pharmaceutical capsule composition according to Table 3.

Table 3

Ingredient	mg/unit dose
Compound IB (10 % drug load as Compound IA)	25
Silicified Microcrystalline Cellulose	196.75
Croscarmellose sodium	12.5
Sodium starch glycolate	12.5
Fumed Silica	0.75
Stearic acid	2.5
Total Fill Weight	250

[0024] In another aspect, the disclosure provides a pharmaceutical capsule composition according to Table 4.

Table 4

Ingredient	mg/unit dose
Compound IB (50 % drug load as Compound IA)	100
Silicified Microcrystalline Cellulose	75.40
Croscarmellose sodium	10.00
Sodium Starch Glycolate	10.00
Fumed silica	0.6
Stearic Acid	4.0
Total Fill Weight	200

[0025] In another aspect, the disclosure provides a pharmaceutical capsule composition according to Table 5, wherein the IB weight equivalents are provided.

Table 5


	mg/unit dose
Ingredient	50mg
Compound IB	63.35
Microcrystalline Cellulose	95.39
Croscarmellose sodium	9.05
Sodium starch glycolate	9.05
Fumed Silica	0.54
Stearic acid	3.62
Total Fill Weight	181.00

[0026] In another aspect, the disclosure provides a pharmaceutical capsule composition according to Table 6, wherein the IB weight equivalents are provided.

Table 6

	mg/unit dose
Ingredient	60mg
Compound IB	73.95
Microcrystalline Cellulose	114.36
Croscarmellose sodium	10.85
Sodium starch glycolate	10.85
Fumed Silica	0.65
Stearic acid	4.34
Total Fill Weight	217.00

[0027] In another aspect, the invention is directed to a pharmaceutical composition comprising compound I, IA, or IB admixed with less than 100 ppm 6,7-dimethoxy-quinoline-



4-ol, the structure of which is , and a pharmaceutically acceptable carrier.

[0028] There are many different aspects and embodiments of the disclosure described herein, and each aspect and each embodiment is non-limiting in regard to the scope of the disclosure. The terms “aspects” and “embodiments” are meant to be non-limiting regardless of where the terms “aspect” or “embodiment” appears in this specification. The transitional term “comprising,” as used herein, which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0029] As used herein, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise or they are expressly defined to mean something different.

[0030] The word “can” is used in a non-limiting sense and in contradistinction to the word “must.” Thus, for example, in many aspects of the invention a certain element is described as “can” having a specified identity, which is meant to convey that the subject element is permitted to have that identity according to the invention but is not required to have it.

[0031] If a group “R” is depicted as “floating” on a ring system, then unless otherwise defined, the substituent(s) “R” can reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the ring atoms, so long as a stable structure is formed.

[0032] When there are more than one such depicted “floating” groups, such as where there are two groups; then, unless otherwise defined, the “floating” groups can reside on any atoms of the ring system, again assuming each replaces a depicted, implied, or expressly defined hydrogen on the ring.

[0033] “Pharmaceutically acceptable salts” include acid addition salts.

[0034] “Pharmaceutically acceptable acid addition salt” refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or mixtures thereof, as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like, or mixtures thereof.

[0035] “Essentially free” as used in the phrase “essentially free of process byproducts or contaminants,” means that a compound or composition as disclosed here in is admixed with 200 parts per million (ppm) or less of such byproducts or contaminants.


[0036] The disclosure is further illustrated by the following examples, which are not to be construed as limiting the disclosure in scope or spirit to the specific procedures described in them. Unless specified otherwise, the starting materials and various intermediates may be

obtained from commercial sources, prepared from commercially available organic compounds, or prepared using well-known synthetic processes.

Processes

Aspect 1: Processes for Making Compounds of Formula I

[0037] Aspect (1) of the invention relates to a process of preparing a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

X^1 is H, Br, Cl, or F;


X^2 is H, Br, Cl, or F;

$n1$ is 1-2; and

$n2$ is 1-2;

the process comprising:

contacting the compound of formula g(1) with reactant z(1) to yield the compound of formula I:



[0038] The reaction is advantageously carried out under suitable reaction conditions.

Non-limiting examples of suitable reaction conditions include using basic conditions. Non-limiting examples of basic conditions that can be used in Aspect (1) include the use of inorganic bases, such as aqueous KOH, NaOH, K_2CO_3 , Na_2CO_3 , K_3PO_4 , Na_3PO_4 , K_2HPO_4 , Na_2HPO_4 , and the like, or mixtures thereof. Other non-limiting examples of suitable reaction conditions include using suitable solvents. Non-limiting examples of suitable solvents that can be used include water miscible solvents, such as THF, acetone, ethanol, and the like, or mixtures thereof. Other non-limiting examples of suitable reaction conditions include using suitable temperatures. Suitable temperatures that may be used for the reaction include a

temperature at a range from about 10 °C to about 30 °C, or alternatively, at a range from about 15 °C to about 28 °C, or alternatively, at a range from about 20 °C to about 25 °C. The product formed by the reaction is in the free base form, and this free base form may be converted into a pharmaceutically acceptable salt thereof by processes known in the art. For example, the compound of formula I can be converted to the L-malate salt by the addition of L-malic acid and a suitable solvent.

[0039] Utilities of the compound of formula I are further described in WO 2005/030140 A2, which is incorporated herein by reference.

Embodiments of Aspect (1) Part A

- [0040] In another embodiment of Aspect (1), X^1 is Cl or F.
- [0041] In another embodiment of Aspect (1), X^2 is Cl or F.
- [0042] In another embodiment of Aspect (1), X^1 is F.
- [0043] In another embodiment of Aspect (1), X^2 is F.
- [0044] In another embodiment of Aspect (1), X^1 is H.
- [0045] In another embodiment of Aspect (1), X^2 is H.
- [0046] In another embodiment of Aspect (1), n_1 is 1.
- [0047] In another embodiment of Aspect (1), n_2 is 1.
- [0048] In another embodiment of Aspect (1), n_1 is 2.
- [0049] In another embodiment of Aspect (1), n_2 is 2.
- [0050] All compounds of formula I for Aspect (1) disclosed above include any of the disclosed alternative embodiments in Part A for each of X^1 , X^2 , n_1 or n_2 , in combination with any other of the disclosed alternative embodiments in Part A for each of X^1 , X^2 , n_1 , or n_2 , as well as a pharmaceutically acceptable salt of any such combination.


Embodiments of Aspect (1) Part B

- [0051] In another embodiment of Aspect (1), n_1 and n_2 are each 1.
- [0052] In another embodiment of Aspect (1), n_1 and n_2 are each 2.
- [0053] In another embodiment of Aspect (1), n_1 is 1; and n_2 is 2.
- [0054] In another embodiment of Aspect (1), n_1 is 2 and n_2 is 1.
- [0055] In another embodiment of Aspect (1), X^1 is H; and X^2 is F.
- [0056] In another embodiment of Aspect (1), X^1 is F; and X^2 is H.
- [0057] In another embodiment of Aspect (1), X^1 and X^2 are each H.
- [0058] In another embodiment of Aspect (1), X^1 and X^2 are each F.

- [0059] In another embodiment of Aspect (1), X^1 is Cl; and X^2 is H.
 [0060] In another embodiment of Aspect (1), X^1 is H; and X^2 is Cl.
 [0061] In another embodiment of Aspect (1), X^1 and X^2 are each Cl.
 [0062] In another embodiment of Aspect (1), X^1 is Cl; and X^2 is F.
 [0063] In another embodiment of Aspect (1), X^1 is F; and X^2 is Cl.

Embodiments of Aspect (1) Part C

[0064] In an embodiment of Aspect (1), the compound of formula g(1) can be made by reacting a compound of formula f(1) with reactant y(1) to yield the compound of g(1):



wherein LG represents a leaving group, and each of X^2 , and n_2 are as defined in Aspect (1), or as in any of the embodiments of Aspect (1) Part A. A non-limiting example of a leaving group includes a halo group such as Cl, Br, or F. Various compounds of reactant y(1) are commercially available, such as 2-fluoro-4-aminophenol and 4-aminophenol. Also, the skilled artisan would be able to make any variation of reactant y(1) using commercially available starting materials and by using known techniques to modify these commercially available starting materials to yield various compounds within the scope of reactant y(1).

[0065] The reaction in this embodiment is advantageously carried out under suitable reaction conditions. Non-limiting examples of suitable reaction conditions include using suitable solvents such as polar solvents. Non-limiting examples of polar solvents that can be used include tetrahydrofuran (THF), dimethylacetamide (DMA), dimethylsulfoxide (DMSO), dimethylformamide (DMF), ethyl acetate, N-methyl pyrrolidone (NMP), propylene carbonate, and the like, or mixtures thereof. In another embodiment, the polar solvent is dimethylacetamide (DMA). In another embodiment, the polar solvent is dimethylsulfoxide (DMSO). In another embodiment, the polar solvent is dimethylformamide (DMF). In another embodiment, the polar solvent is ethyl acetate. In another embodiment, the polar solvent is N-methyl pyrrolidone (NMP). In another embodiment, the polar solvent is propylene carbonate. In another embodiment, the solvent is a mixture of solvents, such as a mixture comprising THF and DMA.

[0066] The reactants f(1) and y(1) can be added together at a temperature ranging from about 10 °C to about 30 °C, or alternatively, from about 15 °C to about 28 °C, or alternatively, from about 20 °C to about 25 °C. The mixture is then heated to a temperature ranging from about 80 °C to about 125 °C, or alternatively, from about 95 °C to about 110 °C, or alternatively, from about 100 °C to about 105 °C, and the selected temperature is maintained until the reaction is complete.

[0067] Other non-limiting examples of suitable reaction conditions in this step of Aspect (1) include the use of a suitable base, such as a metal hydroxide or a non-nucleophilic base. Examples of metal hydroxides include sodium hydroxide or potassium hydroxide. Non-limiting examples of non-nucleophilic bases that can be used include lithium diisopropylamide, lithium tetramethylpiperidide, and alkali metal alkoxides such as sodium tert-butoxide, potassium tert-butoxide, sodium-pentoxide, and the like, or mixtures thereof. Preferably, the base is sodium tert-butoxide or sodium tert-pentoxide. In one embodiment, the base is sodium tert-pentoxide. Typically the sodium tert-pentoxide is commercially available as 35 weight percent solution of base in tetrahydrofuran, or as a 95 weight percent solid reagent. Preferably, the sodium tert-pentoxide is a 95 weight percent solid.


[0068] Typically, approximately 1.1 to 3.0 molar equivalents of base are used relative the moles of f(1) that are used. More preferably, 1.3 to 2.5 molar equivalents of base are used relative the moles of f(1) that are used. More preferably, 1.5 to 2.2 molar equivalents of base are used relative the moles of f(1) that are used. More preferably, 1.7 to 2.1 molar equivalents of base are used relative the moles of f(1) that are used.

[0069] Typically, the amount of molar equivalents of amino phenol that are used exceeds the molar equivalents of base that are used. In one embodiment, 1.1 to 2 molar equivalents of amino phenol are used relative to the molar equivalents of base that are used.

[0070] Once the reaction is substantially complete, the reaction mixture can be cooled to a temperature ranging from about 10 °C to about 25 °C. Precooled water can be charged at a rate to maintain a temperature that ranges from about 5 °C to about 35 °C. Alternatively, the precooled water can be charged at a rate to maintain a temperature that ranges from about 10 °C to about 25 °C. As a non-limiting example, the precooled water can be at a temperature ranging from about 0 °C to about 10 °C. As another non-limiting example, the precooled water can be at a temperature ranging from about 2 °C to about 7 °C. The precipitate can be collected by filtration under standard conditions and purified by standard purification techniques.

Embodiments of Aspect (1) Part D

[0071] In an embodiment of Aspect (1), the compound of formula f(1) can be made by converting a compound of formula e(1) to the compound of formula f(1):




wherein LG represents a leaving group. Non-limiting examples of leaving groups that can be used include halo groups (e.g., Cl, Br, or F) that can be added by halogenating agents. Non-limiting examples of halogenating agents that can be used include chlorinating agents, such as SOCl_2 , SO_2Cl_2 , COCl_2 , PCl_5 , POCl_3 , and the like.

[0072] The reaction is advantageously carried out under suitable reaction conditions. Non-limiting examples of suitable reaction conditions in Part D of Aspect (1) include the use of suitable solvents. Non-limiting example of suitable solvents that can be used during the halogenation of the compound of formula e(1) include a polar, aprotic solvent, such as CH_3CN , DMF, and the like, or mixtures thereof. In other embodiments, the chlorination can be carried out using POCl_3 in acetonitrile, COCl_2 in DMF, or SOCl_2 in DMF. The addition of the chlorination agent is advantageously carried out at a temperature ranging from about 60 °C to about 90 °C. In another embodiment, the addition of the chlorination agent can be carried out at a temperature ranging from about 70 °C to about 85 °C. In another embodiment, the addition of the chlorination agent can be carried out at a temperature ranging from about 74 °C to about 80 °C. The product can then be collected by filtration and purified using standard techniques.

Embodiments of Aspect (1) Part E

[0073] In an embodiment of Aspect (1), reactant z(1) can be made by reacting reactant z(1a) with a chlorinating agent to yield reactant z(1):




wherein X^1 is Br, Cl, or F; and $n1$ is 1-2. Compounds of reactant $z(1a)$ can be made according to the process described in Example 25 of WO 2005/030140 A2, and the skilled artisan would be able to make any necessary substitutions using commercially available starting materials to come up with various compounds within the scope of reactant $z(1a)$. Example 25 in WO 2005/030140 A2 is incorporated herein by reference.

[0074] The reaction is advantageously carried out under suitable reaction conditions. Non-limiting examples of suitable reaction conditions include using a chlorinating agent such as $POCl_3$, oxalyl chloride, and the like. In another embodiment, oxalyl chloride is used as a chlorinating agent. Non-limiting examples of suitable reaction conditions include carrying out the reaction at a temperature in the range from about 0 °C to about 25 °C, or alternatively at a temperature in the range from about 5 °C to about 20 °C. Other non-limiting examples of suitable reaction conditions include carrying out the reaction in a suitable solvent. Non-limiting examples of suitable solvents that can be used include polar aprotic solvents, such as halogenated hydrocarbons (e.g., dichloromethane and chloroform), ethers (e.g., Et_2O), dioxane, tetrahydrofuran (THF) containing catalytic DMF, and the like, or mixtures thereof. The resulting solution containing reactant $z(1)$ can be used, without further processing, to make the compound of formula I.

Other Embodiments of Aspect (1)

[0075] In another embodiment of Aspect (1), the compound of formula I is a compound of formula IA-1:




IA-1


or a pharmaceutically acceptable salt thereof, wherein:

X^1 is H, Cl, Br, or F; and X^2 is H, Cl, Br, or F. Compound IA can be in the free base form or it can be converted to a pharmaceutically acceptable salt thereof. Accordingly, compound IA can be converted to its L-malate salt by the addition of L-malic acid and a suitable solvent.


[0076] In another embodiment of Part D of Aspect (1), the compound of formula e(1) is compound e(2):




and the compound of formula f(1) is compound f(2):




[0077] In another embodiment of Part C of Aspect (1), the compound of formula f(1) is compound f(2):



reactant y(1) is reactant (y)(2):




wherein X^2 is hydrogen or fluoro; and
the compound of formula g(1) is of formula g(2):




[0078] In a further embodiment, the reaction employs a non-nucleophilic base. In a further embodiment, the non-nucleophilic base is an alkali metal alkoxide; and the reaction is carried out in a polar solvent. In a further embodiment, the alkali metal alkoxide is sodium tert-butoxide, and the polar solvent is DMA.


[0079] In another embodiment of Part C of Aspect (1), the compound of formula f(1) is compound f(2):




reactant y(1) is reactant (y)(3):




wherein X^2 is hydrogen or fluoro; and
the compound of formula g(1) is compound g(3):




[0080] In another embodiment of Aspect (1) of this disclosure, the compound of formula g(1) is compound g(3):



reactant z(1) is reactant (z)(2):



the compound of formula I is compound IA:



IA

[0081] In a further embodiment, the reaction is carried out in the presence of an inorganic base. In a further embodiment, the inorganic base is K₂CO₃, and the solvent employed in this reaction is a combination of THF and H₂O.

[0082] In another embodiment of Aspect (1) of this disclosure, X¹ and X² for each of formula g(1) and reactant z(1) are each selected from Cl or F. In another embodiment, X¹ and X² for each of formula g(2), and reactant z(1) are both F.


[0083] The compound of formula f(2), or a pharmaceutically acceptable salt thereof, can be made by converting the compound of formula e(2) to a compound of formula f(2) with a chlorinating agent in a suitable solvent:




The compound of formula f(2) can be in its free base form or converted to a pharmaceutically acceptable salt thereof. The reaction conditions that can be used in this aspect include any of the reaction conditions disclosed in Part E of Aspect (1).

Aspect 2: Processes for Making Compounds of Formula g(2)

[0084] Aspect (2) of the disclosure relates to a process of preparing compound g(2):



or a pharmaceutically acceptable salt thereof; the process comprising reacting compound f(2) with reactant y(3) under basic conditions (e.g., using 2,6-lutidine) in an appropriate solvent to yield compound g(3):




The reaction conditions that can be used in this aspect include any of the reaction conditions disclosed in Part C of Aspect (1).


[0085] Alternative reaction conditions that can be used in this aspect include any of the reaction conditions disclosed in Parts C and D of Aspect (1).

Aspect 3: Processes for Making Compounds of IB

[0086] As indicated above, in one aspect, the invention provides a process for preparing compound IB:



from compound IA:



IA;

comprising:

- (a) heating and agitating a mixture comprising compound IA and L-malic acid, methylethyl ketone, and water;
- (b) cooling the mixture;
- (c) vacuum distilling the mixture successively; and
- (d) isolating the compound of IB by filtration.

[0087] In one embodiment of this aspect, compound IA is admixed with a sufficient amount of L-malic acid in a methylethyl ketone (MEK)/water (1:1) mixture. Alternatively, L-malic acid is added as a solution in water to a mixture of compound IA in methyl ethyl ketone. Generally the amount of L-malic is greater than 1 molar equivalent relative to compound IA. The mixture of compound IA and L-malic acid in MEK/water is heated at about 40-70 °C, and preferably at about 50-60 °C, and more preferably at about 55-60 °C with agitation, such as by stirring or the like, for about 1 to about 5 hours. At the end of the heating, the mixture is optionally clarified by filtering to give a clear solution. The resulting clear solution is then vacuum distilled from 1 to about 5 times at 150 to 200 mm Hg and a maximum jacket temperature of 55 °C to provide the desired crystalline compound of IB.

[0088] In one embodiment, L-malic acid is charged as a solution in water to compound IA. Generally the amount of L-malic is greater than 1 molar equivalent relative to compound IA. The mixture of compound IA and L-malic acid in MEK/water is heated at about 40-70 °C, and preferably at about 50-60 °C, and more preferably at about 55-60 °C with agitation, such as by stirring or the like, for about 1 to about 5 hours. At the end of the heating, the mixture is optionally clarified by filtering to give a clear solution which is at a temperature of about 30-40 °C, and more preferably at a temperature of about 33-37 °C. This clear solution is optionally seeded to facilitate crystallization. After seeding, the resulting mixture is vacuum distilled as provided above.

[0089] In one embodiment, compound IB is in the N-1 form. In another embodiment, compound IB is in the N-2 form. In another embodiment, compound IB is a mixture of the N-1 form and the N-2 form. Processes for preparing the N-1 and N-2 forms of compound IB

are disclosed in WO 2010/083414 (PCT/US2010021194), the entire contents of which are incorporated herein by reference.

[0090] In another embodiment, the disclosure relates to compound IA or IB admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment, the compound is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[0091] In another embodiment, the disclosure relates to compound IA admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment, the compound is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[0092] In another embodiment, the disclosure relates to compound IB admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment, the compound is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[0093] In another embodiment, the disclosure relates to compound IB in the N-1 form admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment, the compound is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[0094] In another embodiment, the disclosure relates to compound IB in the N-2 form admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment, the compound is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[0095] In another embodiment, the disclosure relates to compound IB as a mixture of the N-1 form and the N-2 form admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment, the compound is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

Pharmaceutical Compositions

[0096] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound I, IA, or IB. Various carriers used in formulating pharmaceutically acceptable compositions and known techniques for their bulk preparation and subsequent production into unit dosage forms are employed to make the pharmaceutical compositions disclosed herein and are described in Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. D. B. Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York. The amount of carriers and excipients used in a composition can be varied proportionally according to the amount of active ingredient used (that is, Compound I, IA or IB).

[0097] In one embodiment, the pharmaceutical composition is a tablet.

[0098] In another embodiment, the pharmaceutical composition is a capsule.

[0099] In another embodiment, the pharmaceutical composition comprises Compound IA.

[00100] In another embodiment, the pharmaceutical composition comprises Compound IB.

[00101] In another embodiment, the pharmaceutical composition comprises Compound IB as the N-1 polymorph.

[00102] In another embodiment, the pharmaceutical composition comprises Compound IB as the N-2 polymorph.

[00103] In another embodiment, the pharmaceutical composition comprises Compound IB as a mixture of the N-1 form and the N-2 form.

[00104] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; one or more fillers; one or more disintegrants; one or more glidants; and one or more lubricants.

[00105] In this embodiment, the filler comprises microcrystalline cellulose.

[00106] In this embodiment, the disintegrant comprises croscarmellose sodium.

[00107] In this embodiment, the disintegrant comprises croscarmellose sodium and sodium starch glycolate.

[00108] In this embodiment, the glidant comprises fumed silica.

[00109] In this embodiment, the lubricant comprises stearic acid.

[00110] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; lactose; hydroxypropyl cellulose; croscarmellose sodium; colloidal silicon dioxide; and magnesium stearate.

[00111] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; hydroxypropyl cellulose; a surfactant; croscarmellose sodium; colloidal silicon dioxide; and magnesium stearate.

[00112] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; croscarmellose sodium; fumed silica; and stearic acid.

[00113] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; anhydrous lactose; hydroxypropyl cellulose; croscarmellose sodium; silicon dioxide; and magnesium stearate.

[00114] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; anhydrous lactose; hydroxypropyl cellulose; a surfactant; croscarmellose sodium; silicon dioxide; and magnesium stearate.

[00115] In another aspect, the disclosure provides a pharmaceutical composition according to Tables 1, 2, 2A, 3, 4, 5, and 6 as provided above. The compositions are prepared according to methods available to the skilled artisan. For example, the Tablet


formulations are prepared by combining, blending, and compacting the components of the tablet compositions. The capsule compositions are prepared by combining and blending the components and then placing the blend in a gelatin capsule.


[00116] For example, the 25 mg capsules (Table 3, 10 percent drug load formulation) are prepared as follows. The drug substance is delumped through a mill. The delumped drug substance is then co-screened with an equal volume Prosolv HD90. The excipients, except for stearic acid, are screened and charged to a blender along with the co-screened drug substance. The mixture is blended in a V-Blender. This process is repeated to manufacture a second subplot of unlubricated blend. The two sublots are then combined together in a V-blender and lubricated with stearic acid which has been co-screened with an equal volume of unlubricated blend. The final blend is then encapsulated into opaque, size 1 gelatin capsules using an automated capsule filling machine. The capsules are then weight sorted through an automatic weight sorter.

[00117] The 100-mg capsules (Table 4, 50% drug load formulation) are manufactured in two equal sublots of 5 kg of blend which are combined prior to lubricant blend. The drug substance is delumped through a mill. The excipients, except for stearic acid, are screened and charged to the mixer along with the delumped drug substance. The mixture is blended with a high shear mixer. The process is repeated to manufacture a second subplot of unlubricated blend. The final blend is then encapsulated into Swedish opaque, size 1 gelatin capsules using an automated capsule filling machine. The capsules are then weight sorted through an automatic weight sorter.

[00118] The 50 and 60 mg capsules (Tables 5 and 6) are prepared in a similar fashion as the 25 and 100 mg capsules.

[00119] In another aspect, the disclosure relates to a pharmaceutical composition comprising a compound of Formula IA or IB and a pharmaceutically acceptable carrier admixed with less than 100 ppm of 6,7-dimethoxy-quinoline-4-ol. 6,7-dimethoxy-quinoline-



4-ol, the structure of which is , can be used as reagent e(1) to make chloride f(1) and is a byproduct that may form during the synthesis of Compound IA or IB. Minimizing the concentration of contaminants or byproducts such as 6,7-dimethoxy-quinoline-4-ol in pharmaceutical compositions destined for human administration is desirable.

[00120] In one embodiment, the pharmaceutical composition as defined in any of the previous embodiments (for example, the pharmaceutical composition of Tables 1, 2, 2A, 3, 4, 5, and 6) is admixed with 100 ppm 6,7-dimethoxy-quinoline-4-ol.

[00121] In another embodiment, the pharmaceutical composition as defined in any of the previous embodiments is admixed with 50 ppm 6,7-dimethoxy-quinoline-4-ol.

[00122] In another embodiment, the pharmaceutical composition as defined in any of the previous embodiments is admixed with 25 ppm 6,7-dimethoxy-quinoline-4-ol.

[00123] In another embodiment, the pharmaceutical composition as defined in any of the previous embodiments is admixed with 15 ppm 6,7-dimethoxy-quinoline-4-ol.

[00124] In another embodiment, the pharmaceutical composition as defined in any of the previous embodiments is admixed with 10 ppm 6,7-dimethoxy-quinoline-4-ol.

[00125] In another embodiment, the pharmaceutical composition as defined in any of the previous embodiments is admixed with 5 ppm 6,7-dimethoxy-quinoline-4-ol.

[00126] In another embodiment, the pharmaceutical composition as defined in any of the previous embodiments is admixed with 2.5 ppm 6,7-dimethoxy-quinoline-4-ol.

[00127] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; one or more fillers; one or more disintegrants; one or more glidants; and one or more lubricants admixed with 100 ppm or less 6,7-dimethoxy-quinoline-4-ol.

[00128] In this embodiment, the filler comprises microcrystalline cellulose.

[00129] In this embodiment, the disintegrant comprises croscarmellose sodium.

[00130] In this embodiment, the disintegrant comprises croscarmellose sodium and sodium starch glycolate.

[00131] In this embodiment, the glidant comprises fumed silica.

[00132] In this embodiment, the lubricant comprises stearic acid.

[00133] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; croscarmellose sodium; fumed silica; and stearic acid; admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment of this embodiment, the composition is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with

5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[00134] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; anhydrous lactose; hydroxypropyl cellulose; a surfactant; croscarmellose sodium; silicon dioxide; and magnesium stearate; admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment of this embodiment, the composition is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[00135] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; croscarmellose sodium; fumed silica; and stearic acid; ; admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment of this embodiment, the composition is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

EXAMPLES


[00136] The invention is illustrated further by the following examples in Scheme 1 and the description thereof, which are not to be construed as limiting the invention in scope or spirit to the specific procedures described in them. Those having skill in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the invention, as demonstrated by the following examples. Those skilled in the art will also recognize that it may be necessary to utilize different solvents or reagents to achieve some of the above transformations. Unless otherwise specified, all reagents and solvents are of standard commercial grade and are used without further purification. The

appropriate atmosphere to run the reaction under, for example, air, nitrogen, hydrogen, argon, and the like, will be apparent to those skilled in the art.

Preparation of N-(4-{{6,7-bis(methoxy)quinolin-4-yl}oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and the (L)-malate salt thereof.

[00137] A synthetic route that can be used for the preparation of N-(4-{{6,7-bis(methoxy)quinolin-4-yl}oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and the (L)-malate salt thereof is depicted in Figure 1:

Figure 1



Preparation of 4-Chloro-6,7-dimethoxy-quinoline

[00138] A reactor was charged sequentially with 6,7-dimethoxy-quinoline-4-ol (47.0 kg) and acetonitrile (318.8 kg). The resulting mixture was heated to approximately 60 °C, and phosphorus oxychloride (POCl₃, 130.6 kg) was added. After the addition of POCl₃, the temperature of the reaction mixture was raised to approximately 77 °C. The reaction was deemed complete (approximately 13 hours) when less than 3% of the starting material remained (in-process high-performance liquid chromatography [HPLC] analysis). The reaction mixture was cooled to approximately 2 – 7 °C and then quenched into a chilled solution of dichloromethane (DCM, 482.8 kg), 26 % NH₄OH (251.3 kg), and water (900 L). The resulting mixture was warmed to approximately 20 – 25 °C, and phases were separated.

The organic phase was filtered through a bed of AW hyflo super-cel NF (Celite; 5.4 kg) and the filter bed was washed with DCM (118.9 kg). The combined organic phase was washed with brine (282.9 kg) and mixed with water (120 L). The phases were separated and the organic phase was concentrated by vacuum distillation with the removal of solvent (approximately 95 L residual volume). DCM (686.5 kg) was charged to the reactor containing organic phase and concentrated by vacuum distillation with the removal of solvent (approximately 90 L residual volume). Methyl t-butyl ether (MTBE, 226.0 kg) was then charged and the temperature of the mixture was adjusted to -20 to -25 °C and held for 2.5 hours resulting in solid precipitate which was then filtered and washed with n-heptane (92.0 kg), and dried on a filter at approximately 25 °C under nitrogen to afford the title compound. (35.6 kg).

Preparation of 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine

[00139] 4-Aminophenol (24.4 kg) dissolved in N,N-dimethylacetamide (DMA, 184.3 kg) was charged to a reactor containing 4-chloro-6,7-dimethoxyquinoline (35.3 kg), sodium t-butoxide (21.4 kg) and DMA (167.2 kg) at 20-25 °C. This mixture was then heated to 100-105 °C for approximately 13 hours. After the reaction was deemed complete as determined using in-process HPLC analysis (<2% starting material remaining), the reactor contents were cooled at 15 to 20 °C and water (pre-cooled, 2 to 7 °C, 587 L) charged at a rate to maintain 15 to 30 °C temperature. The resulting solid precipitate was filtered, washed with a mixture of water (47 L) and DMA (89.1 kg) and finally with water (214 L). The filter cake was then dried at approximately 25 °C on filter to yield crude 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine (59.4 kg wet, 41.6 kg dry calculated based on LOD). Crude 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine was refluxed (approximately 75 °C) in a mixture of tetrahydrofuran (THF, 211.4 kg) and DMA (108.8 kg) for approximately 1 hour and then cooled to 0-5 °C and aged for approximately 1 h after which time the solid was filtered, washed with THF (147.6 kg) and dried on a filter under vacuum at approximately 25 °C to yield 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine (34.0 kg).

Alternative Preparation of 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine

[00140] 4-chloro-6,7-dimethoxyquinoline (34.8 kg) and 4-aminophenol (30.8 kg) and sodium tert pentoxide (1.8 equivalents) 88.7 kg, 35 wt percent in THF) were charged to a reactor, followed by N,N-dimethylacetamide (DMA, 293.3 kg). This mixture was then heated to 105-115 °C for approximately 9 hours. After the reaction was deemed complete as

determined using in-process HPLC analysis (<2% starting material remaining), the reactor contents were cooled at 15 to 25 °C and water (315 kg) was added over a two hour period while maintaining the temperature between 20 and 30 °C. The reaction mixture was then agitated for an additional hour at 20 to 5 °C. The crude product was collected by filtration and washed with a mixture of 88 kg water and 82.1 kg DMA, followed by 175 kg water. The product was dried on a filter drier for 53 hours. The LOD showed less than 1% w/w.

[00141] In an alternative procedure, 1.6 equivalents of sodium tert-pentoxide were used and the reaction temperature was increased from 110-120 °C. In addition, the cool down temperature was increased to 35-40 °C and the starting temperature of the water addition was adjusted to 35-40 °C, with an allowed exotherm to 45 °C.

Preparation of 1-(4-fluorophenylcarbamoyl)-cyclopropanecarboxylic acid

[00142] Triethylamine (19.5 kg) was added to a cooled (approximately 5 °C) solution of cyclopropane-1,1-dicarboxylic acid (24.7 kg) in THF (89.6 kg) at a rate such that the batch temperature did not exceed 5 °C. The solution was stirred for approximately 1.3 hours, and then thionyl chloride (23.1 kg) was added, keeping the batch temperature below 10 °C. When the addition was complete, the solution was stirred for approximately 4 h keeping temperature below 10 °C. A solution of 4-fluoroaniline (18.0 kg) in THF (33.1 kg) was then added at a rate such that the batch temperature did not exceed 10 °C. The mixture was stirred for approximately 10 hours after which the reaction was deemed complete. The reaction mixture was then diluted with isopropyl acetate (218.1 kg). This solution was washed sequentially with aqueous sodium hydroxide (10.4 kg, 50 % dissolved in 119 L of water) further diluted with water (415 L), then with water (100 L) and finally with aqueous sodium chloride (20.0 kg dissolved in 100 L of water). The organic solution was concentrated by vacuum distillation (100 L residual volume) below 40 °C followed by the addition of n-heptane (171.4 kg), which resulted in the precipitation of solid. The solid was recovered by filtration and washed with n-Heptane (102.4 kg) resulting in wet crude, 1-(4-fluorophenylcarbamoyl)-cyclopropanecarboxylic acid (29.0 kg). The crude, 1-(4-fluorophenylcarbamoyl)-cyclopropanecarboxylic acid was dissolved in methanol (139.7 kg) at approximately 25 °C followed by the addition of water (320 L) resulting in slurry which was recovered by filtration, washed sequentially with water (20 L) and n-heptane (103.1 kg) and then dried on the filter at approximately 25 °C under nitrogen to afford the title compound (25.4 kg).

Preparation of 1-(4-Fluoro-phenylcarbamoyl)-cyclopropanecarbonyl chloride

[00143] Oxalyl chloride (12.6 kg) was added to a solution of 1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid (22.8 kg) in a mixture of THF (96.1 kg) and N, N-dimethylformamide (DMF; 0.23 kg) at a rate such that the batch temperature did not exceed 25 °C. This solution was used in the next step without further processing.

Alternative Preparation of 1-(4-Fluoro-phenylcarbamoyl)-cyclopropanecarbonyl chloride

[00144] A reactor was charged with 1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid (35 kg), 344 g DMF, and 175kg THF. The reaction mixture was adjusted to 12-17 °C and then to the reaction mixture was charged 19.9 kg of oxalyl chloride over a period of 1 hour. The reaction mixture was left stirring at 12-17 °C for 3 to 8 hours. This solution was used in the next step without further processing.

Preparation of cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide (Compound IA)

[00145] The solution from the previous step containing 1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarbonyl chloride was added to a mixture of compound 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine (23.5 kg) and potassium carbonate (31.9 kg) in THF (245.7 kg) and water (116 L) at a rate such that the batch temperature did not exceed 30 °C. When the reaction was complete (in approximately 20 minutes), water (653 L) was added. The mixture was stirred at 20-25 °C for approximately 10 hours, which resulted in the precipitation of the product. The product was recovered by filtration, washed with a pre-made solution of THF (68.6 kg) and water (256 L), and dried first on a filter under nitrogen at approximately 25 °C and then at approximately 45 °C under vacuum to afford the title compound (41.0 kg, 38.1 kg, calculated based on LOD).

Alternative Preparation of cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide

[00146] A reactor was charged with 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine (35.7 kg, 1 equivalent), followed by 412.9 kg THF. To the reaction mixture was charged a solution of 48.3 K₂CO₃ in 169 kg water. The acid chloride solution of described in the Alternative Preparation of 1-(4-Fluoro-phenylcarbamoyl)-cyclopropanecarbonyl chloride above was transferred to the reactor containing 4-(6,7-dimethoxy-quinoline-4-yloxy)-

phenylamine while maintaining the temperature between 20-30 °C over a minimum of two hours. The reaction mixture was stirred at 20-25 °C for a minimum of three hours. The reaction temperature was then adjusted to 30-25 °C and the mixture was agitated. The agitation was stopped and the phases of the mixture were allowed to separate. The lower aqueous phase was removed and discarded. To the remaining upper organic phase was added 804 kg water. The reaction was left stirring at 15-25 °C for a minimum of 16 hours.

[00147] The product precipitated. The product was filtered and washed with a mixture of 179 kg water and 157.9 THF in two portions. The crude product was dried under a vacuum for at least two hours. The dried product was then taken up in 285.1 kg THF. The resulting suspension was transferred to reaction vessel and agitated until the suspension became a clear (dissolved) solution, which required heating to 30-35 °C for approximately 30 minutes. 456 kg water was then added to the solution, as well as 20 kg SDAG-1 ethanol (ethanol denatured with methanol over two hours. The mixture was agitated at 15-25 °C for at least 16 hours. The product was filtered and washed with a mixture of 143 kg water and 126.7 THF in two portions. The product was dried at a maximum temperature set point of 40 °C.

[00148] In an alternative procedure, the reaction temperature during acid chloride formation was adjusted to 10-15 °C. The recrystallization temperature was changed from 15-25 °C to 45-50 °C for 1 hour and then cooled to 15-25 °C over 2 hours.

Preparation of cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L) malate salt (Compound IB)

[00149] Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide (1-5; 13.3 kg), L-malic acid (4.96 kg), methyl ethyl ketone (MEK; 188.6 kg) and water (37.3 kg) were charged to a reactor and the mixture was heated to reflux (approximately 74 °C) for approximately 2 hours. The reactor temperature was reduced to 50 to 55 °C and the reactor contents were filtered. These sequential steps described above were repeated two more times starting with similar amounts of 1-5 (13.3 kg), L-Malic acid (4.96 kg), MEK (198.6 kg) and water (37.2 kg). The combined filtrate was azeotropically dried at atmospheric pressure using MEK (1133.2 kg) (approximate residual volume 711 L; KF ≤ 0.5 % w/w) at approximately 74 °C. The temperature of the reactor contents was reduced to 20 to 25 °C and held for approximately 4 hours resulting in solid precipitate which was filtered, washed with MEK (448 kg) and dried under vacuum at 50°C to afford the title compound (45.5 kg).

Alternative Preparation of cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L) malate salt

[00150] Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide (47.9 kg), L-malic acid (17.2), 658.2 kg methyl ethyl ketone, and 129.1 kg water (37.3 kg) were charged to a reactor and the mixture was heated 50-55 °C for approximately 1-3 hours, and then at 55-60 °C for an additional 4-5 hours. The mixture was clarified by filtration through a 1 µm cartridge. The reactor temperature was adjusted to 20-25 °C and vacuum distilled with a vacuum at 150-200 mm Hg with a maximum jacket temperature of 55 °C to the volume range of 558-731 L.

[00151] The vacuum distillation was performed two more times with the charge of 380 kg and 380.2 kg methyl ethyl ketone, respectively. After the third distillation, the volume of the batch was adjusted to 18 v/w of Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide by charging 159.9 kg methyl ethyl ketone to give a total volume of 880L. An additional vacuum distillation was carried out by adjusting 245.7 methyl ethyl ketone. The reaction mixture was left with moderate agitation at 20-25 °C for at least 24 hours. The product was filtered and washed with 415.1 kg methyl ethyl ketone in three portions. The product was dried under a vacuum with the jacket temperature set point at 45 °C.

[00152] In an alternative procedure, the order of addition was changed so that a solution of 17.7 kg L-malic acid dissolved in 129.9 kg water was added to Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide (48.7 kg) in methyl ethyl ketone (673.3 kg).

Preparation of Compound IB, Form N-1

[00153] A solution was prepared by adding tetrahydrofuran (12 mL/g-bulk-LR (limiting reagent); 1.20 L) and N-(4-[[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (100 g; 1.00 equiv; 100.00 g) and (L)-malic acid (1.2 equiv (molar); 32.08 g) to a 1 L reactor. Water (0.5317 mL/g-bulk-LR; 53.17 mL) was added and the solution was heated to 60 °C and maintained at that temperature for one hour until the solids were fully dissolved. The solution was passed through a Polish Filter.

[00154] At 60 °C, acetonitrile (12 mL/g-bulk-LR; 1.20 L) was added over a period of 8 hours. The solution was held at 60 °C for 10 hours. The solution was then cooled to 20 °C and held for 1 hour. The solids were filtered and washed with acetonitrile (12 mL/g-bulk-LR;

1.20 L). The solids were dried at 60 °C (25 mm Hg) for 6 hours to afford compound (I), Form N-1 (108 g; 0.85 equivalent; 108.00 g; 85.22% yield) as a white crystalline solid.

Alternate Preparation of Compound IB, Form N-1

[00155] A solution was prepared with 190 mL tetrahydrofuran (110 mL), methyl isobutyl ketone, and 29 mL water. Next, 20 mL of this solution were transferred into an amber bottle, and then saturated by adding N-(4-{{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (L)-malate until a thick slurry formed, and aging for at least 2 hours with stirring at room temperature. The solids were removed by filtration through a Buchner funnel, rendering a clear saturated solution.

[00156] Separately, a powder blend was made with known amounts of two batches of compound IB: (1) 300 mg of batch 1, which contained approximately 41% compound IB, Form N-1 and 59% compound IB, Form N-2 by Raman spectroscopy analysis, and (2) 200 mg of batch 2, which had a XPRD pattern similar to compound IB, Form N-2.

[00157] The compound IB, Form N-1 and compound (I), Form N-2 powder blend was added into the saturated solution, and the slurry was aged under magnetic stirring at room temperature for 25 days. The slurry was then sampled and filtered through a Buchner funnel to obtain 162 mg of wet cake. The wet cake was dried in a vacuum oven at 45 °C to afford 128 mg of crystalline compound IB in the N-1 form.

Preparation of Crystalline Compound IB, Form N-2

Preparation of Crystalline Compound IB, Form N-2 Seed Crystals

[00158] A solution was prepared by combining 20 ml of acetone and 300 mg of compound IA (N-(4-{{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide) in a 25ml screw capped vial. Next, 0.758ml of a 0.79M (L)-malic acid stock solution was added to the vial with magnetic stirring. The solution was then left stirring for 24 hours at ambient temperature. The sample was then suction filtered with 0.45µm PTFE filter cartridge and dried *in vacuo* at ambient temperature overnight.

Preparation of Crystalline Compound IB, Form N-2.

[00159] To a reactor were added N-(4-{{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (48 g; 1.00 equiv; 48.00 g) and tetrahydrofuran (16.5 mL/g-bulk-LR; 792.00 mL). The water content was adjusted to 1 wt% water. The solution was heated to 60 °C. Once dissolved, the solution was passed through a polish filter to provide the first solution.

[00160] In a separate reactor, (L)-malic acid (1.2 equiv (molar); 15.40 g) was dissolved into methyl isobutyl ketone (10 mL/g-bulk-LR; 480.00 mL) and tetrahydrofuran (1 mL/g-bulk-LR; 48.00 mL). Next, 50 mL of the (L)-malic acid solution was added to the first solution at 50 °C. Seed crystals were added (1%, 480 mg) and the malic acid solution was added at 50 °C dropwise via an addition funnel (1.3 mL/min over 3 hours). The slurry was held at 50 °C for 18 hours and then was cooled to 25 °C over 30 minutes. The solids were filtered, and washed with 20% tetrahydrofuran/methyl isobutyl ketone (10V, 480 mL). The solids were dried under vacuum at 60 °C for 5 hours to afford compound IB (55.7 g; 0.92 equivalent; 55.70 g; 91.56% yield) as an off-white crystalline solid.

Stability Studies of Pharmaceutical Compositions

[00161] The pharmaceutical capsule compositions of Tables 3 and 4 were prepared by mixing the ingredients according to processes known in the art.

Table 3

Ingredient	mg/unit dose
Compound IB (10 % drug load as Compound IA)	25
Microcrystalline Cellulose	196.75
Croscarmellose sodium	12.5
Sodium starch glycolate	12.5
Fumed Silica	0.75
Stearic acid	2.5
Total Fill Weight	250

Table 4

Ingredient	mg/unit dose
Compound IB (50 % drug load as Compound IA)	100
Silicified Microcrystalline Cellulose	75.40
Croscarmellose sodium	10.00
Sodium Starch Glycolate	10.00
Fumed silica	0.6
Stearic Acid	4.0
Total Fill Weight	200

[00162] The capsule compositions were subjected to stability studies to monitor the formation of 6,7-dimethoxy-quinoline-4-ol at various temperatures and relative humidities over time. The results are summarized in Tables 7A and 7B and Tables 8A and 8B.

Table 7A: Stability of 25 Mg Capsules (Table 3)

	Conditions	Bottle A1	Bottle A2	Bottle A3	Bottle A4
		PPM of 6,7-dimethoxy-quinoline-4-ol			
Initial T=0	25 °C/60% RH	2	2	3	3
1 Month	25 °C/60% RH	3	4	5	NA
	30 °C/75% RH	4	4	NA	NA
	40 °C/75% RH	9	9	10	NA
3 Months	25 °C/60% RH	5	5	7	NA
	30 °C/75% RH	7	6	NA	NA
	40 °C/75% RH	22	23	24	NA
6 Months	25 °C/60% RH	6	6	7	7 (3M in blister)
	30 °C/75% RH	9	9	NA	NA
	40 °C/75% RH	40	44	43	27 (3M in blister)
9 Months	25 °C/60% RH	7	7	9	8 (6M in blister)
	30 °C/75% RH	13	12	NA	NA
	40 °C/75% RH	NA	NA	68	60 (6M in blister)

M=Months; NA=Not Applicable; RH= Relative Humidity; PPM= Parts per Million. A portion of Bottle A4 was repackaged in a blister pack after being stored in bottles for 3 months.

Table 7B: Stability of 25 Mg Capsules (Table 3)

	Conditions	Bottle B1	Bottle B	Bottle B3	Bottle B4
		PPM of 6,7-dimethoxy-quinoline-4-ol			
Initial T=0	25 °C/60% RH	3	1	2	2
1 Month	25 °C/60% RH	<2	<2	<2	NA
	30 °C/75% RH	<2	<2	NA	NA
	40 °C/75% RH	2	<2	<2	NA
3 Months	25 °C/60% RH	2	<2	<2	NA
	30 °C/75% RH	2	<2	NA	NA
	40 °C/75% RH	3	<2	<2	NA
6 Months	25 °C/60% RH	<2	<2	<2	<2 (3M in blister)
	30 °C/75% RH	2	<2	NA	NA
	40 °C/75% RH	4	<2	3	3 (3M in blister)
9 Months	25 °C/60% RH	<2	<2	<2	<2 (6M in blister)
	30 °C/75% RH	3	<2	NA	NA
	40 °C/75% RH	NA	NA	5	4 (6M in blister)

A portion of Bottle B4 was repackaged in a blister pack after being stored in bottles for 3 months.

Table 8A: Stability of 100 Mg Capsules (Table 4)

	Conditions	Bottle A1	Blister A2	Bottle A3
		PPM of 6,7-dimethoxy-quinoline-4-ol		
Initial T=0	25 °C/60% RH	4	4	6
1 Month	25 °C/60% RH	4	4	6
	30 °C/75% RH	4	NA	6
	40 °C/75% RH	6	6	9
3 Months	25 °C/60% RH	5	5	7
	30 °C/75% RH	6	NA	7
	40 °C/75% RH	10	10	12
6 Months	25 °C/60% RH	5	5	
	30 °C/75% RH	6	NA	
	40 °C/75% RH	11	17	

M=Months; NA=Not Applicable; RH= Relative Humidity; PPM= Parts per Million.

Table 8B: Stability of 100 Mg Capsules (Table 4)

	Conditions	Bottle B1	Blister B2	Bottle B3
		PPM of 6,7-dimethoxy-quinoline-4-ol		
Initial T=0	25 °C/60% RH	1	1	2
1 Month	25 °C/60% RH	<2	<2	<2
	30 °C/75% RH	<2	<2	2
	40 °C/75% RH	<2	<2	2
3 Months	25 °C/60% RH	<2	<2	<2
	30 °C/75% RH	<2	NA	<2
	40 °C/75% RH	<2	<2	2
6 Months	25 °C/60% RH	<2	<2	
	30 °C/75% RH	<2	NA	
	40 °C/75% RH	2	2	

M=Months; NA=Not Applicable; RH= Relative Humidity; PPM= Parts per Million.


[00163] The results summarized in Tables 7A and 7B and 8A and 8B indicate that formation of 6,7-dimethoxy-quinoline-4-ol was minimized to 50 ppm or less over time in the capsule formulations.

[00164] The foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity and understanding. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications can be made while remaining within the spirit and scope of the invention. It will be obvious to one of skill in the art that

changes and modifications can be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled. All references cited herein are incorporated by reference in their entirety.

CLAIMS

1. A process for preparing a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

X^1 is H, Br, Cl, or F;


X^2 is H, Br, Cl, or F;

n_1 is 1-2; and


n_2 is 1-2;

the process comprising:

contacting the compound of formula g(1) with reactant z(1) to yield the compound of formula I:




2. The process according to claim 1, wherein the compound of formula g(1) is made by reacting a compound of formula f(1) with reactant y(1) to yield the compound of formula g(1):




wherein LG represents a leaving group, and each X^2 and n_2 are as defined in claim 1.

3. The process according to claim 2, wherein the compound of formula f(1) is made by converting compound e(1) to the compound of formula f(1):




wherein LG represents a leaving group.

4. The process according to claim 1, wherein reactant z(1) is made by reacting reactant z(1a) with a chlorinating agent to yield reactant z(1):



wherein X^1 is Br, Cl, or F; and $n1$ is 1-2.

5. The process according to claim 1, wherein the compound of formula I is compound IA-1:




or a pharmaceutically acceptable salt thereof, wherein:


X^1 is H, Cl, Br, or F; and

X^2 is H, Cl, Br, or F.


6. The process according to claim 5, wherein the compound of formula f(1) is compound f(2):




reactant y(1) is reactant (y)(2):




wherein X^2 is hydrogen or fluoro; and
the compound of formula g(1) is of formula g(2):




7. The process according to claim 6, wherein the reaction employs a non-nucleophilic base.
8. The process according to claim 7, wherein the non-nucleophilic base is an alkali metal alkoxide; and the reaction is carried out in a polar solvent.
9. The process according to claim 8, wherein the alkali metal alkoxide is sodium tert-butoxide, and the polar solvent is DMA.
10. The process according to claim 8, wherein the alkali metal alkoxide is sodium tert-pentoxide, and the polar solvent is DMA.
11. The process according to claim 1, wherein the compound of formula g(1) is of compound g(3):



reactant z(1) is reactant z(2):




the compound of formula I is compound IA:



12. The process according to claim 11, wherein the reaction is carried out in the presence of an inorganic base.


13. The process according to claim 12, wherein the inorganic base is K_2CO_3 , and the solvent employed in this reaction is a combination of THF and H_2O .

14. A process for preparing compound IB:



IB

from compound IA:




IA

comprising:


- (a) heating and agitating a mixture comprising compound IA and L-malic acid, methylethyl ketone, and water;
- (b) cooling the mixture;
- (c) vacuum distilling the mixture successively; and
- (d) isolating the compound of IB by filtration.

15. A process for preparing compound IB:



IB

from compound IA:



IA

comprising:

- (a) heating and agitating a mixture comprising compound IA and L-malic acid, methylethyl ketone, and water;
 - (b) cooling the mixture;
 - (c) seeding the mixture with the compound of IB;
 - (d) vacuum distilling the mixture; and
 - (e) isolating the compound of IB by filtration.
16. Compound IA or IB admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
17. Compound IB admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
18. Compound IB in the N-1 form admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
19. Compound IB in the N-2 form admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
20. Compound IB as a mixture of the N-1 form and N-2 form admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
21. A pharmaceutical composition according to Table 1.

Table 1

Ingredient	% w/w
Compound I	31.68
Microcrystalline Cellulose (Avicel PH102)	38.85
Lactose anhydrous 60 M	19.42
Hydroxypropyl Cellulose, EXF	3.00
Croscarmellose Sodium	3.00
Total Intra-granular	95.95
Silicon dioxide, Colloidal PWD	0.30
Croscarmellose Sodium	3.00
Magnesium Stearate	0.75
Total	100.00

22. A pharmaceutical composition according to Table 2.

Table 2

Ingredient	(% w/w)
Compound I	25.0-33.3
Microcrystalline Cellulose, NF	q.s
Hydroxypropyl Cellulose, NF	3
Poloxamer, NF	0-3
Croscarmellose Sodium, NF	6.0
Colloidal Silicon Dioxide, NF	0.5
Magnesium Stearate, NF	0.5-1.0
Total	100

23. A pharmaceutical composition according to Table 2A.

Table 2A

Ingredient	% w/w
Compound IB (10 % drug load as Compound IA)	12.67
MCC	51.52
Lactose	25.76
Hydroxypropyl cellulose	3.0
Croscarmellose Sodium	6.0
Colloidal Silicon Dioxide	0.3
Magnesium Stearate	0.75
Total	100

24. A pharmaceutical composition according to Table 3.

Table 3

Ingredient	mg/unit dose
Compound IB (10 % drug load as Compound IA)	25
Silicified Microcrystalline Cellulose	196.75
Croscarmellose sodium	12.5
Sodium starch glycolate	12.5
Fumed Silica	0.75
Stearic acid	2.5
Total Fill Weight	250

25. A pharmaceutical composition according to Table 4.

Table 4

Ingredient	mg/unit dose
Compound IB (50 % drug load as Compound IA)	100
Silicified Microcrystalline Cellulose	75.40
Croscarmellose sodium	10.00
Sodium Starch Glycolate	10.00
Fumed silica	0.6
Stearic Acid	4.0
Total Fill Weight	200

26. A pharmaceutical composition according to Table 5.

Table 5

Ingredient	mg/unit dose
Compound IB (10 % drug load as Compound IA)	50mg
Microcrystalline Cellulose	63.35
Croscarmellose sodium	95.39
Sodium starch glycolate	9.05
Fumed Silica	9.05
Stearic acid	0.54
Total Fill Weight	3.62
	181.00

27. A pharmaceutical composition according to Table 6.

Table 6

Ingredient	mg/unit dose
Compound IB	60mg
Microcrystalline Cellulose	73.95
Croscarmellose sodium	114.36
Sodium starch glycolate	10.85
Fumed Silica	10.85
Stearic acid	0.65
Total Fill Weight	4.34
	217.00

28. The pharmaceutical composition of claims 20-27 admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

29. The pharmaceutical composition of claims 20-27 admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

30. The pharmaceutical composition of claims 20-27 admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
31. The pharmaceutical composition of claims 20-27 admixed with 15 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
32. The pharmaceutical composition of claims 20-27 admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
33. The pharmaceutical composition of claims 20-27 admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
34. The pharmaceutical composition of claims 20-27 admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2012/024591

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D215/227 A61K31/47 A61P35/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2010/083414 A1 (EXELIXIS INC [US]; ST CLAIR BROWN ADRIAN [GB]; LAMB PETER [US]; GALLAG) 22 July 2010 (2010-07-22) cited in the application Scheme 1 on page24; claims;claim 11 -----	1-34



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 May 2012

Date of mailing of the international search report

25/05/2012

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Wolf, Claudia

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2012/024591

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2010083414 A1	22-07-2010	AR 075025 A1	02-03-2011
		AU 2010204619 A1	01-09-2011
		CA 2758030 A1	22-07-2010
		CN 102388024 A	21-03-2012
		EP 2387563 A1	23-11-2011
		KR 20120013301 A	14-02-2012
		SG 173014 A1	29-08-2011
		TW 201036948 A	16-10-2010
		US 2012035212 A1	09-02-2012
		WO 2010083414 A1	22-07-2010

Electronic Patent Application Fee Transmittal

Application Number:	16151653			
Filing Date:	04-Oct-2018			
Title of Invention:	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds			
First Named Inventor/Applicant Name:	Jo Ann Wilson			
Filer:	Meghan Mary Klaric/Amy Peters			
Attorney Docket Number:	224990/10-039C3-US/439942			
Filed as Large Entity				
Filing Fees for Utility under 35 USC 111(a)				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
RCE- 1ST REQUEST	1801	1	1300	1300
Total in USD (\$)				1300

Electronic Acknowledgement Receipt

EFS ID:	37021842
Application Number:	16151653
International Application Number:	
Confirmation Number:	6871
Title of Invention:	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
First Named Inventor/Applicant Name:	Jo Ann Wilson
Customer Number:	91684
Filer:	Meghan Mary Klaric/Amy Peters
Filer Authorized By:	Meghan Mary Klaric
Attorney Docket Number:	224990/10-039C3-US/439942
Receipt Date:	29-AUG-2019
Filing Date:	04-OCT-2018
Time Stamp:	16:15:25
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	\$ 1300
RAM confirmation Number	E20198SG17015960
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		2019_08_29_16_02_20.pdf	691207	yes	15
			716453f344223432d54215536f3a65f49fbc6be2		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Miscellaneous Incoming Letter		1	2	
	Request for Continued Examination (RCE)		3	7	
	Request for Continued Examination (RCE)		8	9	
	Information Disclosure Statement (IDS) Form (SB08)		10	14	
	Miscellaneous Incoming Letter		15	15	
Warnings:					
Information:					
2	Non Patent Literature	A_H_Kibbe_Annexure_VII_Handbook_of_Pharmactutical_Excipients_3rd_Edition.PDF	936316	no	21
			aab3d4f2927ef8daa9c170f2842951dcfb53fbc1		
Warnings:					
Information:					
3	Foreign Reference	WO2012109510_EX10-039C-PC.PDF	1776520	no	49
			a77657fbc2df8d4ee7ee0ed4cb7d67a9b17fe6da		
Warnings:					
Information:					
4	Fee Worksheet (SB06)	fee-info.pdf	30325	no	2
			0d31fba3e21f1fd30269a8f154db58d49ade858b		
Warnings:					
Information:					
102 of 264					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

VIA EFS

August 29, 2019

Commissioner for Patents
United States Patent and Trademark Office
P. O. Box 1450
Alexandria, VA 22313

Re: US Patent Application No.: 16/151,653
Inventors: Jo Ann Wilson, et al.
Filing Date: October 4, 2018
Title: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
Attorney Docket No.: 224990/10-039C3-US/439942

Dear Sir or Madam:

Enclosed for filing please find the following documents:

1. This Cover Letter to the Commissioner for Patents;
2. Request for Continued Examination;
3. Request for Continued Examination Transmittal (PTO/SB/30);
4. Information Disclosure Statement (PTO/SB/08a);
5. Foreign Patent Literature (1 document);
6. Non-Patent Literature (1 document); and
7. Certificate of Transmission under 37 C.F.R. § 1.8(a).

It is believed that the Information Disclosure Statement filed herewith satisfies the requirement under 37 C.F.R. § 1.114 for a submission accompanying a Request for Continued Examination. The fee set forth in 37 C.F.R. § 1.17(e)(1) is also submitted herewith.

The Applicant notes that the filing of the enclosed Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement qualifies as prior art under 35 U.S.C. §§ 102 or 103, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). It is believed that no fee is due pursuant to 37 C.F.R. § 1.97(b)(4).

It is believed that due for this submission is the \$1,300.00 fee set forth in 37 C.F.R. § 1.17(e)(1) for a first Request for Continued Examination. The Applicant hereby authorizes the Office to charge this \$1,300.00 to Deposit Account Number 503145, referencing Attorney Docket Number 224990/10-039C3-US/439942. It is believed that no other fees are due at this time. However, if there are any additional charges required, or any credits, please apply them to

HONIGMAN

Commissioner for Patents

August 29, 2019

Page 2

Deposit Account Number 503145, referencing Attorney Docket Number 224990/10-039C3-US/439942.

Very truly yours,

HONIGMAN LLP

/Meghan M. Klaric/

Meghan M. Klaric
Reg. No. 71,226

MMK/ayp

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors:	Jo Ann Wilson, et al.	Art Unit:	1625
Application No.:	16/151,653	Examiner:	Timothy R. Rozof
Filing Date:	October 4, 2018	Conf. No.:	6871
Atty. Docket No.:	224990/10-039C3-US/439942		

Title: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 223313-1450

REQUEST FOR CONTINUED EXAMINATION UNDER 37 C.F.R. § 1.114

This submission is responsive to the Notice of Allowance in this application dated June 5, 2019.

Remarks begin on page 2.

Inventors: Jo Ann Wilson, et al.
Application No.: 16/151,653
Filing Date: October 4, 2018
Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1625
Examiner: Timothy R. Rozof
Conf. No.: 6871

REMARKS

REQUEST FOR CONTINUED EXAMINATION

It is believed that the Information Disclosure Statement filed herewith satisfies the requirement under 37 C.F.R. § 1.114 for a submission accompanying a Request for Continued Examination. The fee set forth in 37 C.F.R. § 1.17(e)(1) is also submitted herewith.

INFORMATION DISCLOSURE STATEMENT

The Applicant notes that the filing of the enclosed Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement qualifies as prior art under 35 U.S.C. § § 102 or 103, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). It is believed that no fee is due pursuant to 37 C.F.R. § 1.97(b)(4).

OTHER C-MET INHIBITOR CASES

The Applicant wishes to make the Examiner aware of the Applicant's other applications related to c-Met inhibitors and their use in the treatment of cancer. For the Examiner's convenience, the Applicant is providing a list of the Applicant's applications directed to the treatment of cancer using c-Met inhibitors. The Applicant understands the Examiner has electronic access to these applications and to the Office Actions that have issued in these applications, and has therefore not included copies with this Response. The Applicant will gladly provide the applications and Office Actions to the Examiner, however, upon request.

Application Number	Filing or 371 Date	Patent Number	Examiner	Status
10/573,336	09/18/2006		Koontz, Tammy J.	Abandoned
11/571,140	12/21/2006	7977345	Moore, Susanna	Expired
11/586,751	10/26/2006	9174947	Ward, Paul V.	Issued
11/753,462	05/24/2007	8178532	Ward, Paul V.	Issued
11/753,503	05/24/2007	8476298	Ward, Paul V.	Expired
11/753,514	05/24/2007	8067436	Bernhardt, Emily A.	Issued
12/393,806	02/26/2009	7579473	Seaman, D. Margaret M.	Issued
12/911,442	10/25/2010		Ward, Paul, V.	Abandoned
13/087,094	04/14/2011		Chickos, Sarah, J.	Abandoned
13/129,183	05/13/2011		Seaman, D. Margaret M.	Abandoned
13/132,650	06/03/2011		Seaman, D. Margaret M.	Abandoned

Inventors: Jo Ann Wilson, et al.
Application No.: 16/151,653
Filing Date: October 4, 2018
Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1625
Examiner: Timothy R. Rozof
Conf. No.: 6871

Application Number	Filing or 371 Date	Patent Number	Examiner	Status
13/145,054	10/20/2011	8877776	Carter, Kendra D	Issued
13/249,815	09/30/2011	8497284	Bernhardt, Emily A.	Issued
13/384,451	07/12/2012	8673912	Anderson, Rebecca L.	Issued
13/389,266	07/12/2012		Perreira, Melissa Jean	Abandoned
13/427,093	03/22/2012		Ward, Paul V.	Abandoned
13/438,964	04/04/2012		Brown-Pettigrew, Angela C.	Abandoned
13/634,275	09/12/2012		Anderson, Rebecca L.	Abandoned
13/753,031	01/29/2013		Pagonakis, Anna	Abandoned
13/753,146	01/29/2013		Pagonakis, Anna	Abandoned
13/810,537	08/26/2013	9724342	Pallay, Michael B.	Issued
13/810,546	08/27/2013		Branson, Daniel L.	Abandoned
13/876,290	11/05/2013		Stone, Christopher R.	Abandoned
13/876,306	11/08/2013		Lee, Andrew P.	Abandoned
13/876,318	10/25/2013		Karol, Jody Lynn	Abandoned
13/888,592	05/07/2013		Ward, Paul V.	Abandoned
13/928,977	06/27/2013		Bernhardt, Emily A.	Abandoned
13/984,559	03/20/2014	9717720	Rozof, Timothy R.	Issued
14/021,614	09/09/2013		Matos Negron, Taina Del Mar	Abandoned
14/115,236	02/28/2014		Anderson, James D.	Pending
14/166,545	01/28/2014		Not Yet Assigned	Abandoned
14/173,973	02/06/2014		Johannsen, Diana B.	Abandoned
14/340,871	07/25/2014	9809549	Carter, Kendra D.	Issued
14/346,570	03/21/2014	10166225	Wang, Shengjun	Issued
14/353,251	04/21/2014	9365516	Murray, Jeffrey H.	Issued
14/356,927	05/08/2014		Baek, Bong-Sook	Pending
14/356,938	05/08/2014		Cerioni, Daniel Lee	Abandoned
14/398,188	10/31/2014	9861624	Henley III, Raymond J.	Issued
14/426,580	03/06/2015		Jean-Louis, Samira J.M.	Abandoned
14/518,733	10/20/2014		Wright, Sarah C.	Abandoned
14/668,312	03/25/2015		Brown-Pettigrew, Angela C.	Abandoned
14/699,683	04/29/2015		Perreira, Melissa Jean	Abandoned
14/776,337	09/14/2015	10273211	Reese, Heidi L.	Issued
14/782,493	10/05/2015		Saeed, Kamal A.	Abandoned
14/782,537	10/05/2015		Alley, Genevieve S.	Pending
14/843,480	09/02/2015		Stone, Christopher R.	Pending
14/847,801	09/08/2015		Ward, Paul V.	Abandoned
14/933,801	11/05/2015		Brown-Pettigrew, Angela C.	Abandoned
15/066,872	03/10/2016		Ward, Paul V.	Abandoned
15/118,738	08/12/2016		Chandrakumar, Nizal S.	Pending
15/126,767	09/16/2016	10159666	Solola, Taofiq A.	Issued
15/133,708	04/20/2016	9969692	Murray, Jeffrey H.	Issued

Inventors: Jo Ann Wilson, et al.
 Application No.: 16/151,653
 Filing Date: October 4, 2018
 Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1625
 Examiner: Timothy R. Rozof
 Conf. No.: 6871

Application Number	Filing or 371 Date	Patent Number	Examiner	Status
15/305,854	10/21/2016		McMillian, Kara Renita	Pending
15/348,716	11/10/2016	10123999	Rozof, Timothy R.	Issued
15/500,312	01/30/2017		Seaman, D. Margaret M.	Pending
15/501,582	02/03/2017		Seaman, D. Margaret M.	Pending
15/426,804	02/07/2017	10039757	Pallay, Michael B.	Issued
15/612,703	06/02/2017	10034873	Pallay, Michael B.	Issued
15/617,725	06/08/2017		Neagu, Irina	Pending
15/618,593	06/09/2017		Carter, Kendra D.	Abandoned
15/621,527	06/13/2017		Carter, Kendra D.	Abandoned
15/688,310	08/28/2017		Ward, Paul V.	Pending
15/955,246	04/17/2018		Not Yet Assigned	Abandoned
16/026,708	07/03/2018		Pallay, Michael B.	Pending
16/093,426	10/12/2018		Not Yet Assigned	Pending
16/095,221	10/19/2018		Not Yet Assigned	Pending
16/142,691	09/26/2018		Brown-Pettigrew, Angela C.	Pending
16/190,869	11/14/2018		Solola, Taofiq A.	Pending
16/230,267	12/21/2018		Soroush, Layla	Pending
16/251,617	01/18/2019		Perreira, Melissa Jean	Pending
16/336,724	03/26/2019		Not Yet Assigned	Pending
16/362,863	03/25/2019		Not Yet Assigned	Pending
16/479,143	07/18/2019		Not Yet Assigned	Pending

Conclusion

It is believed that due for this submission is the \$1,300.00 fee set forth in 37 C.F.R. § 1.17(e)(1) for a first Request for Continued Examination. The Applicant hereby authorizes the Office to charge this \$1,300.00 to Deposit Account Number 503145, referencing Attorney Docket Number 224990/10-039C3-US/439942. It is believed that no other fees are due at this time. However, if there are any additional charges required, or any credits, please apply them to Deposit Account Number 503145, referencing Attorney Docket Number 224990/10-039C3-US/439942.

Inventors: Jo Ann Wilson, et al.
Application No.: 16/151,653
Filing Date: October 4, 2018
Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1625
Examiner: Timothy R. Rozof
Conf. No.: 6871

Respectfully submitted,

Honigman LLP

/Meghan M. Klaric/

Dated: August 29, 2019

Reg. No. 71,226
315 East Eisenhower Parkway, Suite 100
Ann Arbor, MI 48108-3330
Telephone: (734) 418-4294
Facsimile: (734) 418-4295

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875				Application or Docket Number 16/151,653		Filing Date 10/04/2018		☐ To be Mailed	
ENTITY: ☒ LARGE ☐ SMALL ☐ MICRO									
APPLICATION AS FILED - PART I									
		(Column 1)	(Column 2)						
FOR		NUMBER FILED	NUMBER EXTRA		RATE (\$)		FEE (\$)		
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))		N/A	N/A		N/A				
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))		N/A	N/A		N/A				
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))		N/A	N/A		N/A				
TOTAL CLAIMS (37 CFR 1.16(i))		minus 20 = *		x \$100 =					
INDEPENDENT CLAIMS (37 CFR 1.16(h))		minus 3 = *		x \$460 =					
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))		If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))									
* If the difference in column 1 is less than zero, enter "0" in column 2.					TOTAL				
APPLICATION AS AMENDED - PART II									
		(Column 1)		(Column 2)	(Column 3)				
AMENDMENT	08/29/2019	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)		ADDITIONAL FEE (\$)	
	Total (37 CFR 1.16(i))	* 20	Minus	** 20	= 0	x \$100 =		0	
	Independent (37 CFR 1.16(h))	* 3	Minus	*** 3	= 0	x \$460 =		0	
	☐ Application Size Fee (37 CFR 1.16(s))								
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))								
						TOTAL ADD'L FEE		0	
		(Column 1)		(Column 2)	(Column 3)				
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)		ADDITIONAL FEE (\$)	
	Total (37 CFR 1.16(i))	*	Minus	**	=	x \$0 =			
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x \$0 =			
	☐ Application Size Fee (37 CFR 1.16(s))								
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))								
						TOTAL ADD'L FEE			
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.						LIE			
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".						/GLORIA J TRAMMELL/			
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".									
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.									

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)**Title of
Invention****Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions
Containing Such Compounds**

As the below named inventor, I hereby declare that:

This declaration
is directed to:

The attached application, or

United States application or PCT international application number 16/151,653
filed on October 4, 2018


The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTORInventor: Khalid ShahDate (Optional): 14 June 2019Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt

EFS ID:	36315951
Application Number:	16151653
International Application Number:	
Confirmation Number:	6871
Title of Invention:	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
First Named Inventor/Applicant Name:	Jo Ann Wilson
Customer Number:	91684
Filer:	Meghan Mary Klaric/Amy Peters
Filer Authorized By:	Meghan Mary Klaric
Attorney Docket Number:	224990/10-039C3-US/439942
Receipt Date:	17-JUN-2019
Filing Date:	04-OCT-2018
Time Stamp:	13:04:05
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Oath or Declaration filed	Shah_Decl.pdf	155885	no	2
			8dcaa3d47b9fd49f20d50572a0f6ac47a6c19cbf		

Warnings:

Information:	
Total Files Size (in bytes):	155885
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.	



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

91684 7590 06/05/2019
JONATHAN P. O'BRIEN, PH.D.
HONIGMAN LLP
650 Trade Centre Way
Suite 200
Kalamazoo, MI 49002-0402

EXAMINER

ROZOF, TIMOTHY R

ART UNIT

PAPER NUMBER

1625

DATE MAILED: 06/05/2019

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
16/151,653	10/04/2018	Jo Ann Wilson	224990/10-039C3- US/439942	6871

TITLE OF INVENTION: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1000	\$0.00	\$0.00	\$1000	09/05/2019

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

91684 7590 06/05/2019
JONATHAN P. O'BRIEN, PH.D.
HONIGMAN LLP
650 Trade Centre Way
Suite 200
Kalamazoo, MI 49002-0402

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

	(Typed or printed name)
	(Signature)
	(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
16/151.653	10/04/2018	Jo Ann Wilson	224990/10-039C3- US/439942	6871

TITLE OF INVENTION: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1000	\$0.00	\$0.00	\$1000	09/05/2019

EXAMINER	ART UNIT	CLASS-SUBCLASS
ROZOF, TIMOTHY R	1625	514-312000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-09 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,

1 _____

(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

2 _____

3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. Fees submitted: ☐ Issue Fee ☐ Publication Fee (if required) ☐ Advance Order - # of Copies _____

4b. Method of Payment: (Please first reapply any previously paid fee shown above)

☐ Electronic Payment via EFS-Web ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)

☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. _____

5. **Change in Entity Status** (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

☐ Applicant asserting small entity status. See 37 CFR 1.27

☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____

Date _____

Typed or printed name _____

Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
16/151,653	10/04/2018	Jo Ann Wilson	224990/10-039C3- US/439942	6871
91684	7590	06/05/2019	EXAMINER	
JONATHAN P. O'BRIEN, PH.D. HONIGMAN LLP 650 Trade Centre Way Suite 200 Kalamazoo, MI 49002-0402			ROZOF, TIMOTHY R	
			ART UNIT	PAPER NUMBER
			1625	
DATE MAILED: 06/05/2019				

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

<i>Notice Requiring Inventor's Oath or Declaration</i>	Application No. 16/151,653	Applicant(s) Jo Ann Wilson	
	Examiner ROZOF, TIMOTHY R	Art Unit 1625	

This notice is an attachment to the Notice of Allowability (PTOL-37), or the Notice of Allowability For A Design Application (PTOL-37D).

An inventor's oath or declaration in compliance with 37 CFR 1.63 or 1.64 executed by or with respect to each inventor has not yet been submitted.

An oath or declaration in compliance with 37 CFR 1.63, or a substitute statement in compliance with 37 CFR 1.64, executed by or with respect to each inventor (for any inventor for which a compliant oath, declaration, or substitute statement has not yet been submitted) **MUST** be filed no later than the date on which the issue fee is paid. See 35 U.S.C. 115(f). Failure to timely comply will result in ABANDONMENT of this application.

A properly executed inventor's oath to declaration has not been received for the following inventor(s):

If applicant previously filed one or more oaths, declarations, or substitute statements, applicant may have received an informational notice regarding deficiencies therein.

The following deficiencies are noted:

INFORMAL ACTION PROBLEMS

- A properly executed inventor's oath or declaration has not been received for the following inventor(s): **Khalid Shah**.

Applicant may submit the inventor's oath or declaration at any time before the Notice of Allowance and Fee(s) Due, PTOL-85, is mailed.

Questions relating to this Notice should be directed to the Application Assistance Unit at 571-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 16/151,653	Applicant(s) Wilson et al.	
	Examiner TIMOTHY R ROZOF	Art Unit 1625	AIA (FITF) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to May 24, 2019, Amendment & Remarks.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on ____.

2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on ____; the restriction requirement and election have been incorporated into this action.

3. ☒ The allowed claim(s) is/are 35-54. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a) ☐ All b) ☐ Some *c) ☐ None of the:

1. ☐ Certified copies of the priority documents have been received.

2. ☐ Certified copies of the priority documents have been received in Application No. ____.

3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: ____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date ____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)	5. ☐ Examiner's Amendment/Comment
2. ☒ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date ____.	6. ☐ Examiner's Statement of Reasons for Allowance
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material ____.	7. ☐ Other ____.
4. ☐ Interview Summary (PTO-413), Paper No./Mail Date. ____.	

/TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625	
--	--

Issue Classification 	Application/Control No. 16/151,653	Applicant(s)/Patent Under Reexamination Wilson et al.
	Examiner TIMOTHY R ROZOF	Art Unit 1625

CPC						
Symbol					Type	Version
A61K	/	31	/	47	F	2013-01-01
C07D	/	215	/	233	I	2013-01-01

CPC Combination Sets							
Symbol				Type	Set	Ranking	Version
	/		/				

NONE		Total Claims Allowed:	
(Assistant Examiner)	(Date)	20	
/TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625	28 May 2019	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	NONE

Issue Classification 	Application/Control No. 16/151,653	Applicant(s)/Patent Under Reexamination Wilson et al.
	Examiner TIMOTHY R ROZOF	Art Unit 1625

INTERNATIONAL CLASSIFICATION			
CLAIMED			
A61K	/	31	/ 47
C07D	/	215	/ 233

NON-CLAIMED			
/		/	

US ORIGINAL CLASSIFICATION	
CLASS	SUBCLASS

CROSS REFERENCES(S)						
CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)					

NONE		Total Claims Allowed:	
(Assistant Examiner)	(Date)	20	
/TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625	28 May 2019	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	NONE

Issue Classification 	Application/Control No. 16/151,653	Applicant(s)/Patent Under Reexamination Wilson et al.
	Examiner TIMOTHY R ROZOF	Art Unit 1625

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47
--

CLAIMS															
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
1	35	10	44	19	53										
2	36	11	45	20	54										
3	37	12	46												
4	38	13	47												
5	39	14	48												
6	40	15	49												
7	41	16	50												
8	42	17	51												
9	43	18	52												

NONE (Assistant Examiner) _____ (Date) _____		Total Claims Allowed: 20	
/TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625 (Primary Examiner) _____ (Date) _____		O.G. Print Claim(s) 1	O.G. Print Figure NONE

<i>Search Notes</i> 	Application/Control No. 16/151,653	Applicant(s)/Patent Under Reexamination Wilson et al.
	Examiner TIMOTHY R ROZOF	Art Unit 1625

CPC - Searched*		
Symbol	Date	Examiner
C07D215/233	05/28/2019	TRR
A61K31/47	05/28/2019	TRR

CPC Combination Sets - Searched*		
Symbol	Date	Examiner

US Classification - Searched*			
Class	Subclass	Date	Examiner

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	Date	Examiner
EAST search (please see attached EAST search report)	05/28/2019	TRR

Interference Search			
US Class/CPC Symbol	US Subclass/CPC Group	Date	Examiner
A61K	31/47	05/28/2019	TRR
C07D	215/233	05/28/2019	TRR

/TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625	
--	--

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	9188	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/05/28 13:45
L2	5538	L1 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/05/28 13:45
L3	2	((("10123999") or ("9717720")).PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2019/05/28 13:50
L4	8459	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2019/05/28 13:59
L5	6531	L4 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/05/28 13:59
L6	514	L5 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/05/28 13:59
L7	95	L6 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2019/05/28 13:59
S1	1868	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2014/10/04 13:11
S2	6107	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/10/04 13:12
S3	4920	S2 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2014/10/04 13:12
S4	476	S3 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2014/10/04 13:14
S5	88	S4 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2014/10/04 13:14
S6	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2014/10/04 13:14
S7	735	S3 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2014/10/04 15:14
S8	11	S5 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2014/10/04 15:15
S10	1907	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2015/06/03 13:56

S11	6748	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2015/06/03 13:56
S12	5294	S11 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2015/06/03 13:56
S13	492	S12 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2015/06/03 13:56
S14	96	S13 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2015/06/03 13:56
S15	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2015/06/03 13:56
S16	748	S12 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2015/06/03 13:56
S17	12	S14 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2015/06/03 13:56
S19	1924	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S20	7064	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/01/07 13:23
S21	5473	S20 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S22	494	S21 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S23	96	S22 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S24	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/01/07 13:23
S25	755	S21 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S26	12	S23 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S27	1924	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S28	7064	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/01/07 13:23
S29	5473	S28 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S30	494	S29 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23

S31	96	S30 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S32	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/01/07 13:23
S33	755	S29 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S34	12	S31 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:23
S35	0	((A61K31/47.cpc.) or (C07D215/233.cpc.)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/01/07 13:33
S36	5706	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:33
S37	4165	S36 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:33
S38	546	S37 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:34
S39	81	S38 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/01/07 13:34
S42	1925	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S43	7164	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S44	5481	S43 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S45	494	S44 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S46	96	S45 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S47	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S48	756	S44 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S49	12	S46 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S50	1925	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S51	7164	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34

S52	5481	S51 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S53	494	S52 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S54	96	S53 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S55	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S56	756	S52 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S57	12	S54 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S58	1925	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S59	7164	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S60	5481	S59 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S61	494	S60 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S62	96	S61 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S63	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S64	756	S60 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S65	12	S62 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S66	1925	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S67	7164	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S68	5481	S67 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S69	494	S68 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S70	96	S69 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34

S71	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S72	756	S68 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S73	12	S70 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S74	0	((A61K31/47.cpc.) or (C07D215/233.cpc.)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/04/28 12:34
S75	5906	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S76	4191	S75 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S77	550	S76 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S78	81	S77 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/04/28 12:34
S79	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S80	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S81	5493	S80 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S82	495	S81 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S83	96	S82 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S84	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S85	757	S81 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S86	12	S83 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S87	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S88	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S89	5493	S88 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36

S90	495	S89 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S91	96	S90 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S92	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S93	757	S89 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S94	12	S91 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S95	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S96	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S97	5493	S96 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S98	495	S97 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S99	96	S98 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S100	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S101	757	S97 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S102	12	S99 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S103	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S104	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36
S105	5493	S104 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S106	495	S105 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S107	96	S106 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S108	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:36

S109	757	S105 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S110	12	S107 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:36
S111	0	((A61K31/47.cpc.) or (C07D215/233.cpc.)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S112	6123	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S113	4231	S112 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S114	566	S113 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S115	82	S114 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S116	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S117	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S118	5493	S117 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S119	495	S118 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S120	96	S119 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S121	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S122	757	S118 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S123	12	S120 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S124	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S125	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S126	5493	S125 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S127	495	S126 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37

S128	96	S127 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S129	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S130	757	S126 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S131	12	S128 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S132	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S133	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S134	5493	S133 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S135	495	S134 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S136	96	S135 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S137	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S138	757	S134 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S139	12	S136 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S140	1927	546/153	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S141	7246	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S142	5493	S141 and @ad<="20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S143	495	S142 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S144	96	S143 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S145	2	("20070054928").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S146	757	S142 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37

S147	12	S144 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S148	0	((A61K31/47.cpc.) or (C07D215/233.cpc.)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2016/08/05 11:37
S149	6123	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S150	4231	S149 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S151	566	S150 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S152	82	S151 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2016/08/05 11:37
S153	6433	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/01/17 13:35
S154	4302	S153 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/01/17 13:35
S155	573	S154 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/01/17 13:35
S156	83	S155 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/01/17 13:35
S157	7130	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/05/23 14:41
S158	4682	S157 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/05/23 14:41
S159	580	S158 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/05/23 14:41
S160	83	S159 and (compound near3 (IA or IB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/05/23 14:41
S161	1	("20120035212").PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2017/06/26 14:37
S162	7223	A61K31/47.cpc. C07D215/233.cpc.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2017/06/28 15:15
S163	1	("20120035212").PN.	US-PGPUB; USPAT	OR	OFF	2017/10/12 15:31
S164	1	("20120035212").PN.	US-PGPUB; USPAT	OR	OFF	2017/10/12 17:17
S165	1	("7169789").PN.	USPAT	OR	OFF	2017/10/12 17:35
S166	8124	((546/153) or (514/312)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2018/06/18 18:05

S167	6268	S166 and @ad< = "20110210"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2018/06/18 18:05
S168	508	S167 and (protein near3 kinase)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2018/06/18 18:05
S169	96	S168 and ((c\$met) or (Ret))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2018/06/18 18:05

5/ 28/ 2019 2:01:43 PM
C:\ Users\ trozof\ Documents\ EAST\ Workspaces\ 16151653.wsp

Doc code: IDS

PTO/SB/08a (02-18)

Doc description: Information Disclosure Statement (IDS) Filed

Approved for use through 11/30/2020. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	16151653
	Filing Date	2018-10-04
	First Named Inventor	Jo Ann Wilson
	Art Unit	1629
	Examiner Name	To be Determined
	Attorney Docket Number	224990/10-039C3-US/439942

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	9724342		2017-08-08	WILSON, et al.	
	2	9809549		2017-11-07	BROWN, et al.	
	3	7579473		2009-08-25	EXELIXIS, INC.	
	4	7977345		2011-07-12	EXELIXIS, INC.	
	5	7999006		2011-08-16	EXELIXIS, INC.	
	6	8067436		2011-11-29	EXELIXIS, INC.	
	7	8178532		2012-05-15	EXELIXIS, INC.	
	8	8314232		2012-11-20	EXELIXIS, INC.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	16151653
	Filing Date	2018-10-04
	First Named Inventor	Jo Ann Wilson
	Art Unit	1629
	Examiner Name	To be Determined
	Attorney Docket Number	224990/10-039C3-US/439942

	9	8476298		2013-07-02	EXELIXIS, INC.	
	10	8497284		2013-07-30	EXELIXIS, INC.	
	11	8673912		2014-03-18	EXELIXIS, INC.	
	12	8877776		2014-11-04	EXELIXIS, INC.	
	13	9174947		2015-11-03	EXELIXIS, INC.	
	14	9365516		2016-06-14	EXELIXIS, INC.	
	15	7166722		2007-01-23	MATSUNAGA, et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20080161305		2008-07-03	FORSYTH, et al.	
	2	20110077233		2011-03-31	BANNEN, et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	16151653
Filing Date	2018-10-04
First Named Inventor	Jo Ann Wilson
Art Unit	1629
Examiner Name	To be Determined
Attorney Docket Number	224990/10-039C3-US/439942

3	20120252840		2012-10-04	AFTAB, et al.	
4	20140066444		2014-03-26	SMITH, et al.	
5	20150057310		2015-02-26	BROWN, et al.	
6	20150202196		2015-07-23	BANNEN, et al.	
7	20160000772		2016-01-07	AFTAB, et al.	
8	20160051532		2016-02-25	AFTAB, et al.	
9	20160229805		2016-08-11	WILSON, et al.	
10	20170143689		2017-05-25	WILSON, et al.	
11	20170266178		2017-09-21	WILSON, et al.	
12	20170275251		2017-09-28	BROWN, et al.	
13	20180002289		2018-01-04	BROWN, et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	16151653
Filing Date	2018-10-04
First Named Inventor	Jo Ann Wilson
Art Unit	1629
Examiner Name	To be Determined
Attorney Docket Number	224990/10-039C3-US/439942

	14	20180037552		2018-02-08	BROWN, et al.	
	15	20090274693		2009-11-05	EXELIXIS, INC.	
	16	20110077233		2011-03-31	EXELIXIS, INC.	
	17	20120070368		2012-03-22	EXELIXIS, INC.	
	18	20120184523		2012-07-19	EXELIXIS, INC.	
	19	20120252840		2012-10-04	EXELIXIS, INC.	
	20	20120282179		2012-11-08	EXELIXIS, INC.	
	21	20130030172		2013-01-31	EXELIXIS, INC.	
	22	20130142790		2013-01-31	EXELIXIS, INC.	
	23	20130143881		2013-01-31	EXELIXIS, INC.	
	24	20130150363		2013-06-06	EXELIXIS, INC.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
 (Not for submission under 37 CFR 1.99)

Application Number		16151653
Filing Date		2018-10-04
First Named Inventor	Jo Ann Wilson	
Art Unit	1629	
Examiner Name	To be Determined	
Attorney Docket Number	224990/10-039C3-US/439942	

	25	20130197230		2013-06-06	EXELIXIS, INC.	
	26	20130252940		2013-06-13	EXELIXIS, INC.	
	27	20130252956		2013-08-01	EXELIXIS, INC.	
	28	20130330377		2013-09-26	EXELIXIS, INC.	
	29	20130337015		2013-09-26	EXELIXIS, INC.	
	30	20140057943		2013-12-12	EXELIXIS, INC.	
	31	20140057908		2013-12-19	EXELIXIS, INC.	
	32	20140066444		2014-02-27	EXELIXIS, INC.	
	33	20140155396		2014-02-27	EXELIXIS, INC.	
	34	20140179736		2014-03-06	EXELIXIS, INC.	
	35	20070054928		2007-03-08	BANNEN, et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	16151653
Filing Date	2018-10-04
First Named Inventor	Jo Ann Wilson
Art Unit	1629
Examiner Name	To be Determined
Attorney Docket Number	224990/10-039C3-US/439942

36	20140200242		2014-06-05	EXELIXIS, INC.	
37	20140228401		2014-06-26	EXELIXIS, INC.	
38	20140302012		2014-07-17	EXELIXIS, INC.	
39	20140323522		2014-08-14	EXELIXIS, INC.	
40	20150057310		2014-10-09	EXELIXIS, INC.	
41	20150196545		2014-10-30	EXELIXIS, INC.	
42	20150202196		2015-02-26	EXELIXIS, INC.	
43	20150376133		2015-07-16	EXELIXIS, INC.	
44	20160000772		2015-07-23	EXELIXIS, INC.	
45	20160051532		2015-12-31	EXELIXIS, INC.	
46	20160185725		2016-01-07	EXELIXIS, INC.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		16151653
Filing Date		2018-10-04
First Named Inventor	Jo Ann Wilson	
Art Unit	1629	
Examiner Name	To be Determined	
Attorney Docket Number	224990/10-039C3-US/439942	

47	20050209247		2005-09-22	CHIRON CORPORATION	
48	20070078159		2007-04-05	MATSUSHIMA, et al.	
49	20110059081		2011-03-10	QUINTILES TRANSNATIONAL CORP.	
50	20140256938		2014-09-11	WISON, et al.	
51	20160220554		2016-08-04	SMITH, et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2009136663	WO		2009-11-12	TAKEDA PHARMACEUTICAL COMPANY LIMITED		☐
	2	2005030140	WO		2005-04-07	EXELIXIS, INC.		☐
	3	2010083414	WO		2010-07-22	EXELIXIS, INC.		☐
	4	2011017639	WO		2011-02-10	EXELIXIS, INC.		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16151653	
	Filing Date		2018-10-04	
	First Named Inventor		Jo Ann Wilson	
	Art Unit		1629	
	Examiner Name		To be Determined	
	Attorney Docket Number		224990/10-039C3-US/439942	

5	2012009722	WO		2012-01-19	EXELIXIS, INC.	☐
---	------------	----	--	------------	----------------	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Kurzrock R et al. "379 POSTER A phase I study of XL 184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC)." European journal of cancer. supplement, vol 6, no 12, 2008-10-01, 119.	☐
	2	European Medicines Agency, "Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: chemical substances", May 2000.	☐
	3	Sigma-Aldrich Corporation, "Cabozantinib Material Safety Data Sheet", Version 5.0, October 20, 2014, retrieved from the internet at http://www.sigmaaldrich.com/MSDS/MSDS/DisplayMSDSPage.do?country=US&language=en&productNumber=CDS009101&brand=ALDRICH&PageToGoToURL=http%3A%2F%2Fwww.sigmaaldrich.com%2Fcatalog%2Fproduct%2Faldrich%2Fcds009101%3Flang%3Den on October 1, 2015.	☐
	4	United States Department of Health and Human Services, "Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products", Revision 2, November 2003, retrieved from the internet at www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073369.pdf on October 1, 2015.	☐
	5	International Search Report for PCT/US2012/024591, mailed May 25, 2012	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/TIMOTHY R ROZOF/	Date Considered	05/28/2019
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	16151653
	Filing Date	2018-10-04
	First Named Inventor	Jo Ann Wilson
	Art Unit	1629
	Examiner Name	To be Determined
	Attorney Docket Number	224990/10-039C3-US/439942

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Meghan M. Klaric/	Date (YYYY-MM-DD)	2019-05-24
Name/Print	Meghan M. Klaric	Registration Number	71,226

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875						Application or Docket Number 16/151,653			
APPLICATION AS FILED - PART I									
(Column 1)		(Column 2)		SMALL ENTITY		OTHER THAN SMALL ENTITY			
FOR	NUMBER FILED	NUMBER EXTRA	RATE(\$)	FEE(\$)		RATE(\$)	FEE(\$)		
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	300		
SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A	N/A			N/A	660		
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	760		
TOTAL CLAIMS (37 CFR 1.16(j))	20	minus 20 = *			OR	x 100 =	0.00		
INDEPENDENT CLAIMS (37 CFR 1.16(h))	3	minus 3 = *				x 460 =	0.00		
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						0.00		
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							0.00		
			TOTAL			TOTAL	1720		
* If the difference in column 1 is less than zero, enter "0" in column 2.									
APPLICATION AS AMENDED - PART II									
(Column 1)		(Column 2)		(Column 3)		SMALL ENTITY		OTHER THAN SMALL ENTITY	
AMENDMENT A		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)	ADDITIONAL FEE(\$)	RATE(\$)	ADDITIONAL FEE(\$)
	Total (37 CFR 1.16(i))	*	Minus	**	=	x	=	OR	x
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x	=	OR	x
	Application Size Fee (37 CFR 1.16(s))							OR	
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR	
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE
AMENDMENT B		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)	ADDITIONAL FEE(\$)	RATE(\$)	ADDITIONAL FEE(\$)
	Total (37 CFR 1.16(i))	*	Minus	**	=	x	=	OR	x
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x	=	OR	x
	Application Size Fee (37 CFR 1.16(s))							OR	
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR	
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.									



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
16/151,653	10/04/2018	Jo Ann Wilson	224990/10-039C3-US/439942

CONFIRMATION NO. 6871

91684
JONATHAN P. O'BRIEN, PH.D.
HONIGMAN LLP
650 Trade Centre Way
Suite 200
Kalamazoo, MI 49002-0402

INFORMAL NOTICE



Date Mailed: 05/29/2019

INFORMATIONAL NOTICE TO APPLICANT

Applicant is notified that the above-identified application contains the deficiencies noted below. No period for reply is set forth in this notice for correction of these deficiencies. However, if a deficiency relates to the inventor's oath or declaration, the applicant must file an oath or declaration in compliance with 37 CFR 1.63, or a substitute statement in compliance with 37 CFR 1.64, executed by or with respect to each actual inventor no later than the expiration of the time period set in the "Notice of Allowability" to avoid abandonment. See 37 CFR 1.53(f).

The item(s) indicated below are also required and should be submitted with any reply to this notice to avoid further processing delays.

- A properly executed inventor's oath or declaration has not been received for the following inventor(s):
Khalid Shah

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at (571) 272-4000 or (571) 272-4200 or 1-888-786-0101.

/agizaw/



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLAIMS	IND CLAIMS
16/151,653	10/04/2018	1629	1880	224990/10-039C3-US/439942	20	3

CONFIRMATION NO. 6871
UPDATED FILING RECEIPT

91684
JONATHAN P. O'BRIEN, PH.D.
HONIGMAN LLP
650 Trade Centre Way
Suite 200
Kalamazoo, MI 49002-0402



Date Mailed: 05/29/2019

Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

Jo Ann Wilson, San Francisco, CA;
Khalid Shah, South San Francisco, CA;

Applicant(s)

Exelixis, Inc., Alameda, CA

Power of Attorney: The patent practitioners associated with Customer Number 91684

Domestic Priority data as claimed by applicant

This application is a DIV of 15/348,716 11/10/2016 PAT 10123999
which is a DIV of 13/984,559 03/20/2014 PAT 9717720
which is a 371 of PCT/US12/24591 02/10/2012
which claims benefit of 61/441,520 02/10/2011
and claims benefit of 61/441,527 02/10/2011

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see <http://www.uspto.gov> for more information.) - None.

Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 10/24/2018

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 16/151,653**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Title

Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

Preliminary Class

514

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific

countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop

technology, manufacture products, deliver services, and grow your business, visit <http://www.SelectUSA.gov> or call +1-202-482-6800.

Electronic Patent Application Fee Transmittal

Application Number:	16151653			
Filing Date:	04-Oct-2018			
Title of Invention:	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds			
First Named Inventor/Applicant Name:	Jo Ann Wilson			
Filer:	Heid Marie Berven/Charles Gregg-Geist			
Attorney Docket Number:	224990/10-039C3-US/439942			
Filed as Large Entity				
Filing Fees for Utility under 35 USC 111(a)				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
LATE FILING FEE FOR OATH OR DECLARATION	1051	1	160	160
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Extension - 5 months with \$0 paid	1255	1	3000	3000
Miscellaneous:				
Total in USD (\$)				3160

Electronic Acknowledgement Receipt

EFS ID:	36111219
Application Number:	16151653
International Application Number:	
Confirmation Number:	6871
Title of Invention:	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
First Named Inventor/Applicant Name:	Jo Ann Wilson
Customer Number:	91684
Filer:	Heid Marie Berven/Charles Gregg-Geist
Filer Authorized By:	Heid Marie Berven
Attorney Docket Number:	224990/10-039C3-US/439942
Receipt Date:	24-MAY-2019
Filing Date:	04-OCT-2018
Time Stamp:	14:04:49
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	\$3160
RAM confirmation Number	052819INTEFSW00002678503145
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Fee Worksheet (SB06)	fee-info.pdf	32836	no	2
			7b897f48b1c7710fc793c74db48e04c925c2442a		
Warnings:					
Information:					
Total Files Size (in bytes):			32836		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors:	Jo Ann Wilson, et al.	Art Unit:	1629
Application No.:	16/151,653	Examiner:	To Be Determined
Filing Date:	October 4, 2018	Conf. No.:	6871
Atty. Docket No.:	224990/10-039C3-US/439942		

Title: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

Commissioner for Patents
United States Patent and Trademark Office
P. O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO FILE MISSING PARTS DATED OCTOBER 26, 2018

Dear Sir or Madam:

This communication is responsive to the Notice to File Missing Parts in this application dated October 26, 2018.

Claim amendments are reflected in the listing of claims that begin on page 2.

Remarks begin on page 11.


Inventors: Jo Ann Wilson, et al.
 Application No.: 16/151,653
 Filing Date: October 4, 2018
 Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1626
 Examiner: To Be Determined
 Conf. No.: 6871

CLAIM AMENDMENTS

1-34. Cancelled.

35. (New) A process for preparing a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

X^1 is H, Br, Cl, or F;


X^2 is Br, Cl, or F;

n_1 is 1-2; and

n_2 is 1-2;

the process comprising:

reacting a compound of formula f(1) with a reactant y(1) in the presence of a non-nucleophilic base which is an alkali metal alkoxide to yield the compound of formula g(1):




wherein LG represents a leaving group; and


contacting a compound of formula g(1) with a reactant z(1) to yield the compound of formula I:

Inventors: Jo Ann Wilson, et al.
 Application No.: 16/151,653
 Filing Date: October 4, 2018
 Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1626
 Examiner: To Be Determined
 Conf. No.: 6871




36. (New) The process according to claim 35, wherein the compound of formula f(1) is made by converting a compound of formula e(1) to the compound of formula f(1):



wherein LG represents a leaving group.

37. (New) The process according to claim 35, wherein reactant z(1) is made by reacting a reactant z(1a) with a chlorinating agent to yield the reactant z(1):




wherein X¹ is Br, Cl, or F; and n1 is 1-2.

38. (New) The process according to claim 35, wherein the compound of formula I is a compound of formula IA-1:

Inventors: Jo Ann Wilson, et al.
 Application No.: 16/151,653
 Filing Date: October 4, 2018
 Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1626
 Examiner: To Be Determined
 Conf. No.: 6871




IA-1

or a pharmaceutically acceptable salt thereof, wherein:


X¹ is H, Cl, Br, or F; and

X² is Cl, Br, or F.

39. (New) The process according to claim 35, wherein the compound of formula f(1) is the compound f(2):



the reactant y(1) is a reactant (y)(2):




wherein X² is fluoro; and

the compound of formula g(1) is a compound of formula g(2):

Inventors: Jo Ann Wilson, et al.
Application No.: 16/151,653
Filing Date: October 4, 2018
Atty. Docket No.: 224990/10-039C3-US/439942


Art Unit: 1626
Examiner: To Be Determined
Conf. No.: 6871



40. (New) The process according to claim 35, wherein the reaction is carried out in a polar solvent.
41. (New) The process according to claim 40, wherein the alkali metal alkoxide is sodium tert-butoxide and the polar solvent is DMA.
42. (New) The process according to claim 40, wherein the alkali metal alkoxide is sodium tert-pentoxide, and the polar solvent is DMA.
43. (New) The process according to claim 35, wherein the reaction is carried out in the presence of an inorganic base.
44. (New) The process according to claim 43, wherein the inorganic base is K₂CO₃, and the reaction is carried out in a solvent comprising a combination of THF and H₂O.
45. (New) A process for preparing a compound of formula I:

Inventors: Jo Ann Wilson, et al.
 Application No.: 16/151,653
 Filing Date: October 4, 2018
 Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1626
 Examiner: To Be Determined
 Conf. No.: 6871



I

or a pharmaceutically acceptable salt thereof, wherein:

X^1 is H, Br or Cl;


X^2 is H;

n_1 is 1-2; and

n_2 is 1-2;


the process comprising:

reacting a compound of formula f(1) with a reactant y(1) in the presence of a non-nucleophilic base which is an alkali metal alkoxide to yield the compound of formula g(1):



wherein LG represents a leaving group; and


contacting a compound of formula g(1) with a reactant z(1) to yield the compound of formula I:



Inventors: Jo Ann Wilson, et al.
 Application No.: 16/151,653
 Filing Date: October 4, 2018
 Atty. Docket No.: 224990/10-039C3-US/439942


Art Unit: 1626
 Examiner: To Be Determined
 Conf. No.: 6871

46. (New) The process according to claim 45, wherein the compound of formula f(1) is made by converting a compound of formula e(1) to the compound of formula f(1):




wherein LG represents a leaving group.

47. (New) The process according to claim 45, wherein reactant z(1) is made by reacting a reactant z(1a) with a chlorinating agent to yield the reactant z(1):



wherein X^1 is H, Br or Cl; and $n1$ is 1-2.

48. (New) The process according to claim 45, wherein the compound of formula I is a compound of formula IA-1:



or a pharmaceutically acceptable salt thereof, wherein:


Inventors: Jo Ann Wilson, et al.
 Application No.: 16/151,653
 Filing Date: October 4, 2018
 Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1626
 Examiner: To Be Determined
 Conf. No.: 6871


X^1 is H, Cl or Br; and

X^2 is H.

49. (New) The process according to claim 45, wherein the compound of formula f(1) is the compound f(2):




the reactant y(1) is a reactant (y)(2):



wherein X^2 is hydrogen; and

the compound of formula g(1) is a compound of formula g(2):



50. (New) The process according to claim 45, wherein the reaction is carried out in a polar solvent.

51. (New) The process according to claim 50, wherein the alkali metal alkoxide is sodium tert-butoxide or sodium tert-pentoxide, and the polar solvent is DMA.


Inventors: Jo Ann Wilson, et al.
 Application No.: 16/151,653
 Filing Date: October 4, 2018
 Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1626
 Examiner: To Be Determined
 Conf. No.: 6871

52. (New) The process according to claim 45, wherein the reaction is carried out in the presence of an inorganic base.

53. (New) The process according to claim 52, wherein the inorganic base is K_2CO_3 , and the reaction is carried out in a solvent comprising a combination of THF and H_2O .

54. (New) A process for preparing a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:


X^1 is F;

X^2 is H; and

n_1 is 2;

the process comprising:

reacting a compound of formula f(1) with a reactant y(1) in the presence of a non-nucleophilic base which is an alkali metal alkoxide to yield the compound of formula g(1):




wherein LG represents a leaving group; and

Inventors: Jo Ann Wilson, et al.
 Application No.: 16/151,653
 Filing Date: October 4, 2018
 Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1626
 Examiner: To Be Determined
 Conf. No.: 6871

contacting a compound of formula g(1) with a reactant z(1) to yield the compound of formula I:



Inventors: Jo Ann Wilson, et al.
Application No.: 16/151,653
Filing Date: October 4, 2018
Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1626
Examiner: To Be Determined
Conf. No.: 6871

REMARKS

Amendments to the Claims

Claims 1-34 are cancelled.

Claims 35-54 are new.

As a result, claims 35-54 are currently pending. No new matter has been added as a result of these amendments.

Notice to File Missing Parts

The United States Patent and Trademark Office issued a Notice to File Missing Parts of Nonprovisional Application on October 25, 2018. The Notice requires submission of excess claims fees, inventor declarations, and the surcharge set forth in 37 C.F.R. § 1.16(f) for late submission of fees or the inventors' declarations. In response, the Applicant submits herewith preliminary claim amendments and the surcharge of \$160.00 set forth in 37 C.F.R § 1.16(f).

OTHER C-MET INHIBITOR CASES

The Applicant wishes to make the Examiner aware of the Applicant's other applications related to c-Met inhibitors and their use in the treatment of cancer. For the Examiner's convenience, the Applicant is providing a list of the Applicant's applications directed to the treatment of cancer using c-Met inhibitors. The Applicant understands the Examiner has electronic access to these applications and to the Office Actions that have issued in these applications, and has therefore not included copies with this Response. The Applicant will gladly provide the applications and Office Actions to the Examiner, however, upon request.

Application Number	Filing or 371 Date	Patent Number	Examiner	Status
10/573,336	09/18/2006		Koontz, Tammy J.	Abandoned
11/571,140	12/21/2006	7977345	Moore, Susanna	Expired
11/586,751	10/26/2006	9174947	Ward, Paul V.	Issued
11/753,462	05/24/2007	8178532	Ward, Paul V.	Issued
11/753,503	05/24/2007	8476298	Ward, Paul V.	Expired
11/753,514	05/24/2007	8067436	Bernhardt, Emily A.	Issued
12/393,806	02/26/2009	7579473	Seaman, D. Margaret M.	Issued
12/911,442	10/25/2010		Ward, Paul, V.	Abandoned

Inventors: Jo Ann Wilson, et al.
 Application No.: 16/151,653
 Filing Date: October 4, 2018
 Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1626
 Examiner: To Be Determined
 Conf. No.: 6871

Application Number	Filing or 371 Date	Patent Number	Examiner	Status
13/087,094	04/14/2011		Chickos, Sarah, J.	Abandoned
13/129,183	05/13/2011		Seaman, D. Margaret M.	Abandoned
13/132,650	06/03/2011		Seaman, D. Margaret M.	Abandoned
13/145,054	10/20/2011	8877776	Carter, Kendra D	Issued
13/249,815	09/30/2011	8497284	Bernhardt, Emily A.	Issued
13/384,451	07/12/2012	8673912	Anderson, Rebecca L.	Issued
13/389,266	07/12/2012		Perreira, Melissa Jean	Abandoned
13/427,093	03/22/2012		Ward, Paul V.	Abandoned
13/438,964	04/04/2012		Brown-Pettigrew, Angela C.	Abandoned
13/634,275	09/12/2012		Anderson, Rebecca L.	Abandoned
13/753,031	01/29/2013		Pagonakis, Anna	Abandoned
13/753,146	01/29/2013		Pagonakis, Anna	Abandoned
13/810,537	08/26/2013	9724342	Pallay, Michael B.	Issued
13/810,546	08/27/2013		Branson, Daniel L.	Abandoned
13/876,290	11/05/2013		Stone, Christopher R.	Abandoned
13/876,306	11/08/2013		Lee, Andrew P.	Abandoned
13/876,318	10/25/2013		Karol, Jody Lynn	Abandoned
13/888,592	05/07/2013		Ward, Paul V.	Abandoned
13/928,977	06/27/2013		Bernhardt, Emily A.	Abandoned
13/984,559	03/20/2014	9717720	Rozof, Timothy R.	Issued
14/021,614	09/09/2013		Matos Negron, Taina Del Mar	Abandoned
14/115,236	02/28/2014		Anderson, James D.	Pending
14/166,545	01/28/2014		Not Yet Assigned	Abandoned
14/173,973	02/06/2014		Johannsen, Diana B.	Abandoned
14/340,871	07/25/2014	9809549	Carter, Kendra D.	Issued
14/346,570	03/21/2014	10166225	Wang, Shengjun	Issued
14/353,251	04/21/2014	9365516	Murray, Jeffrey H.	Issued
14/356,927	05/08/2014		Baek, Bong-Sook	Pending
14/356,938	05/08/2014		Cerioni, Daniel Lee	Abandoned
14/398,188	10/31/2014	9861624	Henley III, Raymond J.	Issued
14/426,580	03/06/2015		Jean-Louis, Samira J.M.	Abandoned
14/518,733	10/20/2014		Wright, Sarah C.	Abandoned
14/668,312	03/25/2015		Brown-Pettigrew, Angela C.	Abandoned
14/699,683	04/29/2015		Perreira, Melissa Jean	Abandoned
14/776,337	09/14/2015	10273211	Reese, Heidi L.	Issued
14/782,493	10/05/2015		Saeed, Kamal A.	Abandoned
14/782,537	10/05/2015		Alley, Genevieve S.	Pending
14/843,480	09/02/2015		Stone, Christopher R.	Pending
14/847,801	09/08/2015		Ward, Paul V.	Abandoned
14/933,801	11/05/2015		Brown-Pettigrew, Angela C.	Abandoned

Inventors: Jo Ann Wilson, et al.
 Application No.: 16/151,653
 Filing Date: October 4, 2018
 Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1626
 Examiner: To Be Determined
 Conf. No.: 6871

Application Number	Filing or 371 Date	Patent Number	Examiner	Status
15/066,872	03/10/2016		Ward, Paul V.	Abandoned
15/118,738	08/12/2016		Chandrakumar, Nizal S.	Allowed
15/126,767	09/16/2016	10159666	Solola, Taofiq A.	Issued
15/133,708	04/20/2016	9969692	Murray, Jeffrey H.	Issued
15/305,854	10/21/2016		McMillian, Kara Renita	Pending
15/348,716	11/10/2016	10123999	Rozof, Timothy R.	Issued
15/500,312	01/30/2017		Seaman, D. Margaret M.	Allowed
15/501,582	02/03/2017		Seaman, D. Margaret M.	Pending
15/426,804	02/07/2017	10039757	Pallay, Michael B.	Issued
15/612,703	06/02/2017	10034873	Pallay, Michael B.	Issued
15/617,725	06/08/2017		Carter, Kendra D.	Pending
15/618,593	06/09/2017		Carter, Kendra D.	Abandoned
15/621,527	06/13/2017		Carter, Kendra D.	Abandoned
15/688,310	08/28/2017		Ward, Paul V.	Pending
15/955,246	04/17/2018		Not Yet Assigned	Abandoned
16/026,708	07/03/2018		Pallay, Michael B.	Pending
16/093,426	10/12/2018		Not Yet Assigned	Pending
16/095,221	10/19/2018		Not Yet Assigned	Pending
16/142,691	09/26/2018		Brown-Pettigrew, Angela C.	Pending
16/190,869	11/14/2018		Not Yet Assigned	Pending
16/230,267	12/21/2018		Not Yet Assigned	Pending
16/251,617	01/18/2019		Not Yet Assigned	Pending
16/336,724	03/26/2019		Not Yet Assigned	Pending
16/362,863	03/25/2019		Not Yet Assigned	Pending

INFORMATION DISCLOSURE STATEMENT

The Applicant notes that the filing of the enclosed Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement qualifies as prior art under 35 U.S.C. § § 102 or 103, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). It is believed that no fee is due pursuant to 37 C.F.R. § 1.97(b)(3). In accordance with 37 C.F.R. § 1.98(d), copies of the cited references are not provided because they were previously provided to the Office in earlier application USSN 15/348,716. The Applicant will gladly provide the references to the Examiner, however, upon request.

Inventors: Jo Ann Wilson, et al.
Application No.: 16/151,653
Filing Date: October 4, 2018
Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: 1626
Examiner: To Be Determined
Conf. No.: 6871

PETITION FOR EXTENSION OF TIME

The Applicant hereby petitions for a five-month extension of time under 37 C.F.R. § 1.136(a) to respond to Notice to File Missing Parts in this application dated October 26, 2018. The fee set forth in 37 C.F.R. § 1.17(a)(5) is submitted herewith.

CONCLUSION AND REQUIRED FEES

It is believed that due with this submission is the five-month Extension of Time Fee of \$3,000.00 and the \$160.00 surcharge for late submission of inventor's oath or declaration. The Applicant hereby authorizes the Patent Office to charge this total of \$3,160.00 to Deposit Account No. 503145, referencing Attorney Docket Number 224990/10-039C3-US/439942.

Respectfully submitted,

HONIGMAN LLP

/Meghan M. Klaric/

Dated: May 24, 2019

Meghan M. Klaric
Reg. No. 71,226
315 East Eisenhower Parkway, Suite 100
Ann Arbor, MI 48108-3330
Telephone: (734) 418-4294
Facsimile: (734) 418-4295

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16151653
	Filing Date		2018-10-04
	First Named Inventor	Jo Ann Wilson	
	Art Unit	1629	
	Examiner Name	To be Determined	
	Attorney Docket Number	224990/10-039C3-US/439942	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	9724342		2017-08-08	WILSON, et al.	
	2	9809549		2017-11-07	BROWN, et al.	
	3	7579473		2009-08-25	EXELIXIS, INC.	
	4	7977345		2011-07-12	EXELIXIS, INC.	
	5	7999006		2011-08-16	EXELIXIS, INC.	
	6	8067436		2011-11-29	EXELIXIS, INC.	
	7	8178532		2012-05-15	EXELIXIS, INC.	
	8	8314232		2012-11-20	EXELIXIS, INC.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16151653	
	Filing Date		2018-10-04	
	First Named Inventor	Jo Ann Wilson		
	Art Unit	1629		
	Examiner Name	To be Determined		
	Attorney Docket Number	224990/10-039C3-US/439942		

	9	8476298		2013-07-02	EXELIXIS, INC.	
	10	8497284		2013-07-30	EXELIXIS, INC.	
	11	8673912		2014-03-18	EXELIXIS, INC.	
	12	8877776		2014-11-04	EXELIXIS, INC.	
	13	9174947		2015-11-03	EXELIXIS, INC.	
	14	9365516		2016-06-14	EXELIXIS, INC.	
	15	7166722		2007-01-23	MATSUNAGA, et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20080161305		2008-07-03	FORSYTH, et al.	
	2	20110077233		2011-03-31	BANNEN, et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	16151653
Filing Date	2018-10-04
First Named Inventor	Jo Ann Wilson
Art Unit	1629
Examiner Name	To be Determined
Attorney Docket Number	224990/10-039C3-US/439942

3	20120252840		2012-10-04	AFTAB, et al.	
4	20140066444		2014-03-26	SMITH, et al.	
5	20150057310		2015-02-26	BROWN, et al.	
6	20150202196		2015-07-23	BANNEN, et al.	
7	20160000772		2016-01-07	AFTAB, et al.	
8	20160051532		2016-02-25	AFTAB, et al.	
9	20160229805		2016-08-11	WILSON, et al.	
10	20170143689		2017-05-25	WILSON, et al.	
11	20170266178		2017-09-21	WILSON, et al.	
12	20170275251		2017-09-28	BROWN, et al.	
13	20180002289		2018-01-04	BROWN, et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	16151653
Filing Date	2018-10-04
First Named Inventor	Jo Ann Wilson
Art Unit	1629
Examiner Name	To be Determined
Attorney Docket Number	224990/10-039C3-US/439942

	14	20180037552		2018-02-08	BROWN, et al.	
	15	20090274693		2009-11-05	EXELIXIS, INC.	
	16	20110077233		2011-03-31	EXELIXIS, INC.	
	17	20120070368		2012-03-22	EXELIXIS, INC.	
	18	20120184523		2012-07-19	EXELIXIS, INC.	
	19	20120252840		2012-10-04	EXELIXIS, INC.	
	20	20120282179		2012-11-08	EXELIXIS, INC.	
	21	20130030172		2013-01-31	EXELIXIS, INC.	
	22	20130142790		2013-01-31	EXELIXIS, INC.	
	23	20130143881		2013-01-31	EXELIXIS, INC.	
	24	20130150363		2013-06-06	EXELIXIS, INC.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		16151653
	Filing Date		2018-10-04
	First Named Inventor	Jo Ann Wilson	
	Art Unit	1629	
	Examiner Name	To be Determined	
	Attorney Docket Number	224990/10-039C3-US/439942	

	25	20130197230		2013-06-06	EXELIXIS, INC.	
	26	20130252940		2013-06-13	EXELIXIS, INC.	
	27	20130252956		2013-08-01	EXELIXIS, INC.	
	28	20130330377		2013-09-26	EXELIXIS, INC.	
	29	20130337015		2013-09-26	EXELIXIS, INC.	
	30	20140057943		2013-12-12	EXELIXIS, INC.	
	31	20140057908		2013-12-19	EXELIXIS, INC.	
	32	20140066444		2014-02-27	EXELIXIS, INC.	
	33	20140155396		2014-02-27	EXELIXIS, INC.	
	34	20140179736		2014-03-06	EXELIXIS, INC.	
	35	20070054928		2007-03-08	BANNEN, et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		16151653
Filing Date		2018-10-04
First Named Inventor	Jo Ann Wilson	
Art Unit	1629	
Examiner Name	To be Determined	
Attorney Docket Number	224990/10-039C3-US/439942	

	36	20140200242		2014-06-05	EXELIXIS, INC.	
	37	20140228401		2014-06-26	EXELIXIS, INC.	
	38	20140302012		2014-07-17	EXELIXIS, INC.	
	39	20140323522		2014-08-14	EXELIXIS, INC.	
	40	20150057310		2014-10-09	EXELIXIS, INC.	
	41	20150196545		2014-10-30	EXELIXIS, INC.	
	42	20150202196		2015-02-26	EXELIXIS, INC.	
	43	20150376133		2015-07-16	EXELIXIS, INC.	
	44	20160000772		2015-07-23	EXELIXIS, INC.	
	45	20160051532		2015-12-31	EXELIXIS, INC.	
	46	20160185725		2016-01-07	EXELIXIS, INC.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		16151653
Filing Date		2018-10-04
First Named Inventor	Jo Ann Wilson	
Art Unit	1629	
Examiner Name	To be Determined	
Attorney Docket Number	224990/10-039C3-US/439942	

	47	20050209247		2005-09-22	CHIRON CORPORATION	
	48	20070078159		2007-04-05	MATSUSHIMA, et al.	
	49	20110059081		2011-03-10	QUINTILES TRANSNATIONAL CORP.	
	50	20140256938		2014-09-11	WISON, et al.	
	51	20160220554		2016-08-04	SMITH, et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²ⁱ	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2009136663	WO		2009-11-12	TAKEDA PHARMACEUTICAL COMPANY LIMITED		☐
	2	2005030140	WO		2005-04-07	EXELIXIS, INC.		☐
	3	2010083414	WO		2010-07-22	EXELIXIS, INC.		☐
	4	2011017639	WO		2011-02-10	EXELIXIS, INC.		☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	16151653
Filing Date	2016-10-04
First Named Inventor	Jo Ann Wilson
Art Unit	1629
Examiner Name	To be Determined
Attorney Docket Number	224990/10-039C3-US/439942

5	2012009722	WO		2012-01-19	EXELIXIS, INC.	☐
---	------------	----	--	------------	----------------	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Kurzrock R et al. "379 POSTER A phase I study of XL 184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC)." European journal of cancer. supplement, vol 6, no 12, 2008-10-01, 119.	☐
	2	European Medicines Agency, "Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: chemical substances", May 2000.	☐
	3	Sigma-Aldrich Corporation, "Cabozantinib Material Safety Data Sheet", Version 5.0, October 20, 2014, retrieved from the internet at http://www.sigmaaldrich.com/MSDS/MSDS/DisplayMSDSPage.do?country=US&language=en&productNumber=CDS009101&brand=ALDRICH&PageToGoToURL=http%3A%2F%2Fwww.sigmaaldrich.com%2Fcatalog%2Fproduct%2Faldrich%2Fcds009101%3Flang%3Den on October 1, 2015.	☐
	4	United States Department of Health and Human Services, "Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products", Revision 2, November 2003, retrieved from the internet at www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073369.pdf on October 1, 2015.	☐
	5	International Search Report for PCT/US2012/024591, mailed May 25, 2012	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	16151653
	Filing Date	2018-10-04
	First Named Inventor	Jo Ann Wilson
	Art Unit	1629
	Examiner Name	To be Determined
	Attorney Docket Number	224990/10-039C3-US/439942

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Meghan M. Klaric/	Date (YYYY-MM-DD)	2019-05-24
Name/Print	Meghan M. Klaric	Registration Number	71,226

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)		Docket Number (Optional) 224990/10-039C3-US/439942																																		
Application Number 16/151,653	Filed October 4, 2018																																			
For Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds																																				
Art Unit 1629	Examiner To be Determined																																			
This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above-identified application. The requested extension and fee are as follows (check time period desired and enter the appropriate fee below): <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;"></th> <th style="text-align: center;"><u>Fee</u></th> <th style="text-align: center;"><u>Small Entity Fee</u></th> <th style="text-align: center;"><u>Micro Entity Fee</u></th> <th style="text-align: center;"></th> </tr> </thead> <tbody> <tr> <td>☐ One month (37 CFR 1.17(a)(1))</td> <td style="text-align: center;">\$200</td> <td style="text-align: center;">\$100</td> <td style="text-align: center;">\$50</td> <td style="text-align: center;">\$ _____</td> </tr> <tr> <td>☐ Two months (37 CFR 1.17(a)(2))</td> <td style="text-align: center;">\$600</td> <td style="text-align: center;">\$300</td> <td style="text-align: center;">\$150</td> <td style="text-align: center;">\$ _____</td> </tr> <tr> <td>☐ Three months (37 CFR 1.17(a)(3))</td> <td style="text-align: center;">\$1,400</td> <td style="text-align: center;">\$700</td> <td style="text-align: center;">\$350</td> <td style="text-align: center;">\$ _____</td> </tr> <tr> <td>☐ Four months (37 CFR 1.17(a)(4))</td> <td style="text-align: center;">\$2,200</td> <td style="text-align: center;">\$1,100</td> <td style="text-align: center;">\$550</td> <td style="text-align: center;">\$ _____</td> </tr> <tr> <td>☒ Five months (37 CFR 1.17(a)(5))</td> <td style="text-align: center;">\$3,000</td> <td style="text-align: center;">\$1,500</td> <td style="text-align: center;">\$750</td> <td style="text-align: center;">\$ 3,000.00</td> </tr> </tbody> </table> ☐ Applicant asserts small entity status. See 37 CFR 1.27. ☐ Applicant certifies micro entity status. See 37 CFR 1.29. Form PTO/SB/15A or B or equivalent must either be enclosed or have been submitted previously. ☐ A check in the amount of the fee is enclosed. ☐ Payment by credit card. Form PTO-2038 is attached. ☐ The Director has already been authorized to charge fees in this application to a Deposit Account. ☒ The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number <u>503145</u>. ☒ Payment made via EFS-Web. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. I am the ☐ applicant. ☒ attorney or agent of record. Registration number <u>71,226</u>. ☐ attorney or agent acting under 37 CFR 1.34. Registration number _____. <table style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <tr> <td style="width: 50%; vertical-align: bottom;"> <u>/Meghan M. Klaric/</u> Signature </td> <td style="width: 50%; vertical-align: bottom;"> <u>May 24, 2017</u> Date </td> </tr> <tr> <td style="vertical-align: bottom;"> <u>Meghan M. Klaric</u> Typed or printed name </td> <td style="vertical-align: bottom;"> <u>734-418-4294</u> Telephone Number </td> </tr> </table> NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. Submit multiple forms if more than one signature is required, see below*.				<u>Fee</u>	<u>Small Entity Fee</u>	<u>Micro Entity Fee</u>		☐ One month (37 CFR 1.17(a)(1))	\$200	\$100	\$50	\$ _____	☐ Two months (37 CFR 1.17(a)(2))	\$600	\$300	\$150	\$ _____	☐ Three months (37 CFR 1.17(a)(3))	\$1,400	\$700	\$350	\$ _____	☐ Four months (37 CFR 1.17(a)(4))	\$2,200	\$1,100	\$550	\$ _____	☒ Five months (37 CFR 1.17(a)(5))	\$3,000	\$1,500	\$750	\$ 3,000.00	<u>/Meghan M. Klaric/</u> Signature	<u>May 24, 2017</u> Date	<u>Meghan M. Klaric</u> Typed or printed name	<u>734-418-4294</u> Telephone Number
	<u>Fee</u>	<u>Small Entity Fee</u>	<u>Micro Entity Fee</u>																																	
☐ One month (37 CFR 1.17(a)(1))	\$200	\$100	\$50	\$ _____																																
☐ Two months (37 CFR 1.17(a)(2))	\$600	\$300	\$150	\$ _____																																
☐ Three months (37 CFR 1.17(a)(3))	\$1,400	\$700	\$350	\$ _____																																
☐ Four months (37 CFR 1.17(a)(4))	\$2,200	\$1,100	\$550	\$ _____																																
☒ Five months (37 CFR 1.17(a)(5))	\$3,000	\$1,500	\$750	\$ 3,000.00																																
<u>/Meghan M. Klaric/</u> Signature	<u>May 24, 2017</u> Date																																			
<u>Meghan M. Klaric</u> Typed or printed name	<u>734-418-4294</u> Telephone Number																																			

☐ * Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.136(a). The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors:	Jo Ann Wilson, et al.	Art Unit:	1629
Application No.:	16/151,653	Examiner:	To Be Determined
Filing Date:	October 4, 2018	Conf. No.:	6871
Atty. Docket No.:	224990/10-039C3-US/439942		

Title: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8(a)

The undersigned hereby certifies that the following documents are being submitted in accordance with 37 C.F.R. § 1.6(a)(4) on the 24th day of May, 2019.

1. Cover Letter to the Commissioner for Patents;
2. Response to Notice to File Missing Parts dated October 25, 2018;
3. Information Disclosure Statement (PTO/SB/08a);
4. Petition for Extension of Time (PTO/AIA/22); and
5. This Certificate of Transmission under 37 C.F.R. § 1.8(a).

/Amy L. Peters/

Amy L. Peters (for Heidi M. Berven, Reg. No. 48,951)

Electronic Patent Application Fee Transmittal

Application Number:	16151653			
Filing Date:	04-Oct-2018			
Title of Invention:	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds			
First Named Inventor/Applicant Name:	Jo Ann Wilson			
Filer:	Meghan Mary Klaric/Amy Peters			
Attorney Docket Number:	224990/10-039C3-US/439942			
Filed as Large Entity				
Filing Fees for Utility under 35 USC 111(a)				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
LATE FILING FEE FOR OATH OR DECLARATION	1051	1	160	160
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Extension - 5 months with \$0 paid	1255	1	3000	3000
Miscellaneous:				
Total in USD (\$)				3160

Electronic Acknowledgement Receipt

EFS ID:	36110674
Application Number:	16151653
International Application Number:	
Confirmation Number:	6871
Title of Invention:	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
First Named Inventor/Applicant Name:	Jo Ann Wilson
Customer Number:	91684
Filer:	Meghan Mary Klaric/Amy Peters
Filer Authorized By:	Meghan Mary Klaric
Attorney Docket Number:	224990/10-039C3-US/439942
Receipt Date:	24-MAY-2019
Filing Date:	04-OCT-2018
Time Stamp:	13:41:01
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		2019_05_24_12_48_01.pdf	1178109	yes	27
			8a87683eac89fa4dd98adb8f8f182be56953b74		

	Multipart Description/PDF files in .zip description		
	Document Description	Start	End
	Miscellaneous Incoming Letter	1	2
	Applicant Response to Pre-Exam Formalities Notice	3	3
	Claims	4	12
	Applicant Arguments/Remarks Made in an Amendment	13	16
	Information Disclosure Statement (IDS) Form (SB08)	17	25
	Extension of Time	26	26
	Miscellaneous Incoming Letter	27	27

Warnings:

Information:

2	Fee Worksheet (SB06)	fee-info.pdf	32688	no	2
			01f37c7ad379fcd391948ae266a65d15bca1d16d		

Warnings:

Information:

Total Files Size (in bytes):	1210797
-------------------------------------	---------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

VIA EFS

May 24, 2019

Commissioner for Patents
United States Patent and Trademark Office
P. O. Box 1450
Alexandria, VA 22313

Re: US Patent Application No.: 16/151,653
Inventors: Jo Ann Wilson, et al.
Filing Date: October 4, 2018
Title: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
Attorney Docket No.: 224990/10-039C3-US/439942

Dear Sir or Madam:

Enclosed for filing please find the following documents:

1. This Cover Letter to the Commissioner for Patents;
2. Response to Notice to File Missing Parts dated October 25, 2018;
3. Information Disclosure Statement (PTO/SB/08a);
4. Petition for Extension of Time (PTO/AIA/22); and
5. Certificate of Transmission under 37 C.F.R. § 1.8(a).

The Applicant notes that the filing of the enclosed Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement qualifies as prior art under 35 U.S.C. § § 102 or 103, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). It is believed that no fee is due pursuant to 37 C.F.R. § 1.97(b)(3). In accordance with 37 C.F.R. § 1.98(d), copies of the cited references are not provided because they were previously provided to the Office in earlier application USSN 15/348,716. The Applicant will gladly provide the references to the Examiner, however, upon request.

It is believed that due with this submission is the five-month Extension of Time Fee of \$3,000.00 and the \$160.00 surcharge for late submission of inventor's oath or declaration. The Applicant hereby authorizes the Patent Office to charge this total of \$3,160.00 to Deposit Account No. 503145, referencing Attorney Docket Number 224990/10-039C3-US/439942.

HONIGMAN

Commissioner for Patents

May 24, 2019

Page 2

Very truly yours,

HONIGMAN LLP

/Meghan M. Klaric/

Meghan M. Klaric

Reg. No. 71,226

MMK/ayp

Enclosures



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
16/151,653	10/04/2018	Jo Ann Wilson	224990/10-039C3-US/439942

CONFIRMATION NO. 6871

91684
JONATHAN P. O'BRIEN, PH.D.
HONIGMAN LLP
650 Trade Centre Way
Suite 200
Kalamazoo, MI 49002-0402

PUBLICATION NOTICE



OC000000105501715

Title:Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

Publication No.US-2019-0030021-A1

Publication Date:01/31/2019

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently <http://www.uspto.gov/patft/>.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Public Records Division. The Public Records Division can be reached by telephone at (571) 272-3150 or (800) 972-6382, by facsimile at (571) 273-3250, by mail addressed to the United States Patent and Trademark Office, Public Records Division, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently <https://portal.uspto.gov/pair/PublicPair>. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

MULTIPLE DEPENDENT CLAIM FEE CALCULATION SHEET Substitute for Form PTO-1360 (For use with Form PTO/SB/06)							Application Number 16151653		Filing Date	
							Applicant(s) Jo Ann Wilson			
							* May be used for additional claims or amendments			
CLAIMS	AS FILED		AFTER FIRST AMENDMENT		AFTER SECOND AMENDMENT			*	*	*
	Indep	Depend	Indep	Depend	Indep	Depend				
1	1									
2		1								
3		1								
4		1								
5		1								
6		1								
7		1								
8		1								
9		1								
10		1								
11		1								
12		1								
13		1								
14	1									
15	1									
16	1									
17	1									
18	1									
19	1									
20	1									
21	1									
22	1									
23	1									
24	1									
25	1									
26	1									
27	1									
28		8								
29		8								
30		8								
31		8								
32		8								
33		8								
34		8								
35										
36										
37										
38										
39										
40										
41										
42										
43										
44										
45										
46										
47										
48										
49										
50										
Total Indep	15		0		0					
Total Depend	68		0		0					
Total Claims	83		0		0					
51										
52										
53										
54										
55										
56										
57										
58										
59										
60										
61										
62										
63										
64										
65										
66										
67										
68										
69										
70										
71										
72										
73										
74										
75										
76										
77										
78										
79										
80										
81										
82										
83										
84										
85										
86										
87										
88										
89										
90										
91										
92										
93										
94										
95										
96										
97										
98										
99										
100										



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLAIMS	IND CLAIMS
16/151,653	10/04/2018	1629	1720	224990/10-039C3-US/439942	34	15

CONFIRMATION NO. 6871

FILING RECEIPT



00000000103323904

91684
JONATHAN P. O'BRIEN, PH.D.
HONIGMAN MILLER SCHWARTZ AND COHN LLP
650 Trade Centre Way
Suite 200
Kalamazoo, MI 49002-0402

Date Mailed: 10/26/2018

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)

Jo Ann Wilson, San Francisco, CA;
Khalid Shah, South San Francisco, CA;

Applicant(s)

Exelixis, Inc., Alameda, CA

Power of Attorney: The patent practitioners associated with Customer Number 91684

Domestic Priority data as claimed by applicant

This application is a DIV of 15/348,716 11/10/2016 PAT 10123999
which is a DIV of 13/984,559 03/20/2014 PAT 9717720
which is a 371 of PCT/US12/24591 02/10/2012
which claims benefit of 61/441,520 02/10/2011
and claims benefit of 61/441,527 02/10/2011

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see <http://www.uspto.gov> for more information.) - None.

Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 10/24/2018

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 16/151,653**

Projected Publication Date: 01/31/2019

Non-Publication Request: No

Early Publication Request: No

Title

Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

Preliminary Class

514

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit <http://www.SelectUSA.gov> or call +1-202-482-6800.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875						Application or Docket Number 16/151,653				
APPLICATION AS FILED - PART I										
(Column 1)		(Column 2)		SMALL ENTITY		OR OTHER THAN SMALL ENTITY				
FOR	NUMBER FILED	NUMBER EXTRA	RATE(\$)	FEE(\$)		RATE(\$)	FEE(\$)			
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	300			
SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A	N/A			N/A	660			
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	760			
TOTAL CLAIMS (37 CFR 1.16(j))	83 minus 20 =	* 63			OR	x 100 =	6300			
INDEPENDENT CLAIMS (37 CFR 1.16(h))	15 minus 3 =	* 12				x 460 =	5520			
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						0.00			
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							820			
			TOTAL			TOTAL	14360			
* If the difference in column 1 is less than zero, enter "0" in column 2.										
APPLICATION AS AMENDED - PART II										
(Column 1)		(Column 2)		(Column 3)		SMALL ENTITY		OR OTHER THAN SMALL ENTITY		
AMENDMENT A		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)	ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)
	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))							OR		
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	
(Column 1)		(Column 2)		(Column 3)		SMALL ENTITY		OR OTHER THAN SMALL ENTITY		
AMENDMENT B		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)	ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)
	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))							OR		
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.										



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
16/151,653	10/04/2018	Jo Ann Wilson	224990/10-039C3-US/439942

CONFIRMATION NO. 6871

FORMALITIES LETTER



91684
JONATHAN P. O'BRIEN, PH.D.
HONIGMAN MILLER SCHWARTZ AND COHN LLP
650 Trade Centre Way
Suite 200
Kalamazoo, MI 49002-0402

Date Mailed: 10/26/2018

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing.

Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- Additional claim fees of \$ **12640** as an undiscounted entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
- Surcharge as set forth in 37 CFR 1.16(f) must be submitted.
The surcharge is due for any one of:
 - late submission of the basic filing fee, search fee, or examination fee,
 - late submission of inventor's oath or declaration,
 - filing an application that does not contain at least one claim on filing, or
 - submission of an application filed by reference to a previously filed application.

SUMMARY OF FEES DUE:

The fee(s) required within **TWO MONTHS** from the date of this Notice to avoid abandonment is/are itemized below. No entity status discount is in effect. If applicant is qualified for small entity status, a written assertion of small entity status must be submitted to establish small entity status. (See 37 CFR 1.27). If applicant is qualified for micro entity status, an acceptable Certification of Micro Entity Status must be submitted to establish micro entity status. (See 37 CFR 1.29 and forms PTO/SB/15A and 15B.)

- \$ **160** surcharge.
- \$ **5520** for **12** independent claims over 3.
- \$ **6300** for **63** total claims over 20.
- \$ **820** for multiple dependent claim surcharge.
- \$(**0**) previous unapplied payment amount.
- \$ **12800** TOTAL FEE BALANCE DUE.

Items Required To Avoid Processing Delays:

Applicant is notified that the above-identified application contains the deficiencies noted below. No period for reply is set forth in this notice for correction of these deficiencies. However, if a deficiency relates to the inventor's oath or declaration, the applicant must file an oath or declaration in compliance with 37 CFR 1.63, or a substitute statement in compliance with 37 CFR 1.64, executed by or with respect to each actual inventor no later than the expiration of the time period set in the "Notice of Allowability" to avoid abandonment. See 37 CFR 1.53(f).

- A properly executed inventor's oath or declaration has not been received for the following inventor(s):
Khalid Shah

Replies must be received in the USPTO within the set time period or must include a proper Certificate of Mailing or Transmission under 37 CFR 1.8 with a mailing or transmission date within the set time period. For more information and a suggested format, see Form PTO/SB/92 and MPEP 512.

Replies should be mailed to:

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web, including a copy of this Notice and selecting the document description "Applicant response to Pre-Exam Formalities Notice".
<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at
(571) 272-4000 or (571) 272-4200 or 1-888-786-0101.


/nhassani/

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

NOTE: This form is to be submitted with the Power of Attorney by Applicant form (PTO/AIA/82B) to identify the application to which the Power of Attorney is directed, in accordance with 37 CFR 1.5, unless the application number and filing date are identified in the Power of Attorney by Applicant form. If neither form PTO/AIA/82A nor form PTO/AIA/82B identifies the application to which the Power of Attorney is directed, the Power of Attorney will not be recognized in the application.

Application Number	TBD
Filing Date	October 4, 2018
First Named Inventor	Jo Ann Wilson
Title	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	224990/10-039C3-US/439942

SIGNATURE of Applicant or Patent Practitioner

Signature		Date (Optional)	2018-10-04
Name	Heidi M. Berven	Registration Number	48951
Title (If Applicant is a juristic entity)	Attorney for Applicant		
Applicant Name (If Applicant is a juristic entity)	Exelixis, Inc.		

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Application Number	Filing Date

(Note: The boxes above may be left blank if information is provided on form PTO/AIA/82A.)

- ☒ I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above:

91684

OR

- ☐ I hereby appoint Practitioner(s) named in the attached list (form PTO/AIA/82C) as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above. (Note: Complete form PTO/AIA/82C.)

Please recognize or change the correspondence address for the application identified in the attached transmittal letter or the boxes above to:

- ☒ The address associated with the above-mentioned Customer Number

OR

- ☐ The address associated with Customer Number:

OR

- ☐ Firm or Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

Exelixis, Inc.

- ☐ Inventor or Joint Inventor (title not required below)
- ☐ Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)
- ☒ Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)
- ☐ Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Signature

Date (Optional)

Name

Jeffrey Hessek

Title

Executive Vice President and General Counsel

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ Total of forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL		Complete if known	
		Application Number	TBD
☐ Applicant asserts small entity status. See 37 CFR 1.27.	Filing Date	October 4, 2018	
☐ Applicant certifies micro entity status. See 37 CFR 1.29. Form PTO/SB/15A or B or equivalent must either be enclosed or have been submitted previously.	First Named Inventor	Jo Ann Wilson	
TOTAL AMOUNT OF PAYMENT (\$)	Examiner Name	TBD	
	Art Unit	TBD	
1,720	Practitioner Docket No.	224990/10-039C3-US/439942	

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 603145 Deposit Account Name: Henigman Miller Schwartz & Cohn LLP

For the above-identified deposit account, the Director is hereby authorized to (check all that apply):

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☐ Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17 ☐ Credit any overpayment of fee(s)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES (U = undiscounted fee; S = small entity fee; M = micro entity fee)

Application Type	FILING FEES			SEARCH FEES			EXAMINATION FEES			Fees Paid (\$)
	U (\$)	S (\$)	M (\$)	U (\$)	S (\$)	M (\$)	U (\$)	S (\$)	M (\$)	
Utility	300	150*	75	660	330	165	760	380	190	\$1,720
Design	200	100	50	160	80	40	600	300	150	
Plant	200	100	50	420	210	105	620	310	155	
Reissue	300	150	75	660	330	165	2,200	1,100	550	
Provisional	280	140	70	0	0	0	0	0	0	

* The \$150 small entity status filing fee for a utility application is further reduced to \$75 for a small entity status applicant who files the application via EFS-Web.

2. EXCESS CLAIM FEES

Fee Description	Undiscounted Fee (\$)	Small Entity Fee (\$)	Micro Entity Fee (\$)
Each claim over 20 (including Reissues)	100	50	25
Each independent claim over 3 (including Reissues)	460	230	115
Multiple dependent claims	820	410	205

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims	Fee (\$)	Fee Paid (\$)
-20 or HP =	x	=	0			

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
-3 or HP =	x	=	0

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$400 (\$200 for small entity) (\$100 for micro entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	/ 50 =	(round up to a whole number) x	=	0

4. OTHER FEE(S)

Non-English specification, \$130 fee (no small or micro entity discount)

Non-electronic filing fee under 37 CFR 1.16(t) for a utility application, \$400 fee (\$200 small or micro entity)

Other (e.g., late filing surcharge)

SUBMITTED BY		Registration No.	Telephone
Signature		(Attorney/Agent) 48951	269-337-7710
Name (Print/Type)	Heidi M. Berven	Date	2018-10-04

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Jo Ann Wilson, et al.
Application No.: To Be Determined
Filing Date: October 4, 2018

Art Unit: To Be Determined
Examiner: To Be Determined
Attorney Docket No.: 224990/10-039C3-US/439942

Title: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. § 1.8(a)

The undersigned hereby certifies that the following documents are being submitted in accordance with 37 C.F.R. § 1.6(a)(4) on the 4th day of October, 2018.

1. This Cover Letter to the Commissioner for Patents;
2. Utility Patent Application Transmittal form (PTO/AIA/15);
3. Application Data Sheet (PTO/AIA/14);
4. Specification, Claims, and Abstract (47 pages);
5. Preliminary Amendment;
6. Inventor Declaration (1);
7. Power of Attorney (PTO/AIA/82);
8. Fee Transmittal form (PTO/SB/17); and
9. Certificate of Transmission under 37 C.F.R. § 1.8(a).

/Amy L. Peters/

Amy L. Peters (for Heidi M. Berven, Reg. No. 48,951)

Electronic Patent Application Fee Transmittal

Application Number:

Filing Date:

Title of Invention:

Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

First Named Inventor/Applicant Name:

Jo Ann Wilson

Filer:

Heid Marie Berven/Amy Peters

Attorney Docket Number:

224990/10-039C3-US/439942

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
UTILITY APPLICATION FILING	1011	1	300	300
UTILITY SEARCH FEE	1111	1	660	660
UTILITY EXAMINATION FEE	1311	1	760	760

Pages:

Claims:

Miscellaneous-Filing:

Petition:

Patent-Appeals-and-Interference:

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
Total in USD (\$)				1720

Electronic Acknowledgement Receipt

EFS ID:	33918477
Application Number:	16151653
International Application Number:	
Confirmation Number:	6871
Title of Invention:	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
First Named Inventor/Applicant Name:	Jo Ann Wilson
Customer Number:	91684
Filer:	Heid Marie Berven/Amy Peters
Filer Authorized By:	Heid Marie Berven
Attorney Docket Number:	224990/10-039C3-US/439942
Receipt Date:	04-OCT-2018
Filing Date:	
Time Stamp:	14:02:42
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	\$ 1720
RAM confirmation Number	100518INTEFSW00000303503145
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		2018_10_04_12_46_41.pdf	5927664	yes	66
			3062d4e2636301b03c1ed7cd7be5cfe7240e984		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Miscellaneous Incoming Letter		1	2	
	Transmittal of New Application		3	3	
	Application Data Sheet		4	11	
	Specification		12	48	
	Claims		49	57	
	Abstract		58	58	
	Preliminary Amendment		59	61	
	Oath or Declaration filed		62	62	
	Power of Attorney		63	64	
	Transmittal Letter		65	65	
	Miscellaneous Incoming Letter		66	66	
	Warnings:				
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	35304	no	2
			17ed70c170e76fc756d3e0941c1a2350661c9157		
Warnings:					
Information:					
201 of 264					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

VIA EFS

October 4, 2018

Commissioner for Patents
United States Patent and Trademark Office
P. O. Box 1450
Alexandria, VA 22313

Re: US Patent Application No.: TBD
Inventors: Jo Ann Wilson, et al.
Filing Date: October 4, 2018
Title: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
Attorney Docket No.: 224990/10-039C3-US/439942

Dear Sir or Madam:

Enclosed for filing please find the following documents:

1. This Cover Letter to the Commissioner for Patents;
2. Utility Patent Application Transmittal form (PTO/AIA/15);
3. Application Data Sheet (PTO/AIA/14);
4. Specification, Claims, and Abstract (47 pages);
5. Preliminary Amendment;
6. Inventor Declaration (1);
7. Power of Attorney (PTO/AIA/82);
8. Fee Transmittal form (PTO/SB/17); and
9. Certificate of Transmission under 37 C.F.R. § 1.8(a).

This application is a divisional application of United States Serial Number 15/348,716, filed November 10, 2016, which is a divisional application of United States Serial Number 13/984,559, filed March 20, 2014, which claims priority under 35 U.S.C. § 371 to Patent Cooperation Treaty application PCT/US2012/024591, filed February 10, 2012, which claims the benefit of United States provisional application number 61/441,520, filed February 10, 2011, and United States provisional application number 61/441,527, filed February 10, 2011, the entire contents of which are incorporated herein by reference.

It is believed that due with this submission is the Basic Utility Application Fee of \$300.00, the Utility Search Fee of \$660.00, and the Utility Examination Fee of \$760.00. The Applicant hereby authorizes the Patent Office to charge this total of \$1,720.00 to Deposit Account No. 503145, referencing Attorney Docket Number 224990/10-039C3-US/439942.

HONIGMAN

Commissioner for Patents

October 4, 2018

Page 2

Very truly yours,

HONIGMAN MILLER SCHWARTZ AND COHN LLP



Heidi M. Berven, Ph.D.

Reg. No. 48,951

HMB/ayp

Enclosures


Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No.	224990/10-039C3-US/439942
	First Named Inventor	Jo Ann Wilson
	Title	Processes for Preparing Oligonucleotide Compositions and Pharmaceutical Compositions Thereof
	Priority Mail Express® Label No.	

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents.</i>	ADDRESS TO: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450
1. ☒ Fee Transmittal Form (PTO/SB/17 or equivalent) 2. ☐ Applicant asserts small entity status. <i>See 37 CFR 1.27</i> 3. ☐ Applicant certifies micro entity status. <i>See 37 CFR 1.28.</i> Applicant must attach form PTO/SB/15A or B or equivalent. 4. ☒ Specification {Total Pages <u>47</u> } Both the claims and abstract must start on a new page. (See MPEP § 608.03(a) for information on the preferred arrangement) 5. ☒ Drawing(s) (35 U.S.C. 113) {Total Sheets <u>4</u> } 6. ☒ Inventor's Oath or Declaration {Total Pages _____} (including substitute statements under 37 CFR 1.64 and assignments serving as an oath or declaration under 37 CFR 1.63(e)) a. ☐ Newly executed (original or copy) b. ☒ A copy from a prior application (37 CFR 1.63(d)) 7. ☒ Application Data Sheet * <i>See note below.</i> <i>See 37 CFR 1.76 (PTO/AIA/14 or equivalent)</i> 8. CD-ROM or CD-R in duplicate, large table, or Computer Program (Appendix) ☐ Landscape Table on CD 9. Nucleotide and/or Amino Acid Sequence Submission (if applicable, items a. – c. are required) a. ☐ Computer Readable Form (CRF) b. ☐ Specification Sequence Listing on: i. ☐ CD-ROM or CD-R (2 copies); or ii. ☐ Paper c. ☐ Statements verifying identity of above copies	ACCOMPANYING APPLICATION PAPERS 10. ☐ Assignment Papers (cover sheet & document(s)) Name of Assignee _____ 11. ☐ 37 CFR 3.73(c) Statement ☒ Power of Attorney (when there is an assignee) 12. ☐ English Translation Document (if applicable) 13. ☐ Information Disclosure Statement (PTO/SB/08 or PTO-1449) ☐ Copies of citations attached 14. ☒ Preliminary Amendment 15. ☐ Return Receipt Postcard (MPEP § 503) (Should be specifically itemized) 16. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed) 17. ☐ Nonpublication Request Under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or equivalent. 18. ☒ Other: <u>Cover Letter, Certificate of Transmission</u> _____ _____ _____

*Note: (1) Benefit claims under 37 CFR 1.78 and foreign priority claims under 1.55 must be included in an Application Data Sheet (ADS).
 (2) For applications filed under 35 U.S.C. 111, the application must contain an ADS specifying the applicant if the applicant is an assignee, person to whom the inventor is under an obligation to assign, or person who otherwise shows sufficient proprietary interest in the matter. See 37 CFR 1.46(b).

19. CORRESPONDENCE ADDRESS
☒ The address associated with Customer Number: 91684 OR ☐ Correspondence address below

Name					
Address					
City	State	Zip Code			
Country	Telephone	Email			
Signature			Date	2018-10-04	
Name (Print/Type)	Heidi M. Berven		Registration No. (Attorney/Agent)	48951	

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	224990/10-039C3-US/439942
		Application Number	
Title of Invention	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds		
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.			

Secrecy Order 37 CFR 5.2:

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Inventor 1					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Jo Ann		Wilson		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	San Francisco	State/Province	CA	Country of Residence	US
Mailing Address of Inventor:					
Address 1	74 Seward Street				
Address 2					
City	San Francisco	State/Province	CA		
Postal Code	94114	Country	US		
Inventor 2					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Khalid		Shah		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	South San Francisco	State/Province	CA	Country of Residence	US
Mailing Address of Inventor:					
Address 1	12 Amberwood Circle				
Address 2					
City	South San Francisco	State/Province	CA		
Postal Code	94080	Country	US		
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button.					Add

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below.
For further information see 37 CFR 1.33(a).

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	224990/10-039C3-US/439942
		Application Number	
Title of Invention	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds		

☐ An Address is being provided for the correspondence information of this application.			
Customer Number	91684		
Email Address	patent@honigman.com	Add Email	Remove Email

Application Information:

Title of the Invention	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds		
Attorney Docket Number	224990/10-039C3-US/439942	Small Entity Status Claimed	☐
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)		Suggested Figure for Publication (if any)	

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)
☐ Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.			
Please Select One:	☒ Customer Number	☐ US Patent Practitioner	☐ Limited Recognition (37 CFR 11.9)
Customer Number	91684		

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	224990/10-039C3-US/439942
		Application Number	
Title of Invention	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.

When referring to the current application, please leave the "Application Number" field blank.

Prior Application Status	Pending	Remove			
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
	Division of	15348716	2016-11-10		
Prior Application Status	Patented	Remove			
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)	Patent Number	Issue Date (YYYY-MM-DD)
15348716	Division of	13984559	2014-03-20	9717720	2017-08-01
Prior Application Status	Pending	Remove			
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
13984559	a 371 of international	PCT/US12/24591	2012-02-10		
Prior Application Status	Expired	Remove			
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
PCT/US12/24591	Claims benefit of provisional	61441520	2011-02-10		
Prior Application Status	Expired	Remove			
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)		
PCT/US12/24591	Claims benefit of provisional	61441527	2011-02-10		
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the Add button.					

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX)¹ the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	224990/10-039C3-US/439942
		Application Number	
Title of Invention	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds		

Application Number	Country ^j	Filing Date (YYYY-MM-DD)	Remove Access Code ^k (if applicable)
Additional Foreign Priority Data may be generated within this form by selecting the Add button.			

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013. NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	224990/10-039C3-US/439942
		Application Number	
Title of Invention	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds		

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

☐ A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

☐ B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	224990/10-039C3-US/439942
		Application Number	
Title of Invention	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds		

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant 1			
If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.			
Clear			
☐ Assignee		☐ Legal Representative under 35 U.S.C. 117	
☒ Person to whom the inventor is obligated to assign.		☐ Person who shows sufficient proprietary interest	
If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:			
Name of the Deceased or Legally Incapacitated Inventor:			
If the Applicant is an Organization check here. ☒			
Organization Name	Exelixis, Inc.		
Mailing Address Information For Applicant:			
Address 1	1851 Harbor Bay Parkway		
Address 2			
City	Alameda	State/Province	CA
Country		Postal Code	94502
Phone Number		Fax Number	
Email Address			
Additional Applicant Data may be generated within this form by selecting the Add button.			

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	224990/10-039C3-US/439942
		Application Number	
Title of Invention	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds		


Assignee 1				
Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.				
If the Assignee or Non-Applicant Assignee is an Organization check here. ☐				
Prefix	Given Name	Middle Name	Family Name	Suffix
Mailing Address Information For Assignee including Non-Applicant Assignee:				
Address 1				
Address 2				
City		State/Province		
Country ¹		Postal Code		
Phone Number		Fax Number		
Email Address				
Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button.				

Signature:

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). However, if this Application Data Sheet is submitted with the **INITIAL** filing of the application and either box A or B is **not** checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature			Date (YYYY-MM-DD)	2018-10-04
First Name	Heidi M.	Last Name	Berven	Registration Number
48951				
Additional Signature may be generated within this form by selecting the Add button.				

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	224990/10-039C3-US/439942
		Application Number	
Title of Invention	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds		

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to U.S. Provisional Application No. 61/441,520, filed February 10, 2011, and 61/441,527, filed February 10, 2011, which are incorporated herein by reference

FIELD OF THE INVENTION

[0002] This disclosure relates to processes for preparing compounds useful for modulating protein kinase enzymatic activity. More specifically, this disclosure relates to processes for preparing quinolines that are useful for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemo-invasion and to pharmaceutical compositions containing such compounds.

BACKGROUND OF THE INVENTION

[0003] Traditionally, dramatic improvements in the treatment of cancer are associated with identification of therapeutic agents acting through novel mechanisms. One mechanism that can be exploited in cancer treatment is the modulation of protein kinase activity because signal transduction through protein kinase activation is responsible for many of the characteristics of tumor cells. Protein kinase signal transduction is of particular relevance in, for example, renal, gastric, head and neck, lung, breast, prostate, and colorectal cancers; hepatocellular carcinoma; as well as in the growth and proliferation of brain tumor cells.

[0004] Protein kinases can be categorized as receptor type or non-receptor type. Receptor-type tyrosine kinases are comprised of a large number of transmembrane receptors with diverse biological activity. For a detailed discussion of the receptor-type tyrosine kinases, see Plowman et al., DN&P 7(6): 334-339, 1994. Since protein kinases and their ligands play critical roles in various cellular activities, deregulation of protein kinase enzymatic activity can lead to altered cellular properties, such as uncontrolled cell growth associated with cancer. In addition to oncological indications, altered kinase signaling is implicated in numerous other pathological diseases, including, for example, immunological disorders, cardiovascular diseases, inflammatory diseases, and degenerative diseases. Therefore, protein kinases are attractive targets for small molecule drug discovery. Particularly attractive targets for small-molecule modulation with respect to antiangiogenic

and antiproliferative activity include receptor type tyrosine kinases c-Met, KDR, c-Kit, Axl, flt-3, and flt-4.

[0005] The kinase c-Met is the prototypic member of a subfamily of heterodimeric receptor tyrosine kinases (RTKs) which include Met, Ron, and Sea. The endogenous ligand for c-Met is the hepatocyte growth factor (HGF), a potent inducer of angiogenesis. Binding of HGF to c-Met induces activation of the receptor via autophosphorylation, resulting in an increase of receptor dependent signaling, which promotes cell growth and invasion. Anti-HGF antibodies or HGF antagonists have been shown to inhibit tumor metastasis *in vivo* (See: Maulik et al Cytokine & Growth Factor Reviews 2002 13, 41-59). c-Met overexpression has been demonstrated on a wide variety of tumor types including breast, colon, renal, lung, squamous cell myeloid leukemia, hemangiomas, melanomas, astrocytomas, and glioblastomas. Additionally, activating mutations in the kinase domain of c-Met have been identified in hereditary and sporadic renal papilloma and squamous cell carcinoma. (See, e.g., Maulik et al., Cytokine & growth Factor reviews 2002 13, 41-59; Longati et al., Curr Drug Targets 2001, 2, 41-55; Funakoshi et al., Clinica Chimica Acta 2003 1-23).


[0006] Inhibition of epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and ephrin signal transduction will prevent cell proliferation and angiogenesis, two key cellular processes needed for tumor growth and survival (Matter A., Drug Disc. Technol. 2001 6, 1005-1024). Kinase KDR (refers to kinase insert domain receptor tyrosine kinase) and flt-4 (fms-like tyrosine kinase-4) are both VEGF receptors. Inhibition of EGF, VEGF, and ephrin signal transduction will prevent cell proliferation and angiogenesis, two key cellular processes needed for tumor growth and survival (Matter A. Drug Disc. Technol. 2001 6, 1005-1024). EGF and VEGF receptors are desirable targets for small molecule inhibition. All members of the VEGF family stimulate cellular responses by binding to tyrosine kinase receptors (the VEGFRs) on the cell surface, causing them to dimerize and become activated through transphosphorylation. The VEGF receptors have an extracellular portion with immunoglobulin-like domains, a single transmembrane spanning region, and an intracellular portion containing a split tyrosine-kinase domain. VEGF binds to VEGFR-1 and VEGFR-2. VEGFR-2 is known to mediate almost all of the known cellular responses to VEGF.

[0007] Kinase c-Kit (also called stem cell factor receptor or steel factor receptor) is a type 3 receptor tyrosine kinase (RTK) belonging to the platelet-derived growth factor receptor subfamily. Overexpression of c-Kit and c-Kit ligand has been described in variety of human

diseases, including human gastrointestinal stromal tumors, mastocytosis, germ cell tumors, acute myeloid leukemia (AML), NK lymphoma, small-cell lung cancer, neuroblastomas, gynecological tumors, and colon carcinoma. Moreover, elevated expression of c-Kit may also relate to the development of neoplasia associated with neurofibromatosis type 1 (NF-1), mesenchymal tumors GISTs, and mast cell disease, as well as other disorders associated with activated c-Kit.

[0008] Kinase Flt-3 (fms-like tyrosine kinase-3) is constitutively activated via mutation, either in the juxtamembrane region or in the activation loop of the kinase domain, in a large proportion of patients with AML (Reilly, *Leuk. Lymphoma*, 2003, 44: 1-7).

[0009] Small-molecule compounds that specifically inhibit, regulate, and/or modulate the signal transduction of kinases, such as c-Met, VEGFR2, KDR, c-Kit, Axl, flt-3, and flt-4 described above, are particularly desirable as a means to treat or prevent disease states associated with abnormal cell proliferation and angiogenesis. One such small-molecule is compound IA, which has the chemical structure:



IA

WO2005/030140 describes the synthesis of compound IA (Table 2, Compound 12, Example 48) and also discloses the therapeutic activity of this molecule to inhibit, regulate, and/or modulate the signal transduction of kinases (Assays, Table 4, entry 289), the entire contents of which is incorporated herein by reference.


[0010] Although therapeutic efficacy is the primary concern for a therapeutic agent, the pharmaceutical composition can be equally important to its development. Generally, the drug developer endeavors to discover a pharmaceutical composition that possesses desirable properties, such as satisfactory water-solubility (including rate of dissolution), storage stability, hygroscopicity, and reproducibility, all of which can impact the processability, manufacture, and/or bioavailability of the drug.

[0011] Accordingly, there is a need for the discovery of new processes for making quinolines such as compound IA that minimize the formation of undesirable process contaminants or byproducts. There is also a need for new pharmaceutical compositions containing quinolines such as compound IA that are essentially free of process byproducts.

SUMMARY OF THE INVENTION

[0012] These and other needs are met by the present disclosure, which is directed to processes for making and compositions containing quinolines or pharmaceutically acceptable salts thereof.

[0013] In one aspect, the disclosure relates to processes for preparing a compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

X¹ is H, Br, Cl, or F;

X² is H, Br, Cl, or F;


n₁ is 1-2; and

n₂ is 1-2.

[0014] Intermediates useful in preparing the above compounds are also disclosed.


[0015] The compounds of formula I are useful as protein kinase modulators, and they inhibit various protein kinases including Ret and c-Met.

[0016] In another aspect, the disclosure provides a process for preparing compound IB:



IB

from compound IA:




IA,

comprising:


- (a) heating and agitating a mixture comprising compound IA and L-malic acid, methylethyl ketone, and water;
- (b) cooling the mixture;
- (c) vacuum distilling the mixture successively; and
- (d) isolating the compound of IB by filtration.

[0017] In another aspect, the disclosure provides a process for preparing compound IB:



IB

from compound IA:



IA,


comprising:

- (a) heating and agitating a mixture comprising compound IA and L-malic acid, methylethyl ketone, and water;
- (b) cooling the mixture;
- (c) seeding the mixture with compound IB;
- (d) vacuum distilling the mixture; and

(e) isolating compound IB by filtration.

[0018] In another aspect, the disclosure provides compound I, IA, or IB admixed with

less than 100 ppm 6,7-dimethoxy-quinoline-4-ol, the structure of which is



[0019] In another aspect, the disclosure provides pharmaceutical compositions containing the compound of formula I, compound IA, or compound IB for oral administration.

[0020] In another aspect, the disclosure provides a pharmaceutical tablet composition according to Table 1.

Table 1

Ingredient	% w/w
Compound I	31.68
Microcrystalline Cellulose (MCC) (Avicel PH102)	38.85
Lactose anhydrous 60 M	19.42
Hydroxypropyl Cellulose, EXF	3.00
Croscarmellose Sodium	3.00
Total Intra-granular	95.95
Silicon dioxide, Colloidal PWD	0.30
Croscarmellose Sodium	3.00
Magnesium Stearate	0.75
Total	100.00

[0021] In another aspect, the disclosure provides a pharmaceutical tablet composition according to Table 2.

Table 2

Ingredient	(% w/w)
Compound I	25.0-33.3
Microcrystalline Cellulose, NF	q.s
Hydroxypropyl Cellulose, NF	3
Poloxamer, NF	0-3
Croscarmellose Sodium, NF	6.0
Colloidal Silicon Dioxide, NF	0.5
Magnesium Stearate, NF	0.5-1.0
Total	100

[0022] In another aspect, the disclosure provides a pharmaceutical tablet composition according to Table 2A.

Table 2A

Ingredient	% w/w
Compound IB (10 % drug load as Compound IA)	12.67
MCC	51.52
Lactose	25.76
Hydroxypropyl cellulose	3.0
Croscarmellose Sodium	6.0
Colloidal Silicon Dioxide	0.3
Magnesium Stearate	0.75
Total	100

[0023] In another aspect, the disclosure provides a pharmaceutical capsule composition according to Table 3.

Table 3

Ingredient	mg/unit dose
Compound IB (10 % drug load as Compound IA)	25
Silicified Microcrystalline Cellulose	196.75
Croscarmellose sodium	12.5
Sodium starch glycolate	12.5
Fumed Silica	0.75
Stearic acid	2.5
Total Fill Weight	250

[0024] In another aspect, the disclosure provides a pharmaceutical capsule composition according to Table 4.

Table 4

Ingredient	mg/unit dose
Compound IB (50 % drug load as Compound IA)	100
Silicified Microcrystalline Cellulose	75.40
Croscarmellose sodium	10.00
Sodium Starch Glycolate	10.00
Fumed silica	0.6
Stearic Acid	4.0
Total Fill Weight	200

[0025] In another aspect, the disclosure provides a pharmaceutical capsule composition according to Table 5, wherein the IB weight equivalents are provided.

Table 5


	mg/unit dose
Ingredient	50mg
Compound IB	63.35
Microcrystalline Cellulose	95.39
Croscarmellose sodium	9.05
Sodium starch glycolate	9.05
Fumed Silica	0.54
Stearic acid	3.62
Total Fill Weight	181.00

[0026] In another aspect, the disclosure provides a pharmaceutical capsule composition according to Table 6, wherein the IB weight equivalents are provided.

Table 6

	mg/unit dose
Ingredient	60mg
Compound IB	73.95
Microcrystalline Cellulose	114.36
Croscarmellose sodium	10.85
Sodium starch glycolate	10.85
Fumed Silica	0.65
Stearic acid	4.34
Total Fill Weight	217.00

[0027] In another aspect, the invention is directed to a pharmaceutical composition comprising compound I, IA, or IB admixed with less than 100 ppm 6,7-dimethoxy-quinoline-

4-ol, the structure of which is  , and a pharmaceutically acceptable carrier.

[0028] There are many different aspects and embodiments of the disclosure described herein, and each aspect and each embodiment is non-limiting in regard to the scope of the disclosure. The terms “aspects” and “embodiments” are meant to be non-limiting regardless of where the terms “aspect” or “embodiment” appears in this specification. The transitional term “comprising,” as used herein, which is synonymous with “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0029] As used herein, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise or they are expressly defined to mean something different.

[0030] The word “can” is used in a non-limiting sense and in contradistinction to the word “must.” Thus, for example, in many aspects of the invention a certain element is described as “can” having a specified identity, which is meant to convey that the subject element is permitted to have that identity according to the invention but is not required to have it.

[0031] If a group “R” is depicted as “floating” on a ring system, then unless otherwise defined, the substituent(s) “R” can reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the ring atoms, so long as a stable structure is formed.

[0032] When there are more than one such depicted “floating” groups, such as where there are two groups; then, unless otherwise defined, the “floating” groups can reside on any atoms of the ring system, again assuming each replaces a depicted, implied, or expressly defined hydrogen on the ring.

[0033] “Pharmaceutically acceptable salts” include acid addition salts.

[0034] “Pharmaceutically acceptable acid addition salt” refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or mixtures thereof, as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like, or mixtures thereof.

[0035] “Essentially free” as used in the phrase “essentially free of process byproducts or contaminants,” means that a compound or composition as disclosed here in is admixed with 200 parts per million (ppm) or less of such byproducts or contaminants.


[0036] The disclosure is further illustrated by the following examples, which are not to be construed as limiting the disclosure in scope or spirit to the specific procedures described in them. Unless specified otherwise, the starting materials and various intermediates may be

obtained from commercial sources, prepared from commercially available organic compounds, or prepared using well-known synthetic processes.

Processes

Aspect 1: Processes for Making Compounds of Formula I

[0037] Aspect (1) of the invention relates to a process of preparing a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

X^1 is H, Br, Cl, or F;


X^2 is H, Br, Cl, or F;

n_1 is 1-2; and

n_2 is 1-2;

the process comprising:

contacting the compound of formula g(1) with reactant z(1) to yield the compound of formula I:



[0038] The reaction is advantageously carried out under suitable reaction conditions. Non-limiting examples of suitable reaction conditions include using basic conditions. Non-limiting examples of basic conditions that can be used in Aspect (1) include the use of inorganic bases, such as aqueous KOH, NaOH, K_2CO_3 , Na_2CO_3 , K_3PO_4 , Na_3PO_4 , K_2HPO_4 , Na_2HPO_4 , and the like, or mixtures thereof. Other non-limiting examples of suitable reaction conditions include using suitable solvents. Non-limiting examples of suitable solvents that can be used include water miscible solvents, such as THF, acetone, ethanol, and the like, or mixtures thereof. Other non-limiting examples of suitable reaction conditions include using suitable temperatures. Suitable temperatures that may be used for the reaction include a

temperature at a range from about 10 °C to about 30 °C, or alternatively, at a range from about 15 °C to about 28 °C, or alternatively, at a range from about 20 °C to about 25 °C. The product formed by the reaction is in the free base form, and this free base form may be converted into a pharmaceutically acceptable salt thereof by processes known in the art. For example, the compound of formula I can be converted to the L-malate salt by the addition of L-malic acid and a suitable solvent.

[0039] Utilities of the compound of formula I are further described in WO 2005/030140 A2, which is incorporated herein by reference.

Embodiments of Aspect (1) Part A

- [0040] In another embodiment of Aspect (1), X¹ is Cl or F.
- [0041] In another embodiment of Aspect (1), X² is Cl or F.
- [0042] In another embodiment of Aspect (1), X¹ is F.
- [0043] In another embodiment of Aspect (1), X² is F.
- [0044] In another embodiment of Aspect (1), X¹ is H.
- [0045] In another embodiment of Aspect (1), X² is H.
- [0046] In another embodiment of Aspect (1), n₁ is 1.
- [0047] In another embodiment of Aspect (1), n₂ is 1.
- [0048] In another embodiment of Aspect (1), n₁ is 2.
- [0049] In another embodiment of Aspect (1), n₂ is 2.
- [0050] All compounds of formula I for Aspect (1) disclosed above include any of the disclosed alternative embodiments in Part A for each of X¹, X², n₁ or n₂, in combination with any other of the disclosed alternative embodiments in Part A for each of X¹, X², n₁, or n₂, as well as a pharmaceutically acceptable salt of any such combination.


Embodiments of Aspect (1) Part B

- [0051] In another embodiment of Aspect (1), n₁ and n₂ are each 1.
- [0052] In another embodiment of Aspect (1), n₁ and n₂ are each 2.
- [0053] In another embodiment of Aspect (1), n₁ is 1; and n₂ is 2.
- [0054] In another embodiment of Aspect (1), n₁ is 2 and n₂ is 1.
- [0055] In another embodiment of Aspect (1), X¹ is H; and X² is F.
- [0056] In another embodiment of Aspect (1), X¹ is F; and X² is H.
- [0057] In another embodiment of Aspect (1), X¹ and X² are each H.
- [0058] In another embodiment of Aspect (1), X¹ and X² are each F.

- [0059] In another embodiment of Aspect (1), X^1 is Cl; and X^2 is H.
 [0060] In another embodiment of Aspect (1), X^1 is H; and X^2 is Cl.
 [0061] In another embodiment of Aspect (1), X^1 and X^2 are each Cl.
 [0062] In another embodiment of Aspect (1), X^1 is Cl; and X^2 is F.
 [0063] In another embodiment of Aspect (1), X^1 is F; and X^2 is Cl.

Embodiments of Aspect (1) Part C

[0064] In an embodiment of Aspect (1), the compound of formula g(1) can be made by reacting a compound of formula f(1) with reactant y(1) to yield the compound of g(1):



wherein LG represents a leaving group, and each of X^2 , and n_2 are as defined in Aspect (1), or as in any of the embodiments of Aspect (1) Part A. A non-limiting example of a leaving group includes a halo group such as Cl, Br, or F. Various compounds of reactant y(1) are commercially available, such as 2-fluoro-4-aminophenol and 4-aminophenol. Also, the skilled artisan would be able to make any variation of reactant y(1) using commercially available starting materials and by using known techniques to modify these commercially available starting materials to yield various compounds within the scope of reactant y(1).

[0065] The reaction in this embodiment is advantageously carried out under suitable reaction conditions. Non-limiting examples of suitable reaction conditions include using suitable solvents such as polar solvents. Non-limiting examples of polar solvents that can be used include tetrahydrofuran (THF), dimethylacetamide (DMA), dimethylsulfoxide (DMSO), dimethylformamide (DMF), ethyl acetate, N-methyl pyrrolidone (NMP), propylene carbonate, and the like, or mixtures thereof. In another embodiment, the polar solvent is dimethylacetamide (DMA). In another embodiment, the polar solvent is dimethylsulfoxide (DMSO). In another embodiment, the polar solvent is dimethylformamide (DMF). In another embodiment, the polar solvent is ethyl acetate. In another embodiment, the polar solvent is N-methyl pyrrolidone (NMP). In another embodiment, the polar solvent is propylene carbonate. In another embodiment, the solvent is a mixture of solvents, such as a mixture comprising THF and DMA.

[0066] The reactants f(1) and y(1) can be added together at a temperature ranging from about 10 °C to about 30 °C, or alternatively, from about 15 °C to about 28 °C, or alternatively, from about 20 °C to about 25 °C. The mixture is then heated to a temperature ranging from about 80 °C to about 125 °C, or alternatively, from about 95 °C to about 110 °C, or alternatively, from about 100 °C to about 105 °C, and the selected temperature is maintained until the reaction is complete.

[0067] Other non-limiting examples of suitable reaction conditions in this step of Aspect (1) include the use of a suitable base, such as a metal hydroxide or a non-nucleophilic base. Examples of metal hydroxides include sodium hydroxide or potassium hydroxide. Non-limiting examples of non-nucleophilic bases that can be used include lithium diisopropylamide, lithium tetramethylpiperidide, and alkali metal alkoxides such as sodium tert-butoxide, potassium tert-butoxide, sodium-pentoxide, and the like, or mixtures thereof. Preferably, the base is sodium tert-butoxide or sodium tert-pentoxide. In one embodiment, the base is sodium tert-pentoxide. Typically the sodium tert-pentoxide is commercially available as 35 weight percent solution of base in tetrahydrofuran, or as a 95 weight percent solid reagent. Preferably, the sodium tert-pentoxide is a 95 weight percent solid.


[0068] Typically, approximately 1.1 to 3.0 molar equivalents of base are used relative the moles of f(1) that are used. More preferably, 1.3 to 2.5 molar equivalents of base are used relative the moles of f(1) that are used. More preferably, 1.5 to 2.2 molar equivalents of base are used relative the moles of f(1) that are used. More preferably, 1.7 to 2.1 molar equivalents of base are used relative the moles of f(1) that are used.

[0069] Typically, the amount of molar equivalents of amino phenol that are used exceeds the molar equivalents of base that are used. In one embodiment, 1.1 to 2 molar equivalents of amino phenol are used relative to the molar equivalents of base that are used.

[0070] Once the reaction is substantially complete, the reaction mixture can be cooled to a temperature ranging from about 10 °C to about 25 °C. Precooled water can be charged at a rate to maintain a temperature that ranges from about 5 °C to about 35 °C. Alternatively, the precooled water can be charged at a rate to maintain a temperature that ranges from about 10 °C to about 25 °C. As a non-limiting example, the precooled water can be at a temperature ranging from about 0 °C to about 10 °C. As another non-limiting example, the precooled water can be at a temperature ranging from about 2 °C to about 7 °C. The precipitate can be collected by filtration under standard conditions and purified by standard purification techniques.

Embodiments of Aspect (1) Part D

[0071] In an embodiment of Aspect (1), the compound of formula f(1) can be made by converting a compound of formula e(1) to the compound of formula f(1):




wherein LG represents a leaving group. Non-limiting examples of leaving groups that can be used include halo groups (e.g., Cl, Br, or F) that can be added by halogenating agents. Non-limiting examples of halogenating agents that can be used include chlorinating agents, such as SOCl_2 , SO_2Cl_2 , COCl_2 , PCl_3 , POCl_3 , and the like.

[0072] The reaction is advantageously carried out under suitable reaction conditions. Non-limiting examples of suitable reaction conditions in Part D of Aspect (1) include the use of suitable solvents. Non-limiting example of suitable solvents that can be used during the halogenation of the compound of formula e(1) include a polar, aprotic solvent, such as CH_3CN , DMF, and the like, or mixtures thereof. In other embodiments, the chlorination can be carried out using POCl_3 in acetonitrile, COCl_2 in DMF, or SOCl_2 in DMF. The addition of the chlorination agent is advantageously carried out at a temperature ranging from about 60 °C to about 90 °C. In another embodiment, the addition of the chlorination agent can be carried out at a temperature ranging from about 70 °C to about 85 °C. In another embodiment, the addition of the chlorination agent can be carried out at a temperature ranging from about 74 °C to about 80 °C. The product can then be collected by filtration and purified using standard techniques.

Embodiments of Aspect (1) Part E

[0073] In an embodiment of Aspect (1), reactant z(1) can be made by reacting reactant z(1a) with a chlorinating agent to yield reactant z(1):




wherein X^1 is Br, Cl, or F; and $n1$ is 1-2. Compounds of reactant $z(1a)$ can be made according to the process described in Example 25 of WO 2005/030140 A2, and the skilled artisan would be able to make any necessary substitutions using commercially available starting materials to come up with various compounds within the scope of reactant $z(1a)$. Example 25 in WO 2005/030140 A2 is incorporated herein by reference.

[0074] The reaction is advantageously carried out under suitable reaction conditions. Non-limiting examples of suitable reaction conditions include using a chlorinating agent such as $POCl_3$, oxalyl chloride, and the like. In another embodiment, oxalyl chloride is used as a chlorinating agent. Non-limiting examples of suitable reaction conditions include carrying out the reaction at a temperature in the range from about 0 °C to about 25 °C, or alternatively at a temperature in the range from about 5 °C to about 20 °C. Other non-limiting examples of suitable reaction conditions include carrying out the reaction in a suitable solvent. Non-limiting examples of suitable solvents that can be used include polar aprotic solvents, such as halogenated hydrocarbons (e.g., dichloromethane and chloroform), ethers (e.g., Et_2O), dioxane, tetrahydrofuran (THF) containing catalytic DMF, and the like, or mixtures thereof. The resulting solution containing reactant $z(1)$ can be used, without further processing, to make the compound of formula I.

Other Embodiments of Aspect (1)

[0075] In another embodiment of Aspect (1), the compound of formula I is a compound of formula IA-1:




IA-1


or a pharmaceutically acceptable salt thereof, wherein:

X^1 is H, Cl, Br, or F; and X^2 is H, Cl, Br, or F. Compound IA can be in the free base form or it can be converted to a pharmaceutically acceptable salt thereof. Accordingly, compound IA can be converted to its L-malate salt by the addition of L-malic acid and a suitable solvent.


[0076] In another embodiment of Part D of Aspect (1), the compound of formula e(1) is compound e(2):




and the compound of formula f(1) is compound f(2):




[0077] In another embodiment of Part C of Aspect (1), the compound of formula f(1) is compound f(2):



reactant y(1) is reactant (y)(2):




wherein X^2 is hydrogen or fluoro; and
the compound of formula g(1) is of formula g(2):




[0078] In a further embodiment, the reaction employs a non-nucleophilic base. In a further embodiment, the non-nucleophilic base is an alkali metal alkoxide; and the reaction is carried out in a polar solvent. In a further embodiment, the alkali metal alkoxide is sodium tert-butoxide, and the polar solvent is DMA.


[0079] In another embodiment of Part C of Aspect (1), the compound of formula f(1) is compound f(2):




reactant y(1) is reactant (y)(3):




wherein X^2 is hydrogen or fluoro; and
the compound of formula g(1) is compound g(3):



[0080] In another embodiment of Aspect (1) of this disclosure, the compound of formula g(1) is compound g(3):




reactant z(1) is reactant (z)(2):



; and

the compound of formula I is compound IA:



IA

[0081] In a further embodiment, the reaction is carried out in the presence of an inorganic base. In a further embodiment, the inorganic base is K_2CO_3 , and the solvent employed in this reaction is a combination of THF and H_2O .

[0082] In another embodiment of Aspect (1) of this disclosure, X^1 and X^2 for each of formula g(1) and reactant z(1) are each selected from Cl or F. In another embodiment, X^1 and X^2 for each of formula g(2), and reactant z(1) are both F.


[0083] The compound of formula f(2), or a pharmaceutically acceptable salt thereof, can be made by converting the compound of formula e(2) to a compound of formula f(2) with a chlorinating agent in a suitable solvent:




The compound of formula f(2) can be in its free base form or converted to a pharmaceutically acceptable salt thereof. The reaction conditions that can be used in this aspect include any of the reaction conditions disclosed in Part E of Aspect (1).

Aspect 2: Processes for Making Compounds of Formula g(2)

[0084] Aspect (2) of the disclosure relates to a process of preparing compound g(2):



or a pharmaceutically acceptable salt thereof; the process comprising reacting compound f(2) with reactant y(3) under basic conditions (e.g., using 2,6-lutidine) in an appropriate solvent to yield compound g(3):




The reaction conditions that can be used in this aspect include any of the reaction conditions disclosed in Part C of Aspect (1).


[0085] Alternative reaction conditions that can be used in this aspect include any of the reaction conditions disclosed in Parts C and D of Aspect (1).

Aspect 3: Processes for Making Compounds of IB

[0086] As indicated above, in one aspect, the invention provides a process for preparing compound IB:



from compound IA:



IA;

comprising:

- (a) heating and agitating a mixture comprising compound IA and L-malic acid, methylethyl ketone, and water;
- (b) cooling the mixture;
- (c) vacuum distilling the mixture successively; and
- (d) isolating the compound of IB by filtration.

[0087] In one embodiment of this aspect, compound IA is admixed with a sufficient amount of L-malic acid in a methylethyl ketone (MEK)/water (1:1) mixture. Alternatively, L-malic acid is added as a solution in water to a mixture of compound IA in methyl ethyl ketone. Generally the amount of L-malic is greater than 1 molar equivalent relative to compound IA. The mixture of compound IA and L-malic acid in MEK/water is heated at about 40-70 °C, and preferably at about 50-60 °C, and more preferably at about 55-60 °C with agitation, such as by stirring or the like, for about 1 to about 5 hours. At the end of the heating, the mixture is optionally clarified by filtering to give a clear solution. The resulting clear solution is then vacuum distilled from 1 to about 5 times at 150 to 200 mm Hg and a maximum jacket temperature of 55 °C to provide the desired crystalline compound of IB.

[0088] In one embodiment, L-malic acid is charged as a solution in water to compound IA. Generally the amount of L-malic is greater than 1 molar equivalent relative to compound IA. The mixture of compound IA and L-malic acid in MEK/water is heated at about 40-70 °C, and preferably at about 50-60 °C, and more preferably at about 55-60 °C with agitation, such as by stirring or the like, for about 1 to about 5 hours. At the end of the heating, the mixture is optionally clarified by filtering to give a clear solution which is at a temperature of about 30-40 °C, and more preferably at a temperature of about 33-37 °C. This clear solution is optionally seeded to facilitate crystallization. After seeding, the resulting mixture is vacuum distilled as provided above.

[0089] In one embodiment, compound IB is in the N-1 form. In another embodiment, compound IB is in the N-2 form. In another embodiment, compound IB is a mixture of the N-1 form and the N-2 form. Processes for preparing the N-1 and N-2 forms of compound IB

are disclosed in WO 2010/083414 (PCT/US2010021194), the entire contents of which are incorporated herein by reference.

[0090] In another embodiment, the disclosure relates to compound IA or IB admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment, the compound is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[0091] In another embodiment, the disclosure relates to compound IA admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment, the compound is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[0092] In another embodiment, the disclosure relates to compound IB admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment, the compound is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[0093] In another embodiment, the disclosure relates to compound IB in the N-1 form admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment, the compound is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[0094] In another embodiment, the disclosure relates to compound IB in the N-2 form admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment, the compound is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[0095] In another embodiment, the disclosure relates to compound IB as a mixture of the N-1 form and the N-2 form admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment, the compound is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment, the compound is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

Pharmaceutical Compositions

[0096] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound I, IA, or IB. Various carriers used in formulating pharmaceutically acceptable compositions and known techniques for their bulk preparation and subsequent production into unit dosage forms are employed to make the pharmaceutical compositions disclosed herein and are described in Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. D. B. Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York. The amount of carriers and excipients used in a composition can be varied proportionally according to the amount of active ingredient used (that is, Compound I, IA or IB).

[0097] In one embodiment, the pharmaceutical composition is a tablet.

[0098] In another embodiment, the pharmaceutical composition is a capsule.

[0099] In another embodiment, the pharmaceutical composition comprises Compound IA.

[00100] In another embodiment, the pharmaceutical composition comprises Compound IB.

[00101] In another embodiment, the pharmaceutical composition comprises Compound IB as the N-1 polymorph.

[00102] In another embodiment, the pharmaceutical composition comprises Compound IB as the N-2 polymorph.

[00103] In another embodiment, the pharmaceutical composition comprises Compound IB as a mixture of the N-1 form and the N-2 form.

[00104] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; one or more fillers; one or more disintegrants; one or more glidants; and one or more lubricants.

[00105] In this embodiment, the filler comprises microcrystalline cellulose.

[00106] In this embodiment, the disintegrant comprises croscarmellose sodium.

[00107] In this embodiment, the disintegrant comprises croscarmellose sodium and sodium starch glycolate.

[00108] In this embodiment, the glidant comprises fumed silica.

[00109] In this embodiment, the lubricant comprises stearic acid.

[00110] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; lactose; hydroxypropyl cellulose; croscarmellose sodium; colloidal silicon dioxide; and magnesium stearate.

[00111] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; hydroxypropyl cellulose; a surfactant; croscarmellose sodium; colloidal silicon dioxide; and magnesium stearate.

[00112] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; croscarmellose sodium; fumed silica; and stearic acid.

[00113] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; anhydrous lactose; hydroxypropyl cellulose; croscarmellose sodium; silicon dioxide; and magnesium stearate.

[00114] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; anhydrous lactose; hydroxypropyl cellulose; a surfactant; croscarmellose sodium; silicon dioxide; and magnesium stearate.

[00115] In another aspect, the disclosure provides a pharmaceutical composition according to Tables 1, 2, 2A, 3, 4, 5, and 6 as provided above. The compositions are prepared according to methods available to the skilled artisan. For example, the Tablet


formulations are prepared by combining, blending, and compacting the components of the tablet compositions. The capsule compositions are prepared by combining and blending the components and then placing the blend in a gelatin capsule.


[00116] For example, the 25 mg capsules (Table 3, 10 percent drug load formulation) are prepared as follows. The drug substance is delumped through a mill. The delumped drug substance is then co-screened with an equal volume Prosolv HD90. The excipients, except for stearic acid, are screened and charged to a blender along with the co-screened drug substance. The mixture is blended in a V-Blender. This process is repeated to manufacture a second subplot of unlubricated blend. The two sublots are then combined together in a V-blender and lubricated with stearic acid which has been co-screened with an equal volume of unlubricated blend. The final blend is then encapsulated into opaque, size 1 gelatin capsules using an automated capsule filling machine. The capsules are then weight sorted through an automatic weight sorter.

[00117] The 100-mg capsules (Table 4, 50% drug load formulation) are manufactured in two equal sublots of 5 kg of blend which are combined prior to lubricant blend. The drug substance is delumped through a mill. The excipients, except for stearic acid, are screened and charged to the mixer along with the delumped drug substance. The mixture is blended with a high shear mixer. The process is repeated to manufacture a second subplot of unlubricated blend. The final blend is then encapsulated into Swedish opaque, size 1 gelatin capsules using an automated capsule filling machine. The capsules are then weight sorted through an automatic weight sorter.

[00118] The 50 and 60 mg capsules (Tables 5 and 6) are prepared in a similar fashion as the 25 and 100 mg capsules.

[00119] In another aspect, the disclosure relates to a pharmaceutical composition comprising a compound of Formula IA or IB and a pharmaceutically acceptable carrier admixed with less than 100 ppm of 6,7-dimethoxy-quinoline-4-ol. 6,7-dimethoxy-quinoline-



4-ol, the structure of which is , can be used as reagent e(1) to make chloride f(1) and is a byproduct that may form during the synthesis of Compound IA or IB. Minimizing the concentration of contaminants or byproducts such as 6,7-dimethoxy-quinoline-4-ol in pharmaceutical compositions destined for human administration is desirable.

[00120] In one embodiment, the pharmaceutical composition as defined in any of the previous embodiments (for example, the pharmaceutical composition of Tables 1, 2, 2A, 3, 4, 5, and 6) is admixed with 100 ppm 6,7-dimethoxy-quinoline-4-ol.

[00121] In another embodiment, the pharmaceutical composition as defined in any of the previous embodiments is admixed with 50 ppm 6,7-dimethoxy-quinoline-4-ol.

[00122] In another embodiment, the pharmaceutical composition as defined in any of the previous embodiments is admixed with 25 ppm 6,7-dimethoxy-quinoline-4-ol.

[00123] In another embodiment, the pharmaceutical composition as defined in any of the previous embodiments is admixed with 15 ppm 6,7-dimethoxy-quinoline-4-ol.

[00124] In another embodiment, the pharmaceutical composition as defined in any of the previous embodiments is admixed with 10 ppm 6,7-dimethoxy-quinoline-4-ol.

[00125] In another embodiment, the pharmaceutical composition as defined in any of the previous embodiments is admixed with 5 ppm 6,7-dimethoxy-quinoline-4-ol.

[00126] In another embodiment, the pharmaceutical composition as defined in any of the previous embodiments is admixed with 2.5 ppm 6,7-dimethoxy-quinoline-4-ol.

[00127] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; one or more fillers; one or more disintegrants; one or more glidants; and one or more lubricants admixed with 100 ppm or less 6,7-dimethoxy-quinoline-4-ol.

[00128] In this embodiment, the filler comprises microcrystalline cellulose.

[00129] In this embodiment, the disintegrant comprises croscarmellose sodium.

[00130] In this embodiment, the disintegrant comprises croscarmellose sodium and sodium starch glycolate.

[00131] In this embodiment, the glidant comprises fumed silica.

[00132] In this embodiment, the lubricant comprises stearic acid.

[00133] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; croscarmellose sodium; fumed silica; and stearic acid; admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment of this embodiment, the composition is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with

5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[00134] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; anhydrous lactose; hydroxypropyl cellulose; a surfactant; croscarmellose sodium; silicon dioxide; and magnesium stearate; admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment of this embodiment, the composition is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

[00135] In another embodiment, the disclosure relates to a pharmaceutical composition comprising Compound IA or IB; microcrystalline cellulose; croscarmellose sodium; fumed silica; and stearic acid; ; admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In one embodiment of this embodiment, the composition is admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol. In another embodiment of this embodiment, the composition is admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

EXAMPLES


[00136] The invention is illustrated further by the following examples in Scheme 1 and the description thereof, which are not to be construed as limiting the invention in scope or spirit to the specific procedures described in them. Those having skill in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the invention, as demonstrated by the following examples. Those skilled in the art will also recognize that it may be necessary to utilize different solvents or reagents to achieve some of the above transformations. Unless otherwise specified, all reagents and solvents are of standard commercial grade and are used without further purification. The

appropriate atmosphere to run the reaction under, for example, air, nitrogen, hydrogen, argon, and the like, will be apparent to those skilled in the art.

Preparation of N-(4-{{6,7-bis(methoxy)quinolin-4-yl}oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and the (L)-malate salt thereof.

[00137] A synthetic route that can be used for the preparation of N-(4-{{6,7-bis(methoxy)quinolin-4-yl}oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and the (L)-malate salt thereof is depicted in Figure 1:

Figure 1



Preparation of 4-Chloro-6,7-dimethoxy-quinoline

[00138] A reactor was charged sequentially with 6,7-dimethoxy-quinoline-4-ol (47.0 kg) and acetonitrile (318.8 kg). The resulting mixture was heated to approximately 60 °C, and phosphorus oxychloride (POCl₃, 130.6 kg) was added. After the addition of POCl₃, the temperature of the reaction mixture was raised to approximately 77 °C. The reaction was deemed complete (approximately 13 hours) when less than 3% of the starting material remained (in-process high-performance liquid chromatography [HPLC] analysis). The reaction mixture was cooled to approximately 2 – 7 °C and then quenched into a chilled solution of dichloromethane (DCM, 482.8 kg), 26 % NH₄OH (251.3 kg), and water (900 L). The resulting mixture was warmed to approximately 20 – 25 °C, and phases were separated.

The organic phase was filtered through a bed of AW hyflo super-cel NF (Celite; 5.4 kg) and the filter bed was washed with DCM (118.9 kg). The combined organic phase was washed with brine (282.9 kg) and mixed with water (120 L). The phases were separated and the organic phase was concentrated by vacuum distillation with the removal of solvent (approximately 95 L residual volume). DCM (686.5 kg) was charged to the reactor containing organic phase and concentrated by vacuum distillation with the removal of solvent (approximately 90 L residual volume). Methyl t-butyl ether (MTBE, 226.0 kg) was then charged and the temperature of the mixture was adjusted to -20 to -25 °C and held for 2.5 hours resulting in solid precipitate which was then filtered and washed with n-heptane (92.0 kg), and dried on a filter at approximately 25 °C under nitrogen to afford the title compound. (35.6 kg).

Preparation of 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine

[00139] 4-Aminophenol (24.4 kg) dissolved in N,N-dimethylacetamide (DMA, 184.3 kg) was charged to a reactor containing 4-chloro-6,7-dimethoxyquinoline (35.3 kg), sodium t-butoxide (21.4 kg) and DMA (167.2 kg) at 20-25 °C. This mixture was then heated to 100-105 °C for approximately 13 hours. After the reaction was deemed complete as determined using in-process HPLC analysis (<2% starting material remaining), the reactor contents were cooled at 15 to 20 °C and water (pre-cooled, 2 to 7 °C, 587 L) charged at a rate to maintain 15 to 30 °C temperature. The resulting solid precipitate was filtered, washed with a mixture of water (47 L) and DMA (89.1 kg) and finally with water (214 L). The filter cake was then dried at approximately 25 °C on filter to yield crude 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine (59.4 kg wet, 41.6 kg dry calculated based on LOD). Crude 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine was refluxed (approximately 75 °C) in a mixture of tetrahydrofuran (THF, 211.4 kg) and DMA (108.8 kg) for approximately 1 hour and then cooled to 0-5 °C and aged for approximately 1 h after which time the solid was filtered, washed with THF (147.6 kg) and dried on a filter under vacuum at approximately 25 °C to yield 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine (34.0 kg).

Alternative Preparation of 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine

[00140] 4-chloro-6,7-dimethoxyquinoline (34.8 kg) and 4-aminophenol (30.8 kg) and sodium tert pentoxide (1.8 equivalents) 88.7 kg, 35 wt percent in THF) were charged to a reactor, followed by N,N-dimethylacetamide (DMA, 293.3 kg). This mixture was then heated to 105-115 °C for approximately 9 hours. After the reaction was deemed complete as

determined using in-process HPLC analysis (<2% starting material remaining), the reactor contents were cooled at 15 to 25 °C and water (315 kg) was added over a two hour period while maintaining the temperature between 20 and 30 °C. The reaction mixture was then agitated for an additional hour at 20 to 5 °C. The crude product was collected by filtration and washed with a mixture of 88 kg water and 82.1 kg DMA, followed by 175 kg water. The product was dried on a filter drier for 53 hours. The LOD showed less than 1% w/w.

[00141] In an alternative procedure, 1.6 equivalents of sodium tert-pentoxide were used and the reaction temperature was increased from 110-120 °C. In addition, the cool down temperature was increased to 35-40 °C and the starting temperature of the water addition was adjusted to 35-40 °C, with an allowed exotherm to 45 °C.

Preparation of 1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid

[00142] Triethylamine (19.5 kg) was added to a cooled (approximately 5 °C) solution of cyclopropane-1,1-dicarboxylic acid (24.7 kg) in THF (89.6 kg) at a rate such that the batch temperature did not exceed 5 °C. The solution was stirred for approximately 1.3 hours, and then thionyl chloride (23.1 kg) was added, keeping the batch temperature below 10 °C. When the addition was complete, the solution was stirred for approximately 4 h keeping temperature below 10 °C. A solution of 4-fluoroaniline (18.0 kg) in THF (33.1 kg) was then added at a rate such that the batch temperature did not exceed 10 °C. The mixture was stirred for approximately 10 hours after which the reaction was deemed complete. The reaction mixture was then diluted with isopropyl acetate (218.1 kg). This solution was washed sequentially with aqueous sodium hydroxide (10.4 kg, 50 % dissolved in 119 L of water) further diluted with water (415 L), then with water (100 L) and finally with aqueous sodium chloride (20.0 kg dissolved in 100 L of water). The organic solution was concentrated by vacuum distillation (100 L residual volume) below 40 °C followed by the addition of n-heptane (171.4 kg), which resulted in the precipitation of solid. The solid was recovered by filtration and washed with n-Heptane (102.4 kg) resulting in wet crude, 1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid (29.0 kg). The crude, 1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid was dissolved in methanol (139.7 kg) at approximately 25 °C followed by the addition of water (320 L) resulting in slurry which was recovered by filtration, washed sequentially with water (20 L) and n-heptane (103.1 kg) and then dried on the filter at approximately 25 °C under nitrogen to afford the title compound (25.4 kg).

Preparation of 1-(4-Fluoro-phenylcarbamoyl)-cyclopropanecarbonyl chloride

[00143] Oxalyl chloride (12.6 kg) was added to a solution of 1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid (22.8 kg) in a mixture of THF (96.1 kg) and N, N-dimethylformamide (DMF; 0.23 kg) at a rate such that the batch temperature did not exceed 25 °C. This solution was used in the next step without further processing.

Alternative Preparation of 1-(4-Fluoro-phenylcarbamoyl)-cyclopropanecarbonyl chloride

[00144] A reactor was charged with 1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid (35 kg), 344 g DMF, and 175kg THF. The reaction mixture was adjusted to 12-17 °C and then to the reaction mixture was charged 19.9 kg of oxalyl chloride over a period of 1 hour. The reaction mixture was left stirring at 12-17 °C for 3 to 8 hours. This solution was used in the next step without further processing.

Preparation of cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide (Compound IA)

[00145] The solution from the previous step containing 1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarbonyl chloride was added to a mixture of compound 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine (23.5 kg) and potassium carbonate (31.9 kg) in THF (245.7 kg) and water (116 L) at a rate such that the batch temperature did not exceed 30 °C. When the reaction was complete (in approximately 20 minutes), water (653 L) was added. The mixture was stirred at 20-25 °C for approximately 10 hours, which resulted in the precipitation of the product. The product was recovered by filtration, washed with a pre-made solution of THF (68.6 kg) and water (256 L), and dried first on a filter under nitrogen at approximately 25 °C and then at approximately 45 °C under vacuum to afford the title compound (41.0 kg, 38.1 kg, calculated based on LOD).

Alternative Preparation of cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide

[00146] A reactor was charged with 4-(6,7-dimethoxy-quinoline-4-yloxy)-phenylamine (35.7 kg, 1 equivalent), followed by 412.9 kg THF. To the reaction mixture was charged a solution of 48.3 K₂CO₃ in 169 kg water. The acid chloride solution of described in the Alternative Preparation of 1-(4-Fluoro-phenylcarbamoyl)-cyclopropanecarbonyl chloride above was transferred to the reactor containing 4-(6,7-dimethoxy-quinoline-4-yloxy)-

phenylamine while maintaining the temperature between 20-30 °C over a minimum of two hours. The reaction mixture was stirred at 20-25 °C for a minimum of three hours. The reaction temperature was then adjusted to 30-25 °C and the mixture was agitated. The agitation was stopped and the phases of the mixture were allowed to separate. The lower aqueous phase was removed and discarded. To the remaining upper organic phase was added 804 kg water. The reaction was left stirring at 15-25 °C for a minimum of 16 hours.

[00147] The product precipitated. The product was filtered and washed with a mixture of 179 kg water and 157.9 THF in two portions. The crude product was dried under a vacuum for at least two hours. The dried product was then taken up in 285.1 kg THF. The resulting suspension was transferred to reaction vessel and agitated until the suspension became a clear (dissolved) solution, which required heating to 30-35 °C for approximately 30 minutes. 456 kg water was then added to the solution, as well as 20 kg SDAG-1 ethanol (ethanol denatured with methanol over two hours. The mixture was agitated at 15-25 °C for at least 16 hours. The product was filtered and washed with a mixture of 143 kg water and 126.7 THF in two portions. The product was dried at a maximum temperature set point of 40 °C.

[00148] In an alternative procedure, the reaction temperature during acid chloride formation was adjusted to 10-15 °C. The recrystallization temperature was changed from 15-25 °C to 45-50 °C for 1 hour and then cooled to 15-25 °C over 2 hours.

Preparation of cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L) malate salt (Compound IB)

[00149] Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide (1-5; 13.3 kg), L-malic acid (4.96 kg), methyl ethyl ketone (MEK; 188.6 kg) and water (37.3 kg) were charged to a reactor and the mixture was heated to reflux (approximately 74 °C) for approximately 2 hours. The reactor temperature was reduced to 50 to 55 °C and the reactor contents were filtered. These sequential steps described above were repeated two more times starting with similar amounts of 1-5 (13.3 kg), L-Malic acid (4.96 kg), MEK (198.6 kg) and water (37.2 kg). The combined filtrate was azeotropically dried at atmospheric pressure using MEK (1133.2 kg) (approximate residual volume 711 L; KF ≤ 0.5 % w/w) at approximately 74 °C. The temperature of the reactor contents was reduced to 20 to 25 °C and held for approximately 4 hours resulting in solid precipitate which was filtered, washed with MEK (448 kg) and dried under vacuum at 50°C to afford the title compound (45.5 kg).

Alternative Preparation of cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L) malate salt

[00150] Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide (47.9 kg), L-malic acid (17.2), 658.2 kg methyl ethyl ketone, and 129.1 kg water (37.3 kg) were charged to a reactor and the mixture was heated 50-55 °C for approximately 1-3 hours, and then at 55-60 °C for an additional 4-5 hours. The mixture was clarified by filtration through a 1 µm cartridge. The reactor temperature was adjusted to 20-25 °C and vacuum distilled with a vacuum at 150-200 mm Hg with a maximum jacket temperature of 55 °C to the volume range of 558-731 L.

[00151] The vacuum distillation was performed two more times with the charge of 380 kg and 380.2 kg methyl ethyl ketone, respectively. After the third distillation, the volume of the batch was adjusted to 18 v/w of Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide by charging 159.9 kg methyl ethyl ketone to give a total volume of 880L. An additional vacuum distillation was carried out by adjusting 245.7 methyl ethyl ketone. The reaction mixture was left with moderate agitation at 20-25 °C for at least 24 hours. The product was filtered and washed with 415.1 kg methyl ethyl ketone in three portions. The product was dried under a vacuum with the jacket temperature set point at 45 °C.

[00152] In an alternative procedure, the order of addition was changed so that a solution of 17.7 kg L-malic acid dissolved in 129.9 kg water was added to Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide (48.7 kg) in methyl ethyl ketone (673.3 kg).

Preparation of Compound IB, Form N-1

[00153] A solution was prepared by adding tetrahydrofuran (12 mL/g-bulk-LR (limiting reagent); 1.20 L) and N-(4-[[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (100 g; 1.00 equiv; 100.00 g) and (L)-malic acid (1.2 equiv (molar); 32.08 g) to a 1 L reactor. Water (0.5317 mL/g-bulk-LR; 53.17 mL) was added and the solution was heated to 60 °C and maintained at that temperature for one hour until the solids were fully dissolved. The solution was passed through a Polish Filter.

[00154] At 60 °C, acetonitrile (12 mL/g-bulk-LR; 1.20 L) was added over a period of 8 hours. The solution was held at 60 °C for 10 hours. The solution was then cooled to 20 °C and held for 1 hour. The solids were filtered and washed with acetonitrile (12 mL/g-bulk-LR;

1.20 L). The solids were dried at 60 °C (25 mm Hg) for 6 hours to afford compound (I), Form N-1 (108 g; 0.85 equivalent; 108.00 g; 85.22% yield) as a white crystalline solid.

Alternate Preparation of Compound IB, Form N-1

[00155] A solution was prepared with 190 mL tetrahydrofuran (110 mL), methyl isobutyl ketone, and 29 mL water. Next, 20 mL of this solution were transferred into an amber bottle, and then saturated by adding N-(4-{{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (L)-malate until a thick slurry formed, and aging for at least 2 hours with stirring at room temperature. The solids were removed by filtration through a Buchner funnel, rendering a clear saturated solution.

[00156] Separately, a powder blend was made with known amounts of two batches of compound IB: (1) 300 mg of batch 1, which contained approximately 41% compound IB, Form N-1 and 59% compound IB, Form N-2 by Raman spectroscopy analysis, and (2) 200 mg of batch 2, which had a XPRD pattern similar to compound IB, Form N-2.

[00157] The compound IB, Form N-1 and compound (I), Form N-2 powder blend was added into the saturated solution, and the slurry was aged under magnetic stirring at room temperature for 25 days. The slurry was then sampled and filtered through a Buchner funnel to obtain 162 mg of wet cake. The wet cake was dried in a vacuum oven at 45 °C to afford 128 mg of crystalline compound IB in the N-1 form.

Preparation of Crystalline Compound IB, Form N-2

Preparation of Crystalline Compound IB, Form N-2 Seed Crystals

[00158] A solution was prepared by combining 20 ml of acetone and 300 mg of compound IA (N-(4-{{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide) in a 25ml screw capped vial. Next, 0.758ml of a 0.79M (L)-malic acid stock solution was added to the vial with magnetic stirring. The solution was then left stirring for 24 hours at ambient temperature. The sample was then suction filtered with 0.45µm PTFE filter cartridge and dried *in vacuo* at ambient temperature overnight.

Preparation of Crystalline Compound IB, Form N-2.

[00159] To a reactor were added N-(4-{{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (48 g; 1.00 equiv; 48.00 g) and tetrahydrofuran (16.5 mL/g-bulk-LR; 792.00 mL). The water content was adjusted to 1 wt% water. The solution was heated to 60 °C. Once dissolved, the solution was passed through a polish filter to provide the first solution.

[00160] In a separate reactor, (L)-malic acid (1.2 equiv (molar); 15.40 g) was dissolved into methyl isobutyl ketone (10 mL/g-bulk-LR; 480.00 mL) and tetrahydrofuran (1 mL/g-bulk-LR; 48.00 mL). Next, 50 mL of the (L)-malic acid solution was added to the first solution at 50 °C. Seed crystals were added (1%, 480 mg) and the malic acid solution was added at 50 °C dropwise via an addition funnel (1.3 mL/min over 3 hours). The slurry was held at 50 °C for 18 hours and then was cooled to 25 °C over 30 minutes. The solids were filtered, and washed with 20% tetrahydrofuran/methyl isobutyl ketone (10V, 480 mL). The solids were dried under vacuum at 60 °C for 5 hours to afford compound IB (55.7 g; 0.92 equivalent; 55.70 g; 91.56% yield) as an off-white crystalline solid.

Stability Studies of Pharmaceutical Compositions

[00161] The pharmaceutical capsule compositions of Tables 3 and 4 were prepared by mixing the ingredients according to processes known in the art.

Table 3

Ingredient	mg/unit dose
Compound IB (10 % drug load as Compound IA)	25
Microcrystalline Cellulose	196.75
Croscarmellose sodium	12.5
Sodium starch glycolate	12.5
Fumed Silica	0.75
Stearic acid	2.5
Total Fill Weight	250

Table 4

Ingredient	mg/unit dose
Compound IB (50 % drug load as Compound IA)	100
Silicified Microcrystalline Cellulose	75.40
Croscarmellose sodium	10.00
Sodium Starch Glycolate	10.00
Fumed silica	0.6
Stearic Acid	4.0
Total Fill Weight	200

[00162] The capsule compositions were subjected to stability studies to monitor the formation of 6,7-dimethoxy-quinoline-4-ol at various temperatures and relative humidities over time. The results are summarized in Tables 7A and 7B and Tables 8A and 8B.

Table 7A: Stability of 25 Mg Capsules (Table 3)

	Conditions	Bottle A1	Bottle A2	Bottle A3	Bottle A4
		PPM of 6,7-dimethoxy-quinoline-4-ol			
Initial T=0	25 °C/60% RH	2	2	3	3
1 Month	25 °C/60% RH	3	4	5	NA
	30 °C/75% RH	4	4	NA	NA
	40 °C/75% RH	9	9	10	NA
3 Months	25 °C/60% RH	5	5	7	NA
	30 °C/75% RH	7	6	NA	NA
	40 °C/75% RH	22	23	24	NA
6 Months	25 °C/60% RH	6	6	7	7 (3M in blister)
	30 °C/75% RH	9	9	NA	NA
	40 °C/75% RH	40	44	43	27 (3M in blister)
9 Months	25 °C/60% RH	7	7	9	8 (6M in blister)
	30 °C/75% RH	13	12	NA	NA
	40 °C/75% RH	NA	NA	68	60 (6M in blister)

M=Months; NA=Not Applicable; RH= Relative Humidity; PPM= Parts per Million. A portion of Bottle A4 was repackaged in a blister pack after being stored in bottles for 3 months.

Table 7B: Stability of 25 Mg Capsules (Table 3)

	Conditions	Bottle B1	Bottle B	Bottle B3	Bottle B4
		PPM of 6,7-dimethoxy-quinoline-4-ol			
Initial T=0	25 °C/60% RH	3	1	2	2
1 Month	25 °C/60% RH	<2	<2	<2	NA
	30 °C/75% RH	<2	<2	NA	NA
	40 °C/75% RH	2	<2	<2	NA
3 Months	25 °C/60% RH	2	<2	<2	NA
	30 °C/75% RH	2	<2	NA	NA
	40 °C/75% RH	3	<2	<2	NA
6 Months	25 °C/60% RH	<2	<2	<2	<2 (3M in blister)
	30 °C/75% RH	2	<2	NA	NA
	40 °C/75% RH	4	<2	3	3 (3M in blister)
9 Months	25 °C/60% RH	<2	<2	<2	<2 (6M in blister)
	30 °C/75% RH	3	<2	NA	NA
	40 °C/75% RH	NA	NA	5	4 (6M in blister)

A portion of Bottle B4 was repackaged in a blister pack after being stored in bottles for 3 months.

Table 8A: Stability of 100 Mg Capsules (Table 4)

	Conditions	Bottle A1	Blister A2	Bottle A3
		PPM of 6,7-dimethoxy-quinoline-4-ol		
Initial T=0	25 °C/60% RH	4	4	6
1 Month	25 °C/60% RH	4	4	6
	30 °C/75% RH	4	NA	6
	40 °C/75% RH	6	6	9
3 Months	25 °C/60% RH	5	5	7
	30 °C/75% RH	6	NA	7
	40 °C/75% RH	10	10	12
6 Months	25 °C/60% RH	5	5	
	30 °C/75% RH	6	NA	
	40 °C/75% RH	11	17	

M=Months; NA=Not Applicable; RH= Relative Humidity; PPM= Parts per Million.

Table 8B: Stability of 100 Mg Capsules (Table 4)

	Conditions	Bottle B1	Blister B2	Bottle B3
		PPM of 6,7-dimethoxy-quinoline-4-ol		
Initial T=0	25 °C/60% RH	1	1	2
1 Month	25 °C/60% RH	<2	<2	<2
	30 °C/75% RH	<2	<2	2
	40 °C/75% RH	<2	<2	2
3 Months	25 °C/60% RH	<2	<2	<2
	30 °C/75% RH	<2	NA	<2
	40 °C/75% RH	<2	<2	2
6 Months	25 °C/60% RH	<2	<2	
	30 °C/75% RH	<2	NA	
	40 °C/75% RH	2	2	

M=Months; NA=Not Applicable; RH= Relative Humidity; PPM= Parts per Million.


[00163] The results summarized in Tables 7A and 7B and 8A and 8B indicate that formation of 6,7-dimethoxy-quinoline-4-ol was minimized to 50 ppm or less over time in the capsule formulations.

[00164] The foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity and understanding. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications can be made while remaining within the spirit and scope of the invention. It will be obvious to one of skill in the art that

changes and modifications can be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled. All references cited herein are incorporated by reference in their entirety.

CLAIMS

1. A process for preparing a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

X^1 is H, Br, Cl, or F;


X^2 is H, Br, Cl, or F;

n_1 is 1-2; and


n_2 is 1-2;

the process comprising:

contacting the compound of formula g(1) with reactant z(1) to yield the compound of formula I:




2. The process according to claim 1, wherein the compound of formula g(1) is made by reacting a compound of formula f(1) with reactant y(1) to yield the compound of formula g(1):




wherein LG represents a leaving group, and each X^2 and n_2 are as defined in claim 1.

3. The process according to claim 2, wherein the compound of formula f(1) is made by converting compound e(1) to the compound of formula f(1):




wherein LG represents a leaving group.

4. The process according to claim 1, wherein reactant z(1) is made by reacting reactant z(1a) with a chlorinating agent to yield reactant z(1):



wherein X^1 is Br, Cl, or F; and n_1 is 1-2.

5. The process according to claim 1, wherein the compound of formula I is compound IA-1:




or a pharmaceutically acceptable salt thereof, wherein:


X^1 is H, Cl, Br, or F; and

X^2 is H, Cl, Br, or F.


6. The process according to claim 5, wherein the compound of formula f(1) is compound f(2):




reactant y(1) is reactant (y)(2):




wherein X^2 is hydrogen or fluoro; and
the compound of formula g(1) is of formula g(2):




7. The process according to claim 6, wherein the reaction employs a non-nucleophilic base.
8. The process according to claim 7, wherein the non-nucleophilic base is an alkali metal alkoxide; and the reaction is carried out in a polar solvent.
9. The process according to claim 8, wherein the alkali metal alkoxide is sodium tert-butoxide, and the polar solvent is DMA.
10. The process according to claim 8, wherein the alkali metal alkoxide is sodium tert-pentoxide, and the polar solvent is DMA.
11. The process according to claim 1, wherein the compound of formula g(1) is of compound g(3):



reactant z(1) is reactant (z)(2):




the compound of formula I is compound IA:



12. The process according to claim 11, wherein the reaction is carried out in the presence of an inorganic base.


13. The process according to claim 12, wherein the inorganic base is K_2CO_3 , and the solvent employed in this reaction is a combination of THF and H_2O .

14. A process for preparing compound IB:



IB

from compound IA:




IA

comprising:


- (a) heating and agitating a mixture comprising compound IA and L-malic acid, methylethyl ketone, and water;
- (b) cooling the mixture;
- (c) vacuum distilling the mixture successively; and
- (d) isolating the compound of IB by filtration.

15. A process for preparing compound IB:



IB

from compound IA:



IA

comprising:

- (a) heating and agitating a mixture comprising compound IA and L-malic acid, methylethyl ketone, and water;
 - (b) cooling the mixture;
 - (c) seeding the mixture with the compound of IB;
 - (d) vacuum distilling the mixture; and
 - (e) isolating the compound of IB by filtration.
16. Compound IA or IB admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
17. Compound IB admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
18. Compound IB in the N-1 form admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
19. Compound IB in the N-2 form admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
20. Compound IB as a mixture of the N-1 form and N-2 form admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
21. A pharmaceutical composition according to Table 1.

Table 1

Ingredient	% w/w
Compound I	31.68
Microcrystalline Cellulose (Avicel PH102)	38.85
Lactose anhydrous 60 M	19.42
Hydroxypropyl Cellulose, EXF	3.00
Croscarmellose Sodium	3.00
Total Intra-granular	95.95
Silicon dioxide, Colloidal PWD	0.30
Croscarmellose Sodium	3.00
Magnesium Stearate	0.75
Total	100.00

22. A pharmaceutical composition according to Table 2.

Table 2

Ingredient	(% w/w)
Compound I	25.0-33.3
Microcrystalline Cellulose, NF	q.s
Hydroxypropyl Cellulose, NF	3
Poloxamer, NF	0-3
Croscarmellose Sodium, NF	6.0
Colloidal Silicon Dioxide, NF	0.5
Magnesium Stearate, NF	0.5-1.0
Total	100

23. A pharmaceutical composition according to Table 2A.

Table 2A

Ingredient	% w/w
Compound IB (10 % drug load as Compound IA)	12.67
MCC	51.52
Lactose	25.76
Hydroxypropyl cellulose	3.0
Croscarmellose Sodium	6.0
Colloidal Silicon Dioxide	0.3
Magnesium Stearate	0.75
Total	100

24. A pharmaceutical composition according to Table 3.

Table 3

Ingredient	mg/unit dose
Compound IB (10 % drug load as Compound IA)	25
Silicified Microcrystalline Cellulose	196.75
Croscarmellose sodium	12.5
Sodium starch glycolate	12.5
Fumed Silica	0.75
Stearic acid	2.5
Total Fill Weight	250

25. A pharmaceutical composition according to Table 4.

Table 4

Ingredient	mg/unit dose
Compound IB (50 % drug load as Compound IA)	100
Silicified Microcrystalline Cellulose	75.40
Croscarmellose sodium	10.00
Sodium Starch Glycolate	10.00
Fumed silica	0.6
Stearic Acid	4.0
Total Fill Weight	200

26. A pharmaceutical composition according to Table 5.

Table 5

Ingredient	mg/unit dose
Compound IB (10 % drug load as Compound IA)	50mg
Microcrystalline Cellulose	63.35
Croscarmellose sodium	95.39
Sodium starch glycolate	9.05
Fumed Silica	9.05
Stearic acid	0.54
Total Fill Weight	3.62
	181.00

27. A pharmaceutical composition according to Table 6.

Table 6

Ingredient	mg/unit dose
Compound IB	60mg
Microcrystalline Cellulose	73.95
Croscarmellose sodium	114.36
Sodium starch glycolate	10.85
Fumed Silica	10.85
Stearic acid	0.65
Total Fill Weight	4.34
	217.00

28. The pharmaceutical composition of claims 20-27 admixed with 100 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

29. The pharmaceutical composition of claims 20-27 admixed with 50 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

30. The pharmaceutical composition of claims 20-27 admixed with 25 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
31. The pharmaceutical composition of claims 20-27 admixed with 15 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
32. The pharmaceutical composition of claims 20-27 admixed with 10 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
33. The pharmaceutical composition of claims 20-27 admixed with 5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.
34. The pharmaceutical composition of claims 20-27 admixed with 2.5 ppm or less of 6,7-dimethoxy-quinoline-4-ol.

(10) International Publication Number
WO 2012/109510 A1(43) International Publication Date
16 August 2012 (16.08.2012)

(51) International Patent Classification:

C07D 215/227 (2006.01) A61P 35/00 (2006.01)
A61K 31/47 (2006.01)

(21) International Application Number:

PCT/US2012/024591

(22) International Filing Date:

10 February 2012 (10.02.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/441,520 10 February 2011 (10.02.2011) US
61/441,527 10 February 2011 (10.02.2011) US(71) Applicant (for all designated States except US): EXELIX-
IS, INC. [US/US]; 210 East Grand Avenue, South San
Francisco, CA 94080 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): WILSON, Jo Ann
[US/US]; 74 Seward Street, San Francisco, CA 94114
(US).(74) Agent: BERVEN, Heldl, M.; Honigman, Miller Schwart
And Cohn, LLP, 350 East Michigan Avenue, Suite 300,
Kalamazoo, MI 49007-3800 (US).

(81) Designated States (unless otherwise indicated, for every


kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PF, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TI, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report (Art. 21(3))

(54) Title: PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CON-
TAINING SUCH COMPOUNDS

(57) Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, Cl, or X2 is H, Br, Cl, or n1 is 1-2; and n2 is 1-2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
As the below named inventor, I hereby declare that: This declaration is directed to: ☐ The attached application, or ☒ United States application or PCT International application number <u>15/348,716</u> filed on <u>November 10, 2016</u> The above-identified application was made or authorized to be made by me. I believe that I am the original inventor or an original joint inventor of a claimed invention in the application. I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both. WARNING: Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available. LEGAL NAME OF INVENTOR Inventor: <u>Jo Ann Wilson</u> Date (Optional): _____ Signature:  Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors:	Jo Ann Wilson, et al.	Art Unit:	To Be Determined
Application No.:	To Be Determined	Examiner:	To Be Determined
Filing Date:	October 4, 2018	Conf. No.:	To Be Determined
Atty. Docket No.:	224990/10-039C3-US/439942		

Title: Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds

Commissioner for Patents
United States Patent and Trademark Office
P. O. Box 1450
Alexandria, VA 223313-1450

PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.115

Dear Sir or Madam:

Prior to examination of the application, please amend the above-referenced application as follows:

Amendments to the specification begin on page 2.

Remarks begin on page 3.

Inventors:	Jo Ann Wilson, et al.	Art Unit:	To Be Determined
Application No.:	To Be Determined	Examiner:	To Be Determined
Filing Date:	October 4, 2018	Conf. No.:	To Be Determined
Atty. Docket No.:	224990/10-039C3-US/439942		

AMENDMENT TO THE SPECIFICATION

On page 1 of the specification, after the title and header, please replace paragraph [0001] with the following paragraph:

[0001] This application is a divisional application of United States Serial Number 15/348,716, filed November 10, 2016, which is a divisional application of United States Serial Number 13/984,559, filed March 20, 2014, which claims priority under 35 U.S.C. § 371 to Patent Cooperation Treaty application PCT/US2012/024591, filed February 10, 2012, which claims the benefit of United States provisional application number 61/441,520, filed February 10, 2011, and United States provisional application number 61/441,527, filed February 10, 2011, the entire contents of which are incorporated herein by reference.

Inventors: Jo Ann Wilson, et al.
Application No.: To Be Determined
Filing Date: October 4, 2018
Atty. Docket No.: 224990/10-039C3-US/439942

Art Unit: To Be Determined
Examiner: To Be Determined
Conf. No.: To Be Determined

REMARKS

Amendments to the Specification


The Applicant has amended the application to state that this application is a divisional application of United States Serial Number 15/348,716, filed November 10, 2016, which is a divisional application of United States Serial Number 13/984,559, filed March 20, 2014, which claims priority under 35 U.S.C. § 371 to Patent Cooperation Treaty application PCT/US2012/024591, filed February 10, 2012, which claims the benefit of United States provisional application number 61/441,520, filed February 10, 2011, and United States provisional application number 61/441,527, filed February 10, 2011, the entire contents of which are incorporated herein by reference. It is believed that no new matter is added through the entry of these amendments.

Conclusion and Required Fees

It is believed that due with this submission is the Basic Utility Application Fee of \$300.00, the Utility Search Fee of \$660.00, and the Utility Examination Fee of \$760.00. The Applicant hereby authorizes the Patent Office to charge this total of \$1,720.00 to Deposit Account No. 503145, referencing Attorney Docket Number 224990/10-039C3-US/439942.

Respectfully submitted,

HONIGMAN MILLER SCHWARTZ AND COHN LLP



Dated: October 4, 2018

Heidi M. Berven, Ph.D.
Reg. No. 48,951
Honigman Miller Schwartz and Cohn LLP
650 Trade Centre Way, Suite 200
Kalamazoo, MI 49002-0402
Telephone: (269) 337-7710
Facsimile: (269) 337-7711

HMB/ayp